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ABSTRACT 
A method was validated for the quantification of para-aminosalicylic acid (PAS) in human 
plasma. The technique consisted of a protein precipitation extraction, followed by high 
performance liquid chromatography with tandem mass spectrometry (LC-MS/MS) 
detection.  Rilmenidine was used as the internal standard (ISTD).  Analyte mean extraction 
yields determined were ~100.3% (CV % = 3.3). The extraction procedure was followed by 
liquid chromatographic separation using a Phenomenex Synergi Hydro-RP (150 x 2.0 mm, 
4µm) analytical column.  An isocratic mobile phase containing methanol, water and formic 
acid (40:59.8:0.2, v/v/v) was used at a flow-rate of 300 µl per minute.  The retention times 
for PAS and rilmenidine were, ~2.4 and ~1.6 minutes, respectively. 
An AB Sciex API 3000 mass spectrometer at unit resolution in the multiple reaction 
monitoring (MRM) mode was used to monitor the transition of the protonated precursor ions 
m/z 154.1 and m/z 181.2 to the product ions m/z 80.2 and m/z 95.2 for PAS and the ISTD, 
respectively.  Electro Spray Ionisation (ESI) was used for ion production. 
Accuracy and precision were assessed over three consecutive, independent runs. The 
calibration curve fits a quadratic (weighted by 1/x concentration) regression for PAS over 
the range 0.391 – 100 µg/ml, based on peak area ratios. A 1:1 and 1:4 dilution of the QC 
Dilution sample showed that concentrations of up to 160 µg/ml of PAS in plasma could be 
analysed reliably when diluted into the calibration range.  
Endogenous matrix components were found to have an insignificant effect on the 
reproducibility of the method, when human plasma originating from eight different sources 
were analysed.  PAS was found to be stable in human plasma for 21 months kept at ~-80°C, 
for up to 21 hours at room temperature and when subjected to 3 freeze-thaw cycles.  Stock 
solutions of PAS in methanol were stable for 2 days when stored at ~80°C and for 24 hours 
when stored at room temperature, ~4°C and ~-20°C. Plasma extracts of the analyte/ISTD 
ratio were shown to be stable on instrument over a period of ~55 hours. Reinjection 
reproducibility experiments indicated that an assay batch may be re-injected within 58 
hours. Quantification of PAS in plasma was not significantly affected by the presence of 
haemolysed blood (2%) in plasma and when Lithium Heparin was used as anti-coagulant 
instead of K3EDTA.  
The best marker for terizidone pharmacokinetics is the analysis of cycloserine, a small polar 
drug with limited potential for absorbing UV that makes it difficult to analyse. A method 
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was validated for the quantification of cycloserine in human plasma, and consisted of a 
protein precipitation extraction and derivatization, followed by high performance liquid 
chromatography with MS/MS detection.  No ISTD was used as no suitable match could be 
found. The mean extraction yield determined was ~77% (CV% = 10.7).  The extraction 
procedure was followed by liquid chromatographic separation using a Gemini NX C18 (50 x 
2.0 mm, 5µ) analytical column. An isocratic mobile phase containing acetonitrile, water and 
formic acid (30:69.9:0.1, v/v/v) was used at a flow-rate of 300 µl per minute.  The retention 
time for cycloserine was ~ 1.5 minutes. 
An AB Sciex API 3000 mass spectrometer at unit resolution in the MRM mode was used to 
monitor the transition of the protonated precursor ion m/z 335.9 to the product ion m/z 157.2 
for cycloserine.  ESI was used for ion production. 
Accuracy and precision were assessed over three consecutive, independent runs.  The 
calibration curve fits a quadratic (weighted by 1/x concentration) regression for cycloserine 
over the range 0.313 – 40.0 µg/ml, based on peak areas.   
A 1:4 dilution of the QC Dilution sample showed that concentrations of up to 64.0 µg/ml of 
cycloserine in plasma could be analysed reliably when diluted into the calibration range and 
no carry over peaks were observed. 
Endogenous matrix components were found to have no effect on the reproducibility of the 
method when human plasma originating from six different sources was analysed. 
Cycloserine was found to be stable in human plasma for up to 18 hours at room temperature, 
and when subjected to 3 freeze-thaw cycles.  Stock solutions of cycloserine in water and 
methanol were stable for 10 days when stored at ~ -80°C and for 18 hours when stored at 
room temperature, ~ 4°C and ~ -20°C.  Long term stability in plasma has been proven for 17 
months at -80°C.  Plasma extracts of the analyte were shown to be stable on instrument over 
a period of ~ 29 hours.  Reinjection reproducibility experiments indicate that an assay batch 
may be re-injected within 29 hours.  Cycloserine is stable in whole blood (on ice) for up to 
30 minutes. 
Both validated methods presented performed well on clinical samples generated from a 
multi drug resistant TB (MDR-TB) research study in children dosed with PAS and 
terizidone. 
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1. INTRODUCTION 
1.1. Brief history of tuberculosis 
Tuberculosis (TB) is caused by a variety of mycobacteria strains, typically either 
Mycobacterium tuberculosis or Mycobacterium bovis. Although the disease can occur in any 
organ of the body it is best known as a disease of the lungs. TB has claimed victims 
throughout much of known human history and may have killed more people than any other 
microbial pathogen [1]. DNA evidence of TB dates back to 17,000 Before Christ (BC) and 
palaeopathological evidence to 8,000 BC, evidence of bony TB has been found dating from 
the Neolithic period in 5,800 BC and in Egyptian mummies dating to 2,400 BC [2, 3]. 
Although microscopy evidence from autopsies laid the foundation for understanding the 
pathogenesis of TB at the end of the 18th century, it was the work of   Théophile Laennec at 
the beginning of the 19th century that made us understand that the multiple forms of TB were 
one single infectious entity [2]. Jean-Antoine Villemin demonstrated the transmissibility of 
Mycobacterium tuberculosis infection in 1865 and Robert Koch identified the tubercle 
bacillus as the etiologic agent in 1882 [4, 5]. In 1907 Clemens von Pirquet developed the 
tuberculin skin test and in 1910 used it to demonstrate latent TB infections in children who 
were carriers of the disease but displayed no symptoms [6].  
Nearly fifty years after the successful identification of Mycobacterium tuberculosis, a 
feasible treatment regime for TB was developed by Selman Waksman and Albert Schatz. 
Selman Waksman worked from 1914-1944 to find a drug with good chemotherapeutic 
response and low toxicity in humans, which led to the discovery of streptomycin [7]. The 
next chemotherapeutic breakthrough was isoniazid in 1952, although the drug was already 
synthesised nearly 50 years earlier [8].  
A vaccine against TB, the Bacille Calmette Guerin (BCG) vaccine, was developed and first 
used in humans in 1921. The vaccine was widely used in Europe during World War I, but 
never gained popularity in the United States. It’s effectiveness against pulmonary 
tuberculosis vary, but it is still the only vaccine currently available with new vaccines in 
development [9].  
While TB steadily declined during the late 19th and early 20th century, the prevalence 
remained high in many parts of the world. TB treatment outcomes are diverged along the 
lines of global economy and it is necessary to understand the different treatment approaches 
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and implementation in high-incidence, low-income countries [2]. Although TB is a 
contagious disease its progress is highly influenced by environmental factors and the 
immunocompetency of the host. Only about one tenth of immunocompetent people infected 
develop symptoms over their lifetimes [10]. Mycobacterium tuberculosis has proved to be a 
very resilient microorganism, with the ability of developing drug resistant mutants if treated 
with one drug alone. The modern standard for TB treatment became a combination of four 
drugs, to keep successful tubercle bacillus mutations at bay [11].  
 
Resurgence of TB, particularly in the developing world, has stimulated research, providing 
new potential tuberculosis vaccines. This resurgence is not only due to the re-emergence of 
dense population centres with poor sanitation (a phenomenon that contributed to TB’s 
prevalence historically in Europe), but is also due to the rise of other diseases that 
compromise immunity such as the human immunodeficiency virus / acquired immune 
deficiency syndrome (HIV/AIDS). When nearly one third of the world’s population 
harbours asymptomatic infections, being able to identify a particular strain of TB and its 
drug resistant status is more crucial than ever before [12].  
 
Although TB is still an epidemic and survey data show it is larger than previously estimated, 
the number of deaths and incident rate globally are decreasing.  “In 2015, there were an 
estimated 10.4 million new (incident) TB cases worldwide, an estimated 1.4 million TB 
deaths and an additional 0.4 million deaths resulting from TB disease among people living 
with HIV. People living with HIV accounted for 1.2 million (11%) of all new TB cases. Six 
countries accounted for 60% of the new cases: India, Indonesia, China, Nigeria, Pakistan 
and South Africa. Worldwide, the rate of decline in TB incidence remained at only 1.5% 
from 2014 to 2015. This rate will need to increase to a 4–5% annual decline by 2020 in 
order to reach the first milestones of the “End TB Strategy” by the World Health 
Organisation (WHO)” [13].  
In 2011 there where an estimated 310 000 incident cases of multidrug resistant (MDR-TB) 
and that increased in 2015 to an estimated 480 000 incident cases. In 2015, an additional 100 
000 people with rifampicin-resistant TB (RR-TB) incidence were reported, they were also 
eligible for MDR-TB treatment and required second line drugs [13, 14]. 
Increasing incidence rates for MDR-TB have been recorded in several settings, with South 
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Africa suffering one of the highest occurrences of MDR-TB and extensively drug resistant 
TB (XDR-TB).  Since 2002, MDR-TB in South Africa has been treated by a standardized 
combination therapy, which includes ofloxacin, kanamycin, ethionamide, ethambutol and 
pyrazinamide. Since 2010, ethambutol has been replaced by cycloserine or terizidone [14].  
“Although the number of TB deaths fell by 22% between 2000 and 2015, TB remained one 
of the top 10 causes of death worldwide in 2015. It is estimated that TB care and prevention 
treatment averted 49 million deaths globally between 2000 and 2015, but important 
diagnostic and treatment gaps persist” [13]. 
The emergence of MDR-TB and XDR-TB threatens disease control efforts throughout the 
world. Drug-resistant tuberculosis may be acquired if bacteria expressing drug resistant 
mutations are positively selected due to: inadequate treatment regimes, poor drug quality or 
patient non-compliance. Alternatively, drug resistant tuberculosis may also occur through 
the transmission of existing resistant strains, termed primary resistance.  High rates of 
primary resistance reflect poor transmission control, often exacerbated by delays in drug 
susceptibility testing and initiation of appropriate treatment [15].   
 
1.2. Treatment of tuberculosis 
The aims of TB treatment are: 
• curing patients of TB in order to restore their quality of life and productivity 
• preventing relapse of TB 
• reducing transmission of TB to others 
• preventing the development and transmission of drug resistant TB 
 
TB drug treatment is sometimes referred to as antitubercular treatment (ATT), and involves 
a combination of the different drugs available. Some TB drugs are only used for the 
treatment of new patients when there is no suggestion of any drug resistance, also called 
drug susceptible TB, and others are only used for the treatment of drug resistant TB. More 
than 90% of people with drug susceptible TB can be cured in six months using a 
combination of first line TB drugs [16]. 
First line drugs are those TB drugs that generally have the greatest bactericidal activity when 
used for TB treatment. The amount of drug that an adult TB patient requires is dependent on 
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their weight.  
For new patients with presumed drug susceptible pulmonary TB, the WHO recommends 
that they receive six months of treatment. This consists of a two-month intensive TB 
treatment phase followed by a four-month continuation phase. The WHO recommends 
isoniazid, rifampicin, pyrazinamide and ethambutol for the intensive treatment phase and 
isoniazid and rifampicin for the continuation phase. 
It is recommended that patients undertake this regime daily for six months, however taking 
the drugs three times a week is also possible in some circumstances. In the interest of 
reducing the further development of resistant strains, it is essential that all the recommended 
TB drugs are taken [17]. 
Treatment of drug resistant TB is more challenging than the treatment of drug susceptible 
TB, and the treatment regime is defined by the type and number of drugs each particular 
strain is resistant to: 
 MDR-TB is caused by a strain of Mycobacterium tuberculosis that are resistant in 
vitro to rifampicin and isoniazid. 
 XDR-TB is caused by a strain of Mycobacterium tuberculosis that are resistant in 
vitro to isoniazid, rifampicin and at least one injectable agent (i.e. amikacin, 
kanamycin or capreomycin) and any of the fluoroquinolones. 
 Mono-resistant TB is caused by strains of Mycobacterium tuberculosis that are 
resistant to just one anti-TB drug. 
 Polyresistant TB is caused by strains of Mycobacterium tuberculosis that are 
resistant to more than one drug, but not isoniazid and rifampicin together.  
 
Resistant strains require the use of second line or reserve drugs that are costlier, cause more 
side effects and need to be taken for longer periods of time, sometimes up to two years [17]. 
The drugs that are used for the treatment of drug resistant TB are grouped according to how 
effective they are, how much experience people have with their use and the drug class. All 
first line anti-TB drugs are in Group 1, apart from streptomycin which is classified with the 
other injectable agents in Group 2 as presented in Table 1. 
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Group 5: Agents with an 
unclear role 
 
Pyrazinamide Kanamycin Levofloxacin PAS ** Clofazimine 
Ethambutol Amikacin Moxifloxacin Cycloserine Linezolid 
Rifampicin  Capreomycin Ofloxacin Terizidone Amoxicillin/clavulanate 
Isoniazid Streptomycin Gatifloxacin Thionamide Thioacetazone 
Rifabutin *   Protionamide Imipenem/cilastatin 
Rifapentine *    High dose isoniazid 
    Clarithromycin 
* New generation 
rifamycins 
   Meropenem/clavulanate 
** para-
Aminosalicylic acid 




New drugs recently added to group 5 are delamanid and bedaquiline. Bedaquiline was 
approved by the FDA in the United States, for use in the treatment of drug resistant TB, 
when no alternatives are available. These drugs have some significant side effects [18]. 
A patient’s access to drug susceptibility testing (DST) and the type of DST available, 
determines the treatment protocol for a patient with drug resistant TB. Clinicians often 
prescribe regimes compiled by an algorithm, or formula, set by a regional or national TB 
treatment program in a country. A DST may take many weeks or months, therefore, initially 
a standard drug regimen is typically provided, until the patient’s drugs can be targeted in 
light of the results. More modern rapid DSTs are available, such as the newer molecular TB 
tests. This allows the clinician access to at least some drug resistance information, and 
thereby allowing for a quicker turnaround time in providing an individualized program of 
TB drug treatment to the patient [19]. 
A major cause of the current drug resistance problems is the complexity and length of even 
the “basic” treatment regime for drug sensitive TB. There is an urgent need for new drugs 
with shorter, simpler regimes as well as new drugs for the treatment of MDR-TB [17]. 
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In areas of minimal or no MDR-TB, TB cure rates of up to 95 per cent can be achieved. 
Cure rates for multi drug resistant TB are lower, typically ranging from around 50% to 70%. 
The fact that cure rates for MDR-TB are so low, mean that MDR-TB continues to spread, 
and globally MDR-TB is becoming an increasingly severe problem [13]. 
Several countries have been testing a new treatment for MDR-TB. This new regime, 
sometimes called the “Bangladesh regime”, requires far fewer drugs to be taken and a 
cheaper, shorter treatment period of around nine months. This regimen prescribes 
gatifloxacin in combination with ethambutol, pyrazinamide, and clofazimine throughout, 
supplemented by kanamycin, prothionamide and isoniazid during the initial four-month 
period [20]. In 2016, the WHO recommended that this treatment regime could be used for 
patients with “uncomplicated MDR-TB”. “Uncomplicated MDR-TB” is defined as TB 
infection by bacteria resistant to rifampicin and isoniazid. This protocol is also 
recommended for individuals who have not yet been treated with second line drugs [17]. 
In order to identify patients who are suitable for this treatment regime, it is necessary to do a 
Line Probe Assay test. This test verifies that the active infection does not already 
demonstrate resistance to one or more of the second line drugs. If the infection does 
demonstrate resistance, a shorter regime with fewer drugs, could not only result in the 
patient not being cured, but also create the selective environment that would encourage the 
bacterium to develop further resistance. The Line Probe Assay test is, however, usually only 
available in national TB reference laboratories [21]. 
All patients receiving TB treatment should be monitored during their treatment to assess 
their response to the drug treatment. Regular monitoring also helps to ensure that patients 
complete their treatment. It can also help to identify and manage adverse drug reactions. 
Patients need to have their weight checked every month, and if the patient’s weight changes 
the drug dosages may need to be adjusted [17]. 
When patients have pulmonary TB, the patient’s response to TB treatment should be 
monitored using sputum smear microscopy. The recommendation from the WHO is that for 
smear positive TB patients treated with first line drugs, a smear microscopy should be 
performed at the end of the two months’ intensive phase of treatment [17]. Sputum should 
be collected when the patient is given the last dose of the intensive phase of treatment. If the 
patient has a positive sputum smear at the end of the intensive phase, then there should be a 
patient assessment carried out, because the positive smear could indicate several different 
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situations. An example is that the patient may have drug resistant TB, and a change in the 
TB drugs they are taking might be needed. Alternatively, patient adherence may have been 
poor, and they might not have been taking their drugs correctly. The assessment might result 
in changes needing to be made to the patient’s treatment, or to their support and supervision. 
Different actions may need to be taken in a variety of other circumstances, such as the 
patient having received treatment before [22]. 
The latest guidelines for the treatment of drug-resistant TB were developed by the WHO in 
2016, based on the retrospective analysis of patient records from at least 32 observational 
studies investigating the impact of type, number of drugs and duration of treatment and 
outcome.  The greatest chance for treatment success was with an intensive phase of second-
line anti-TB drugs for 7–8.5 months and a total treatment duration of 25–27 months [17]. 
The initial regimen was composed of at least four active drugs during the intensive phase 
and three drugs during the continuation phase. Active second line anti-TB drugs include 
injectable anti-TB drugs such as: kanamycin, amikacin and capreomycin; fluoroquinolones 
like: moxifloxacin, ofloxacin and gatifloxacin; oral bacteriostatic second line anti-TB drugs 
like: ethionamide, prothionamide, cycloserine, terizidone and para-aminosalicylic acid and 
class 5 anti-TB drugs that include: clofazimine, linezolid, amoxicillin clavulanate, 
clarithromycin, imipenem high-dose isoniazid, meropenem / clavulanate, delamanid and 
bedaquiline [18, 23]. 
 
The drugs which this project will focus on are two oral bacteriostatic second line anti-TB 
drugs para-aminosalicylic acid (PAS) and cycloserine / terizidone. 
 
1.3. Aim of this research 
This project aimed to develop and validate selective and sensitive LC-MS/MS methods to 
determine PAS and cycloserine / terizidone in biological matrixes, applicable to clinical 
studies where subjects were exposed to therapeutic doses of these drugs. 
PAS is a poorly tolerated bacteriostatic agent and cycloserine / terizidone use is hindered by 
serious central nervous system toxicity. As with other oral bacteriostatic second-line anti-TB 
agents, little is known about their pharmacokinetics (PK) / pharmacodynamics (PD) and 
how that correlates to their activities. 
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In vitro animal models and human pharmacokinetic studies in concert are necessary to 
define the lowest exposure necessary for maximal bacteriostatic effect, to identify lower and 
more tolerable doses that retain similar efficacy. For these studies, more sensitive, accurate 
and efficient analytical methods are needed to generate quality PK data. Quality PK data 
will lead to better recommendations regarding dosing and duration of treatment needed to 
maximize efficacy with acceptable safety and tolerability for these oral bacteriostatic second 
line anti-TB drugs. 
 
2. METHOD DEVELOPMENT 
2.1. Introduction 
The quantification of chemical entities in different biological matrices, bioanalytical 
chemistry, is constantly changing and more must be done in shorter time. Bioanalytical 
chemistry is an important component within medical and pharmaceutical research both for 
drug discovery and development. The cost of developing drugs has increased significantly 
and the drive towards higher productivity and shorter development times is crucial in all the 
areas of the drug discovery process [24]. On the other hand, analytical methods employed 
for the determination of drugs and their metabolites in biological samples are key 
determinants in generating reproducible and reliable data. The focus of bioanalysis in the 
pharmaceutical industry is to provide a quantitative measurement of the active drug and / or 
metabolite(s) for the accurate assessment of PK data, toxicokinetics, bioequivalence (BE) 
and exposure-response (PK/PD) relationships in the drug discovery and development 
process as described in Figure 1 [25, 26]. 
 
Figure 1. Flowchart of drug discovery and development studies [27]. 
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The quality of these studies, which are often used to support regulatory filings and other 
evaluations, is directly related to the conduct of the underlying bioanalysis. Therefore, the 
application of best practices in bioanalytical method development, validation and associated 
sample analysis is key to an effective discovery and development program leading to the 
successful registration and commercialization of a drug product [28]. 
The analytical chain describes the process of method development and includes sampling, 
sample preparation, separation or extraction techniques, detection and evaluation of the 
results. Analytical method development is the process of creating a procedure to enable a 
compound of interest to be identified and quantified in a suitable matrix, against established 
acceptance criteria for specific characteristics. It is essential to employ well-characterized 
and fully validated analytical methods to yield reliable results, which can be satisfactorily 
interpreted [29, 30]. 
 
2.2. Literature survey 
One of the starting points for method development is a thorough literature survey, a 
compound can often be measured by several methods.  The optimum technique should be 
identified based on the intended purpose and scope of the analytical method. A survey on 
published assay methods can save time and money during method development. Analytical 
information obtained during a literature survey may provide: the chemical properties and 
stability of the analyte, type of instrumentation, type of column, type of extraction, type of 
matrices and anticoagulant used, the linear range, the method limit of detection and 
quantitation [31].  
Clinical information is essential for the method development phase, to define what the limit 
of quantitation and the linear range of the method needs to be. Therefore, dose and sampling 
times are important information to obtain during the literature survey. Clinical information 
is usually obtained from the study protocol, a document that describes how a clinical trial 
will be conducted (the objective(s), design, methodology, statistical considerations and 
organization of a clinical trial,) and ensures the safety of the trial subjects and integrity of 
the data collected [32]. After all the information is obtained from the literature survey, a 
procedure is outlined in an action plan or method development plan. 
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2.3. Method development plan 
The method development plan is the starting point of the method development process. 
Information from the literature survey is used, but if very little or no information is 
available, a new method is developed based on the chemical properties of the drug to be 
assayed. From existing knowledge of our test drugs, the following techniques were 
identified as potentially useful. 
 
2.3.1. Chromatographic systems 
 
A combination of different factors will determine the type of chromatographic system to be 
used: availability of instruments, instrumentation used in published assays, selectivity 
needed, the limit of quantitation and the cost of the analysis. 
The most common chromatographic systems available for medical and pharmaceutical 
research are high performance liquid chromatography (HPLC) and gas chromatography 
(GC). Historically most of the volatile and more basic drugs were analysed on GC systems 
and the more non-volatile and acidic drugs were assayed on HPLC systems. 
 
2.3.1.1. High Performance Liquid Chromatography  
HPLC (high-pressure liquid chromatography), is a technique in analytical chemistry used to 
separate, identify, and quantify components in a mixture. A pump passes a liquid solvent, 
called the mobile phase, containing the sample mixture under high pressure through a 
column filled with a solid adsorbent material, called the stationary phase. Each component 
in the sample interacts slightly differently with the adsorbent material, causing different 
flow rates for the different components and leading to the separation of the components as 
they elute out of the column. Each component is then “detected” by the detector that 
converts the component concentrations into an electronic response acquired by a data 
acquisition system as represented in Figure 2 [33].  
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Figure 2. Schematic representation of an HPLC unit 
 
2.3.1.2. Gas Chromatography (GC) 
In gas chromatography an inert gas such as helium, or an unreactive gas such as nitrogen is 
used as the mobile phase or carrier gas. Helium remains the most commonly used carrier gas 
in about 90% of instruments although hydrogen is preferred for improved separations. The 
stationary phase is a microscopic layer of adsorbent material, normally a liquid or polymer, 
inside a piece of glass or metal tubing called a column. The sample mixture is evaporated 
into gas and moved through the column, the components in the sample mixture would 
interact with the column and separate. The column normally sits inside a column oven, a 
heat gradient as well as the flow of the carrier gas elute the components from the column to 
be detected, as presented in Figure 3. The instrument used to perform gas chromatography is 
called a gas chromatograph. Conventional GC sometimes involved tedious derivatisation 
reactions in order to obtain good chromatography and separation [34]. 
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Figure 3. Schematic representation of a gas chromatograph 
 
In the last decade, there have been tremendous advancements in the field of mass 
spectrometry, with the development of new interfaces, ionisation and detection techniques. 
These advancements have resulted in the rapid emergence of widespread commercial use of 
hyphenated liquid chromatography mass spectrometry (LC-MS/MS) based assays, which 
have largely replaced conventional HPLC and GC assays [35].  
Advancement in sample handling and extraction instrumentation has been seen with the use 
of multi-well plates, automated robotic sample processing and electronic data reporting 
becoming common place [26]. 
 
2.3.2. Detection instrumentation 
The most common detectors used in high performance liquid chromatography (HPLC) are 
variable wavelength (UV), fluorescence (FLD), electrochemical (EC) and mass 
spectrometer (MS) detectors. In gas chromatography (GC) the most common detectors are 
nitrogen phosphorus (NPD), electron capture (ECD), flame ionisation (FID) and mass 
spectrometer (MS) detectors. Each one of these detectors have some advantages and some 
disadvantages and need to be carefully selected for a specific assay. 
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2.3.2.1. UV/Vis Detectors 
UV detection is one of the most common types of HPLC detectors. It measures the ability of 
solutes to absorb light at a particular wavelength(s) in the ultraviolet (UV) or visible (Vis) 
wavelength range.  
There are three common types of UV/Vis absorbance detectors: 
 Fixed Wavelength Detectors (FWD), the absorbance of only one given wavelength is 
monitored by the system at all times (usually 254 nm), this is the simplest and 
cheapest of the UV/Vis detectors, but the types of compounds that can be detected 
are limited. 
 The Variable Wavelength Detector (VWD), monitors a single wavelength at any 
given time, but any wavelength in a wide spectral range can be selected (190-900 
nm). This detector is more expensive and requires more advanced optics, but can be 
used to detect a wider range of compounds. 
 The Photo Diode Array Detector (PDA) operates by simultaneously monitoring 
absorbance of solutes at several different wavelengths‚ the detector uses a series or 
an array of several detector cells within the instrument, with each responding to 
changes in absorbance at different wavelengths. The entire spectrum of a compound 
can be read in a minimum amount of time, useful in detecting the presence of poorly 
resolved peaks or peak contaminants [36].  
2.3.2.2. Fluorescence Detectors 
Fluorescence detection is a selective HPLC detector that measures the ability of eluting 
solutes to fluoresce at a given set of excitation and emission wavelengths. Fluorescence can 
be used to selectively detect any compound that absorbs and emits light at the chosen set of 
excitation and emission wavelengths. Typical applications are in the analysis of drugs, food 
additives and environmental pollutants [36]. 
 
2.3.2.3. Electrochemical Detectors 
Electrochemical detectors are used to monitor any compound in the mobile phase that can 
undergo an oxidation or reduction‚ electrochemical detection coupled with liquid 
chromatography is sometimes referred to as LC/EC. These detectors can be made specific 
for a given compound or class of compounds by selecting the conditions at the electrodes‚ 
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the detector has high selectivity with a low background signal [36]. 
 
2.3.2.4. Nitrogen–phosphorus detectors 
The nitrogen–phosphorus detector (NPD) is a common GC detector. A form of thermionic 
detector where nitrogen and phosphorus alter the work function on a specially coated bead, 
creating a current proportional to sample concentration. It responds selectively to most 
organic compounds that contain phosphorus or nitrogen down to picogram levels and is 
mass flow dependant. It is useful for analysis of drugs and pesticides containing phosphorus 
[37]. 
 
2.3.2.5. Electron Capture Detection 
Electron capture detection (ECD) is another GC detector, which uses a radioactive beta 
particle (electron) source to measure the degree of electron capture. ECD is used for the 
detection of molecules containing electronegative elements and functional groups like 
halogens, carbonyl, nitriles, nitro groups, and organometallics. In this type of detector, either 
nitrogen or 5% methane in argon is used as the mobile phase carrier gas. The carrier gas 
passes between two electrodes placed at the end of the column. Adjacent to the anode 
(negative electrode) resides a radioactive foil such as 63Ni. The radioactive foil emits beta 
particles (electrons), which collides with and ionizes the carrier gas to generate more ions 
resulting in a current. It is a very specific detector, non-destructive in nature and widely used 
in environmental analysis, e.g. organochlorine pesticide [37].  
 
2.3.2.6. Flame Ionization detector (FID) 
In the flame ionization detector (FID), electrodes are placed adjacent to a flame fuelled by 
hydrogen / air near the exit of the column. When carbon containing compounds exit the 
column they are pyrolyzed by the flame. This detector works only for organic / hydrocarbon 
containing compounds due to the ability of the carbons to form cations and electrons upon 
pyrolysis, which generates a current between the electrodes. The increase in current is 
translated and appears as a peak in a chromatogram. FIDs have low detection limits (a few 
picograms per millilitre) but they are unable to generate ions from carbonyl containing 
carbons. FID compatible carrier gasses include helium, hydrogen, nitrogen, and argon [37].  
 
Development and validation of selective and sensitive LC-MS/MS methods for the determination of para-Aminosalicylic Acid and 




Page 30  
2.3.2.7. Thermal conductivity detector (TCD) 
The thermal conductivity detector is a GC detector less sensitive than the FID, and is used 
for preparative applications. It is a non-destructive universal detector and response depends 
on the thermal conductivity difference between the carrier gas and the eluted components. 
This method also responds to inorganic gases such as CO, CO2, NH3, CS2, N2, etc [37]. 
 
2.3.2.8. Mass Spectrometers (MS) 
Mass Spectrometers (MS), also called mass analysers, are compound specific detectors and 
give unambiguous identification of sample components, often used in conjunction with 
HPLC and GC. The rich chemical information available from spectra allows identification 
of unknown components in samples, even when a standard is not available for comparison. 
Mass spectrometry is ideal for drug metabolism, product stability, natural product 
elucidation, forensic analysis and all areas of analysis where structural elucidation and 
identification is critical. Drug discovery and diagnostics are two important areas where rapid 
identification of sample components are key to successful problem-solving.  
The mass spectrometer cannot determine the mass of an uncharged atom or molecule. The 
uncharged species must first be ionized so that it can be repelled and attracted by the fields 
generated in the mass analyser. A mass spectrometer determines the mass-to-charge ratio of 
an ion, this is usually referred to as m/z (mass divided by the charge). Since the charge on 
most small molecule ions created in a mass spectrometer is 1, m/z is equivalent to the mass. 
For the mass of an ion to be determined, the ions must pass through the analyser region of 
the mass spectrometer on its way to the detector. In order to do this, the ions must be in a 
gas phase. All mass analysers have the means to separate and detect gas-phase ions and it is 
through this method that determines the information content of a given experiment. As ion 
production, mass separation and ion detection are common to all mass analysers, the method 
in which ions are introduced into an analyser, how ions of different masses are separated and 
how they are detected can be quite different with each specific mass analyser. Some 
analysers introduce ions into the mass analysers as a continuous beam (quadrupoles and 
magnetic sector analysers) of ions and others as a pulse (time of flight, ion trap and Fourier 
transform analysers). Some spectrometers separate ions in space while others are traps that 
separate ions in time [35].  
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2.3.2.8.1. Quadrupole Mass Analysers 
Quadrupoles consist of four precisely parallel rods (called poles) spaced around a central 
axis, represented in Figure 4. An ion source produces ions that moves through the mass 
analyser along the axis of the quadrupoles by applying a voltage gradient. The voltage 
needed for the ions to move is as little as 5 – 10 eV and therefore quadrupoles are 
considered low energy mass analysers.  
Applying a specific voltage, with a specific radio frequency (RF) and direct current (DC), 
and alternating the voltages between opposing sets of quadrupoles creates the “mass filter”. 
By using a specific voltage gradient on opposite sets of quadrupole rods a complete range of 
masses can be passed through the detector.  
 
Figure 4. Schematic of a quadrupole MS 
 
Ions with a specific mass-to-charge ratio requires a certain voltage to pass through the filter 
and be detected. Quadrupoles are versatile mass analysers and suitable for high throughput 
and production applications. The most common type of quadrupole setup used today are the 
triple quadrupole instruments which consist of 3 sets of quadrupoles in tandem. The first set 
of quadrupoles (Q1), analyse the intact charged molecule, the second set of quadrupoles 
produce fragmentations of the molecule and the third set of quadrupoles (Q3) analyse the 
fragments. This has become the standard tool used in LC-MS/MS for clinical assays [35].  
2.3.2.8.2. Ion Trap Mass Analysers 
This mass analyser works by first trapping ions then detecting them based on their m/z 
ratio’s. Because an ion trap is a variation on the quadrupole mass filter, it is sometimes 
referred to as a quadrupole ion trap. By alternating the voltages between the electrodes and 
applying the same focussing principals as in the quadrupoles setup, ions are “trapped” or 
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focused in a 3-dimensional volume, as represented in Figure 5.  
 
 
Figure 5. Schematic of an ion trap MS 
Ions are detected by placing them in unstable orbits, which causes them to leave the trap and 
transit to the detector. An ion trap consists of two endcap electrodes and a ring electrode. By 
adding a gas like helium, the trap encourages ions to migrate to the centre of the trap. The 
tighter the ions are focused the more efficient their detection. After trapping and focusing 
the ions, collision dissociation takes place and tandem mass spectrometry can be performed. 
This capability provides the analyst with rich structure information and therefore 
applications of ion traps have been found in combinatorial chemistry and drug metabolism 
[35]. 
 
2.3.2.8.3. Time-of-Flight Analysers 
One of the simplest mass analysers is called the time-of-flight (TOF) mass analyser. These 
analysers operate on the principal that an ion’s velocity of travel is mass dependant i.e. the 
smaller the mass of an ion, the higher it’s velocity relative to heavier ions. A typical TOF 
mass analyser consist of an ion source, a flight tube, a reflectron and a detector as 
represented in Figure 6. An ion source produces ions that are accelerated down the flight 
tube through the use of a high voltage. Each mass entering the flight tube will travel at 
different velocities. As the initial bundle of ions travel down the flight tube, they are 
separated and arrive at the detector at different times. The arrival time of each ion is directly 
related to its mass or in this case, m/z. 
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Figure 6. Schematic of a TOF MS 
TOF mass analysers are ideal for determining the chemical structure of compounds because 
of their sensitivity and high-speed scanning. TOF mass analysers are often used in tandem 
with quadrupoles, which allow for high efficiency in the first analyser and high selectivity 
scanning in the second analyser. TOF is unrivalled for applications where high molecular 
weight is important, for example the analysis of polymers and biopolymers, because it has a 
large mass range and practically no upper limit [35].  
 
2.3.2.8.4. Magnetic Sector Mass Analysers 
Organic chemistry and analysis have been dominated by the high-resolution application of 
the magnetic sector mass analysers for the past 30 years. Ions created in the source are 
accelerated down the ion beam into the analyser with typical voltages of 4-8 kV, represented 
in Figure 7. The radius of curvature in a given magnetic field of the sector mass analyser is a 
function of the m/z. Ions will follow different radius curves through the magnetic field based 
on their mass. Ions of different masses are then separated and scanned by a fixed detector by 
varying either the magnetic field or the ion source voltage. To achieve a high resolution, 
magnetic sector analysers are coupled with electromagnetic sectors to generate different 
kinetic energies and separate mixtures of ions. 
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Figure 7. Schematic of a Magnetic Sector MS 
Magnetic sector mass analysers are reliability instruments with a high dynamic range, 
making them a competitive alternative for qualitative analysis [35].  
 
2.3.2.8.5. Fourier Transform-MS 
The Fourier transform mass spectrometer (FTMS) consists of a cell formed by excitation 
plates and detector or trapping plates. A very high vacuum (<10-6 Torr) creates a vacuum 
chamber inside the cell. As ions pass through the cell they are trapped by a combination of a 
high magnetic field and electric potentials applied to the detector or trapping plates, as 
represented schematically in Figure 8. As the magnetic field inside the cell is increased, the 
ions begin to rotate within the cell around the axis of the magnetic field. The rotation is 
detected indirectly through an induced current generated on the detector plates as the ions 
pass near the plates. As the frequency of the rotation is inversely proportional to the mass, 
the frequency of ion rotation can be converted to mass through what is called Fourier 
transform. 
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Figure 8. Schematic of a Fourier Transform MS 
The advantages of FTMS is high resolution (>500,000), high mass accuracy, simplicity and 
versatility. This spectrometer is most often used for qualitative and not quantitative analysis. 
A disadvantage of the FTMS use its high cost [35].  
 
Coupling liquid chromatography to mass spectrometry is called interfacing, and is the 
conversion process where the liquid phase is evaporated into a gas phase, atmospheric 
pressure is reduced to high vacuum and ionization takes place. A wide variety of 
commercial alternative interfaces exist, electrospray (ES), atmospheric pressure chemical 
ionization (APCI), particle beam (PB), continuous flow fast atom bombardment (CFFAB) 
and thermo-spray (TS) [35].  
 
2.3.3. Extraction techniques  
 
Extraction techniques have long served as valuable tools to analytical chemists, particularly 
during the last century when selective and sensitive instrumentation were not generally 
available. Yet even today, despite the constant development of selective and sensitive 
detection instrumentation, analytical chemists are constantly challenged to perform 
determinations in which available instrumentation is inadequate for the task without prior 
separation steps to provide pre-concentration or the required selectivity. The methods used 
for treating biological samples prior to their introduction into chromatographic systems 
generally fall into one of two categories, extraction or direct injection. Three of the main 
techniques used in the bioanalytical field to separate drugs from very complex biological 
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fluids like blood, serum, plasma, urine etc., are: protein precipitation (PPT), liquid-liquid 
extraction (LLE) and solid phase extraction (SPE). 
 
2.3.3.1. Protein precipitation 
Drugs can be isolated from biological fluids like whole blood, serum and plasma by 
deproteination of the specific biological fluid before it is injected into the chromatographic 
system. Deproteination can be done by the addition of organic solvents like: acetonitrile, 
acetone, methanol etc., and ionic salts such as, ammonium sulphate, perchloric acid and 
trifluoracetic acid [38]. 
 
2.3.3.2. Liquid-liquid extraction 
Liquid-liquid extraction (LLE) is one of the oldest techniques for isolating desired 
components from a mixture. The principal used is to separate the mixture by using two 
immiscible solvents, an aqueous solvent or phase and an immiscible organic solvent or 
organic phase. The compound in the mixture are separated by their ability to partitioned in 
the two immiscible solvents. The compounds are distributed between the two phases in 
which one is immiscible to the other. The compound of choice can be selected from the 
mixture by creating the perfect partitioning environment, by choosing the proper potential of 
hydrogen (pH) and extraction solvent. The initial solvent needs to be a suitable solvent to 
dissolve the mixture, for example an aqueous matrix like plasma or serum, a second solvent 
is added that is immiscible with the first. The two solvents are thoroughly mixed and 
allowed to separate into layers. The components of the mixture will be distributed among the 
two layers as determined by their partition coefficient. The less dense solvent will be the 
upper layer, while the denser solvent will be the lower layer. The compounds in the mixture 
will separate between the two layers based on their solubility in that specific layer, the more 
soluble the more likely it is to reside in that layer. The compounds in each layer are isolated 
when the two immiscible layers are separated. If one of the layers is an aqueous layer, 
separation can be done by freezing. Most hydrophilic compounds are found in the more 
polar aqueous phase and the hydrophobic compounds in the organic phase. Compounds 
extracted into the organic phase are easily recovered by evaporation of the organic solvent, 
the residue can then be reconstituted in an appropriate solvent. The LLE technique is a very 
cost-effective extraction procedure compared to solid phase extraction (SLE) and generally a 
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cleaner extract than PPT [25]. 
 
2.3.3.3. Solid phase extraction 
Solid phase extraction (SPE) use a stationary sorbent or solid phase to retain the compound 
of choice from a mixture. SPE can be used to extract a compound from biological matrix as 
well as concentrate the sample. Different extraction sorbents can be used and knowledge of 
the mechanism of interaction between the compound and sorbent can be used to select the 
compound of choice from a complex mixture.  Understanding the chemical properties of the 
compound and sorbent, like polarity, hydrophobicity and solubility helps with retaining the 
selective compound. The most common retention mechanism in SPE are based on van der 
Waals forces (non-polar interactions), hydrogen bonding, dipole-dipole forces (polar 
interactions) and the cation-anion interactions (ionic interactions). Stationary sorbents are 
packed inside a cartridge or column and is available in different chemistries, this include 
reverse phase, normal phase and ion exchange. Sample is normally loaded onto the 
stationary phase and either vacuum of positive pressure is used to force the sample through 
the cartridge [39].  
SPE extraction generally follows the following protocol: Pre-treatment of sample, 
conditioning of the cartridge, loading of the sample, washing the cartridge and then an 
elution step. 
1. The pre-treatment of the sample includes steps to avoid blocking of the cartridge 
and better absorption of the compound to the stationary phase, this include 
dilutions, pH adjustment, deprotonation and centrifugation.  
2. Conditioning of the cartridge is very important and this allows the sample solvent 
to penetrate the pores of the stationary phase and interact with the compound. In 
reverse phase SPE solvents such as methanol, acetonitrile, isopropyl alcohol or 
tetrahydrofuran is used and in normal phase solutions like hexane, ethers or 
chloroform. 
3. The loading step involves loading the pre-treated sample onto the conditioned 
cartridge for the compound to be retained on the stationary sorbent.  
3.1 In reverse phase sorbents, hydrophobic interactions are used to retain the 
compound and involve a polar sample matrix and a non-polar stationary 
phase. Retention occurs via non-polar interactions between the analyte and the 
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sorbent functional groups, due to Van der Waals or dispersion forces. When 
an analyte is in its neutral form, it becomes more hydrophobic and retention 
strengthens. Therefore, in general, acidic compounds are best retained at a pH 
value at least 2 pH units below the compound’s acidic dissociation constant 
(pKa) value, and basic compounds are best retained at 2 pH units above the 
compound’s pKa value. 
3.2 In normal phase sorbents, hydrophilic interactions are used to retain the 
compound and involve a polar analyte, a mid to non-polar matrix and a polar 
stationary phase. Retention of analyte is primary due to interactions between 
polar functional groups off the analyte and polar groups on the sorbent surface 
due to hydrogen bonding and dipole-dipole, induced dipole-dipole and pi-pi 
forces.  
3.3 In ion exchange, the electrostatic attraction of charged groups on the 
compound and the charged groups on the sorbent’s surface are used to retain 
the compound. Anionic (negatively charged) compounds can be isolated on an 
aliphatic quaternary amine group that is bonded to the silica surface and 
cationic compounds are isolated by using the silica with aliphatic sulfonic acid 
groups that are bonded to the silica surface. 
4. The washing step is the cleaning step, as the compound is retained, the SPE 
column can be washed with solutions and solvents that do not disrupt these 
interactions and therefore flush the sample of complex matrixes like proteins and 
salts.  
5. The elution step is used to elute the retained compound from the stationary sorbent 
or cartridge, a solvent or solution is used that would disrupt the interactions 
between the stationary sorbent and the compound. The eluted fraction then 
contains the analyte of choice and can be used as is or further concentred by 
evaporation and reconstitution steps [25]. 
2.3.4. Matrix effect 
 
Variability of instrument response due to the differences in the physiological state of 
matrices is called the matrix effect. Especially with LC-MS/MS based procedures and 
methods, appropriate steps should be taken to minimise the matrix effect. In general, cleaner 
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samples, changes to the chromatography or the use of deuterated internal standards are 
recommended to minimise the matrix effect. Matrix effect should always be tested if the 
nature of the matrix changes from that used during initial method validation [26]. 
 
2.3.5. Robustness of the method 
 
During the early stages of method development, the robustness of methods should be 
evaluated.  Robustness of a method is very important and measures the capability of the 
method to remain unaffected under different conditions, such testing should be performed 
during development of the analytical procedure. This is particularly important when 
methods are transferred between facilities, the method executed by different analysts or a 
significant time lapse between periods of operation occur [29, 40]. The analytical procedure 
should be described and documented in a standard operating procedure (SOP), this will 
allow for the procedure to be reproduced within set acceptance criteria [30]. 
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3. METHOD VALIDATION 
Selective and sensitive analytical methods for the quantitative evaluation of drugs and their 
metabolites (analytes) are critical for the successful conduct of preclinical and/or 
biopharmaceutics and clinical pharmacology studies [41, 42]. “Bioanalytical method 
validation includes all of the procedures that demonstrate that a particular method used for 
quantitative measurement of analytes in a given biological matrix, such as blood, plasma, 
serum, or urine, is reliable and reproducible for the intended use” [32]. The fundamental 
tests that need to be included in validating a method include selectivity (specificity), 
accuracy, precision, recovery, calibration / standard curve reproducibility, stability and 
ruggedness [40, 43]. Validation involves the documentation of all procedures and measuring 
it against a set of acceptance criteria, this process continues to evolve. Today more statistical 
considerations are given to the reliability and suitability of a method and set guidelines are 
used [44, 45]. The acceptability of analytical data today corresponds directly to the criteria 
set in the guidelines used to validate the method [28, 46]. 
 
3.1. Parameters for the validation process 
3.1.1. Selectivity (specificity) 
 
Selectivity is the ability of an analytical method to select the compound of choice from a 
complex mixture of components. Blanks from the appropriate matrix (plasma, urine, or 
other matrix) should be obtained from at least six different sources. Selectivity is then 
proven in each individual matrix at the lower limit of quantification (LLOQ). The method 
should be free from interferences due to endogenous matrix compounds, metabolites, 
concomitant medication or decomposition products. This should be tested for each analyte 




The accuracy of an analytical method describes the difference between a test results 
obtained by the method to the true value. Accuracy is determined by replicate analysis of 
samples containing known amounts of the analyte, normally this is determined by the 
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quality control standards. Accuracy should be measured using a minimum of five 
determinations per concentration level, at three concentrations levels representing the 
expected concentrations range. The mean value should be within 15% of the actual value 
except at LLOQ, where it should not deviate by more than 20%. The deviation of the mean 




The precision of an analytical method describes the ability to reproduce the same result 
when the procedure is applied repeatedly to multiple aliquots of a single sample.  Precision 
should be measured using at least five determinations per concentration level. A minimum 
of three concentrations levels representing the expected concentrations range [29]. The 
precision determined at each concentration level should not exceed 15% of the coefficient of 
variation (CV) except for the LLOQ, where it should not exceed 20%. Precision should also 
be assessed during a single analytical run (intra batch), and between-runs (inter batch), 
which measures precision over time and may involve different analysts, equipment, 




The recovery is the comparison of the amount analyte recovered during an extraction by 
comparing the response of an extracted sample to the response of an un-extracted sample at 
the same concentration level. Thus, recovery could also be called the extraction efficiency of 
an analytical method and is expressed as a percentage. Recovery of the analyte need not be 
100%, but more important is that the recovery is consistent, precise and reproducible for 
both analyte and ISTD at all concentration levels. Recovery experiments are performed at 
three concentrations (low, medium, and high) [45]. 
3.1.5. Calibration / Standard Curve 
A calibration or standard curve is constructed from a set of calibrations standards, samples 
of known concentrations of the analyte, that span the entire concentration range. According 
to the FDA guidelines at least 6 non-zero calibrators should be used and be prepared in the 
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same matrix as the intended samples they will be used for. Concentrations of standards 
should be chosen based on the concentration range expected in a particular study and this 
should be generated separately for each analyte in the sample. A calibration curve should 
consist of a double blank sample (matrix sample processed without ISTD), a blank sample 
(matrix sample processed with ISTD), and six to eight non-zero samples covering the 
expected range, including LLOQ” [29]. 
 
3.1.5.1. Lower Limit of Quantification 
The lower limit of quantification is the lowest standard being used to construct a calibration 
curve and should meet at least the following conditions:  
 The analyte response or peak height at the LLOQ should be at least 5 times higher 
than the noise around the peak.  
 Analyte peak (response) should be reproducible with a precision of 20% and 
accuracy of 80–120%.  
 
3.1.5.2. Calibration Curve / Standard Curve / Concentration-Response 
The simplest regression model that fits the concentration-response relationship should be 
used. Selection of weighting and use of a complex regression equation must be justified. The 
following conditions should be met in developing a calibration curve: 
 Within 20% deviation of the LLOQ from nominal concentration 
 Within 15% deviation of standards other than LLOQ from nominal concentration  
At least four out of six non-zero standards should meet the above criteria, including the 
LLOQ and the calibration standard at the highest concentration. Excluding some of the 




Stability of the drug must be tested in the solutions used for the initial stock preparation and 
working solutions, as well as in the intended matrix, for short and long-term storage 
conditions.  Conditions used in stability experiments should reflect situations likely to be 
encountered during actual sample handling and analysis.  Stability procedures should also 
evaluate the stability of the analyte in the intended matrix during sample collection (whole 
Development and validation of selective and sensitive LC-MS/MS methods for the determination of para-Aminosalicylic Acid and 




Page 43  
blood stability), long-term storage (frozen at the intended storage temperature) and short-
term for handling and extraction (bench top, room temperature and freeze thaw stability).  
All stability determinations should use a set of samples prepared from a freshly made stock 
solution of the analyte in the appropriate analyte-free, interference-free biological matrix. 
Stock solutions of the analyte for stability evaluation should be prepared in an appropriate 
solvent at known concentrations [29, 30].  
 
3.1.6.1. Stock Solution Stability 
Stock solutions of the drug and ISTD should be evaluated in the appropriate solutions and for 
the period that at least covers the intended time of use. After completion of the desired 
storage time, the stability should be tested by comparing the stored solution with a freshly 
prepared solution at the same concentration [29]. 
 
3.1.6.2. Short Term Stability 
High and low concentrations of the analyte, in the intended matrix, should be tested at room 
temperature after being kept at this temperature for a selected period of time, normally 
between 4 and 24 hours. This time period should cover at least the time it takes to extract the 
batch for analysis [29]. 
 
3.1.6.3. Freeze-Thaw Stability 
Analyte stability should be determined after three freeze-thaw cycles. High and low 
concentrations of the analyte should be stored at the intended storage temperature for at least 
24 hours and then thawed completely for the first cycle. The sample is then refrozen for 12 
to 24 hours. The freeze-thaw cycle should be repeated two more times, then analysed after 
the third cycle [45]. 
 
3.1.6.4. Long Term Matrix Stability 
The long-term stability is tested in the intended matrix and the intended temperature for a 
selected period of time. The duration of the long-term stability should cover the time from 
collection of the samples until it is being analysed. Long term stability is done at high and 
low concentrations with at least 3 replicates at each concentration from 3 different stored 
aliquots. The concentrations of all the stability samples should be compared to nominal 
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values for the standards at the appropriate concentrations [45]. 
 
3.1.6.5. Post Preparative Stability 
The stability of the processed samples should be determined in the injection solution. This is 
tested during the autosampler stability and reinjection stability test. This will determine the 
total batch run time and ultimately the batch size. In the FDA guidelines comparing post 
preparative samples with freshly prepared samples is proposed, but statistical approaches 
based on confidence limits for evaluation of an analyte’s stability in a biological matrix can 
be used. This should clearly be stated and described in the standard operating procedures 
(SOPs) [29, 30]. 
 
3.2. Validation Process 
3.2.1. Bioanalytical Method Validation for Biological Matrix 
 
The fundamental parameters to ensure the acceptability of the performance of a 
bioanalytical method validation include accuracy, precision, selectivity, sensitivity, 
reproducibility, and stability [41, 46]. 
The bioanalytical method should be well documented, in the form of a protocol, study plan, 
report or SOP. Each step in the method process should be investigated to determine the 
extent to which environmental, matrix, material, or procedural variables have on the 
quantification of analyte in the matrix from collection of the sample up to the time of 
analysis [32].  
The same biological matrix that will be used for the test samples should be used for 
validating the method. The accuracy, precision, reproducibility, response function, and 
selectivity of the method for the analyte in the presence of endogenous substances, 
metabolites, and known degradation products should be established for the analyte in this 
matrix. It is important to consider the potential variability of quantitation in the matrix due 
to the physiological nature of the sample. With LC-MS/MS-based procedures, appropriate 
steps should be taken to ensure the absence of matrix effects, especially if the matrix differs 
from that used during method validation [32]. 
A bioanalytical method should be validated for its intended use or application. All 
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experiments supporting the conclusions about the validity of the method should be described 
in the method validation report. 
For selectivity, there should be evidence that the substance being quantified is the intended 
analyte. The stability of the analyte and its metabolites in the intended matrix during the 
collection process and the sample storage period should be assessed during the validation. 
For additional matrix stability testing, the stability of the analyte in the matrix from dosed 
subjects should be tested [29, 45]. 
“The concentration range over which the analyte will be determined should be defined in the 
bioanalytical method, based on evaluation of actual standard samples over the range, 
including their statistical variation. This defines the standard calibration curve. 
In consideration of high throughput analyses, including but not limited to multiplexing, 
multicolumn, and parallel systems, sufficient quality control (QC) samples should be used to 
assess variability of the assay. The number of QC samples required for validation is 
determined by the run size which are interspersed in a predetermined manner in each batch 
to avoid bias” [29].  
With the drive towards better quality method validations, guidance and acceptance criteria 
set out by the FDA and EMEA guideline are the standards most modern laboratories work 
towards  [28, 29, 30].  
 
3.2.1.1. Specific Recommendations for Method Validation 
 
The number of standards used should be a function of the dynamic range. The larger the 
range the more standards should be included. A minimum of six non-zero standards is the 
acceptance criteria. Additional standard concentrations may be required for standard curves 
that are non-linear. 
The standard curve should cover the entire range of expected concentrations. Enough 
standards should be used to adequately define the relationship between concentration and 
response. The relationship between response and concentration must be demonstrated to be 
continuous and reproducible. The ability to dilute samples to concentrations above that of 
the original upper limit of the standard curve should be demonstrated by accuracy and 
precision parameters in the validation. Standard curve fitting is determined by applying the 
simplest model that adequately describes the concentration-response relationship using 
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appropriate weighting and statistical tests for most appropriate fit. Reported method 
validation data should include all outliers. Calculations of accuracy and precision may 
exclude values that are statistically determined as outliers, but all outliers should be reported 
in the final data [46]. 
LLOQ is the lowest concentration of the standard curve that can be measured with 
acceptable accuracy and precision. The LLOQ should be established using at least five 
samples, independent of standards, and determining the coefficient of variation and/or the 
appropriate confidence interval. The LLOQ should not be confused with the limit of 
detection and/or the low QC sample. The highest standard that can be measured with 
acceptable accuracy and precision defines the upper limit of quantification (ULOQ) of an 
analytical method. 
For validation of the bioanalytical method, accuracy and precision should be determined 
using a minimum of five determinations per concentration level (excluding blank samples). 
The mean value should be within 15% of the theoretical value, except at LLOQ, where it 
should not deviate by more than 20%. The precision around the mean value should not 
exceed 15% of the CV, except for LLOQ, where it should not exceed 20% of the CV. Other 
methods of assessing accuracy and precision that meet these limits may be acceptable [30, 
32]. 
The accuracy and precision, with which known concentrations of analyte in biological 
matrix can be determined, should be demonstrated. This can be accomplished by analysis of 
replicate sets of analyte samples of known concentrations, such as QC samples from an 
equivalent biological matrix. At a minimum, three concentrations representing the entire 
range of the standard curve should be studied: one within 3x the lower limit of 
quantification (LLOQ) (low QC sample), one near the centre (middle QC), and one near the 
upper boundary of the standard curve (high QC) [42]. 
The stability of the analyte in its biological matrix at intended storage temperatures should 
be established. The influence of freeze-thaw cycles (a minimum of three cycles at two 
concentrations in triplicate) should be reported. The stability of the analyte in matrix at 
ambient temperature should be evaluated over a time period equal to the typical sample 
preparation, sample handling, and analytical run times. Reinjection reproducibility should be 
evaluated to determine if an analytical run could be reanalysed in the case of instrument 
failure [46]. 
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The specificity of the assay methodology should be established using a minimum of six 
independent sources of the same matrix. For hyphenated mass spectrometry-based methods, 
however, testing six independent matrices for interference may not be important. In the case 
of LC-MS and LC-MS/MS-based procedures, matrix effects should be investigated to 
ensure that precision, selectivity, and sensitivity will not be compromised. Method 
selectivity should be evaluated during method development and throughout method 
validation and can continue throughout application of the method to actual study samples 
[46].  
Acceptance / rejection criteria for spiked, matrix-based calibration standards and validation 
QC samples should be based on the nominal (theoretical) concentration of analytes. Specific 
criteria can be set up in advance and achieved for accuracy and precision over the range of 
the standards, if so desired [29, 30]. 
 
3.2.2. Preparation of calibration standards and quality control samples in 
biological fluids 
 
There are important factors to consider when calibration standards and quality control 
samples are prepared in biological fluids. The calibration standards and quality control 
samples should, where possible, be prepared in the same biological fluid as the intended use 
of that method, i.e. if the test samples are going to be analysed in plasma then the calibration 
standards and quality control samples should be prepared in plasma. The anticoagulant 
reagent used for the biological fluid should be the same [29].  
The correct calibration range is important, it should cover the concentrations found in the 
study samples.  To determine the correct range for a specific dose can be done practically by 
pooling small amounts of all the samples at a specific time point, and then analyse the 
profile and determine the maximum and minimum values in that profile, but this can only be 
done if samples are available and the analyte stability allows for such an experiment. 
Secondly if the samples are not available a thorough literature and clinical protocol review is 
important, to determine a calibration range for the specific dosing regimen.  
The storage of the calibration standards and quality control samples should also be 
considered and, where possible, be in the same container and at the same temperature as the 
samples to be analysed [29, 30]. 
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3.3. Performing validations 
Calibration standards and quality control samples prepared in the appropriate matrix are 
extracted and assayed according to a protocol, study plan, report, and/or SOPs. 
The calibration standards and quality controls are interspersed in a predetermined manner in 
each batch to avoid bias. After a batch is run, the chromatograms are inspected and the data 
evaluated against documented acceptance criteria. The calibration curves are plotted, 
regression equations determined, and the quality controls calculated as unknowns using the 
regression equation that had previously been selected, this would constitute a validation 
batch. For a full validation, three such validation batches should be run consecutively. Full 
validation batches are necessary when developing and implementing a bioanalytical method 
for the first time, for a new drug entity, and when metabolites are added to an existing assay 
for quantification. Partial validations are modifications of validated analytical methods that 
do not necessarily require full validations. Partial validations can range from as little as one 
inter assay accuracy and precision determination to a “nearly” full validation, typical 
changes that fall in this category, but are not limited to method transfer between 
laboratories, instrument and software changes, change in species matrix (e.g. rat plasma to 
mouse plasma), changes in matrix within a species (e.g. human plasma to human urine), rare 
matrixes and a change in the anti-coagulant. Another type of validation is a cross validation, 
which is performed to compare bioanalytical methods and is necessary when two or more 
methods are used to generate data within the same study [26].  
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4. METHOD DEVELOPMENT AND VALIDATION OF AN 
ANALYTICAL ASSAY METHOD FOR THE 
DETERMINATION OF PARA-AMINOSALICYLIC ACID 
IN HUMAN PLASMA 
 
4.1. Objective 
A sensitive and specific liquid chromatography-tandem mass spectrometry method was 
developed for the quantification of para-aminosalicylic acid (PAS) in human plasma. The 
objective was to develop a method to analyse clinical samples and contribute to the better 
understanding of the pharmacokinetics of PAS. 
 
4.2. Literature survey 
4.2.1. Clinical information 
 
PAS, also known as 4-aminosaliccylic acid, has been used as an anti-TB drug since 1946, 
and for nearly 15 years, starting in 1955, PAS was considered a first-line drug in a 
combination regimen with isoniazid and streptomycin [47].  Currently PAS is considered an 
oral bacteriostatic second line anti-TB drug used for MDR-TB [48, 49].  
PAS is a bacteriostatic drug against Mycobacterium tuberculosis which also inhibits the 
onset of bacterial resistance to streptomycin and isoniazid.  There are two mechanisms 
responsible for PAS's bacteriostatic action against Mycobacterium tuberculosis.  Firstly, 
PAS interfere with bacterial folic acid synthesis.   It binds to pteridine synthetase with 
greater affinity than para-aminobenzoic acid (PABA), effectively inhibiting the synthesis of 
folic acid [50]. As bacteria are unable to use external sources of folic acid, cell growth and 
multiplication slows. Secondly, PAS inhibits the synthesis of the cell wall component, 
mycobactin, thus reducing iron uptake by Mycobacterium tuberculosis [47, 51]. 
The minimum inhibitory concentration (MIC) of PAS for Mycobacterium tuberculosis is  
1 µg/ml. There are two major considerations in the clinical pharmacology of PAS. Firstly, 
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the prompt production of a toxic inactive metabolite under acidic conditions and secondly, 
the short serum half-life of one hour for the free drug, after 4–5 hours the plasma 
concentration of the drug is minimal, which justifies the need for doses of 10–12 g to 
maintain bacteriostatic activity. PAS is metabolised in the intestines and liver via acetylation 
into N-acetyl-para-aminosalycylic acid (AcPAS). More than 80% of the drug is excreted by 
the kidney through glomerular filtration and tubular secretion [47]. PAS acts preferentially 
on extracellular bacilli.  New delayed-release formulations produce higher PAS exposures, 
overcoming the rapid metabolism and clearance of early formulations. The drug can 
currently be administered in granules stored in 4 mg envelopes, replacing the former 500 mg 
capsules.  The delayed-release granules contain an acid-resistant coating to protect against 
degradation in the stomach; the granules are designed to escape the usual restriction on 
gastric emptying of large particles.  The coating dissolves promptly (within 1 minute) at the 
neutral pH found in the small intestine or in neutral foods. This granular slow-release form 
of PAS, also called para-aminosalicyclic acid delayed-release granules (PACER granules) 
has been available for nearly two decades and has been found to cause less intolerance by 
several studies in TB patients and healthy volunteers [52].  The use of PAS is limited by its 
toxicities ranging from gastrointestinal irritation, myxoedema, hypokalaemia, life 
threatening hypersensitive reactions and vitamin B12 deficiency [53].  PAS is readily 
absorbed from the gastro-intestine tract and the median time to peak serum / plasma 
concentrations is 6 hours following a single 4-g dose in healthy adults. The ingestion of 4 g 
of PAS granules lead to a maximum serum concentration of 20–60 µg/ml after 4–6 hours 
[47]. 
Co-administration of other TB drugs have a minimal effect on the pharmacokinetics of PAS 
in adults. However, co-administration of food delays the time to maximum concentration 
(Tmax).  High-fat food significantly increases the maximum drug concentration (Cmax) and 
area under the curve (AUC0-∞) by 1.5 and 1.7-fold, respectively, and extended the finite time 
taken for the drug to appear in systemic circulation (tlag). Concomitant dosing of orange 
juice and anti-acids has minimal effect on both rate and extent of drug absorption. The 
administration of PAS with appropriate food therefore, increases the time that plasma 
concentrations remain above the target concentration and should be taken with a high-fat 
meal whenever practical [54]. 
Co-administration of other drugs may impact the pharmacokinetics of PAS in adults. One 
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study compared PAS pharmacokinetics between HIV-uninfected and HIV-coinfected TB 
patients [52]. The study reported that PAS concentrations in HIV-infected patients was 
reduced and that the co-administration of Efavirenz (EFV) played a role in this deficit, a 
52% increase in PAS clearance was seen when co-administered with EFV. An overall 
reduction of approximately 30% PAS exposure should be expected in HIV-infected TB 
patients who are on concurrent EFV. When ARV therapy contains EFV, once-daily dosing 
up to 12 g PAS in these patients is not recommended. If maintenance of PAS concentrations 
above the MIC is desired a regimen of 4 g twice daily provides sufficient pharmacodynamic 
coverage of a probability of target attainment (PTA) above 90% over dosing interval, and a 
PTA of 100% is achieved with trice-daily regimen of 12g/day [52]. 
Resistance to PAS is associated with mutations of mycobacterial thyA, but this mechanism 
accounts for only 6% of phenotyping resistance [53]. 
 
4.2.2. Analytical information 
 
4.2.2.1. Chemical information  
4.2.2.1.1.  para-Aminosalicylic acid (PAS) 
Synonym: 4-Aminosalicylic acid 
Molecular formula: C7H7NO3 
Molecular weight: 153.14 
 
Figure 9. Chemical Structure of PAS 
 
4.2.2.1.2.  Rilmenidine 
Molecular formula: C10H16N2O 
Molecular weight: 180.25 
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Figure 10. Chemical Structure of Rilmenidine 
4.2.2.2. Analytical information 
An analytical method has been developed for PAS in urine [55]. It is used as the 
pharmacokinetic marker to determine the p-amino benzoic acid excretion index. The 
technique analyses urine samples on a fluorescence spectrometer. PAS is measured as 
ternary complexes with terbium and tri-n-ocylphosphine oxide in weakly acidic aqueous 
solutions. Sensitising of fluorescence of lanthanide ions, especially europium and terbium 
ions, by organic donors have been studied extensively in recent years, with the aim of 
developing spectrofluorometric methods for quantifying organic analytes. A limit of 
detection of 0.02 µmol/L, and a calibration range of 0–40 µmol/L was obtained for PAS in 
the urine samples. The main disadvantage of this method is interference from certain 
endogenous and extraneous compounds through severely overlapping spectra [55]. 
A capillary zone electrophoresis method has been developed for the determination of PAS 
and its metabolite AcPAS in urine [56]. A linear relationship is observed between time 
normalized peak area and the concentration of the analyte and metabolite with correlation 
coefficients greater than 0.9990. The method could be applied to measure PAS and its 
metabolite in urine without any sample pre-treatment. Good separation of the analytes can 
be achieved in a run of 12 minutes with an added 3 minutes for the capillary wash. The 
range and concentration of the standard concentration curves presented was 6.6–800 µg/ml 
for PAS and 70.0–4000 µg/ml for AcPAS [56]. 
An ion pair reagent reversed-phase high performance liquid chromatography method has 
been described to determine anti-tuberculosis drugs and their metabolites in biological fluids 
[57]. The method is based on the ion interaction reagents technique and uses a mobile phase 
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of 5 mM octylammonium o-phoshate with HPLC and a UV/VIS detector. The reported limit 
of detection for PAS was 68 µg/L.  The sample preparation made use of ultra-filtration and 
the assay ran in 25 minutes [57]. 
Another HPLC method presented describes the analysis of PAS and its metabolites in 
plasma and in cerebrospinal fluid (CSF) and brain tissue samples, using fluorescence 
detection [48]. The technique involves a one-step protein precipitation, with the sample 
fractionated on a reverse phase C18 column with a gradient mobile phase. The optimised 
method used gradient chromatography with 17.5 mM potassium phosphate buffer and 
methanol over a 25 minutes run time. The calibration range reported was 0.05–500 µg/ml in 
plasma, and 0.017–166.7 µg/g in a CSF and brain tissue samples. Studies on the freeze-thaw 
stability over 3 cycles, as well as long term stability over 2 weeks revealed no significant 
decrease in concentrations of both PAS and AcPAS [48]. 
A UPLC-MS/MS method has been described for the simultaneous analysis of nine second-
line anti-TB drugs to be used as a therapeutic drug monitoring (TDM) assay [58]. The 
method makes use of a 3M hydrochloric acid (HCl) acidified methanol extraction, 
neutralized by sodium hydroxide (NaOH). The samples were separated on a HSS T3 
(Waters, 50.0 x 2.1mm, 5µ) column using gradient chromatography with 10 mM 
Ammonium formate in 0.1% formic acid in water and 0.1% formic acid in acetonitrile. The 
run time was 3 minutes. The single ion reaction monitoring (SRM) transition used for PAS 
was m/z of 154.1 →119.0, with a calibration range of 5–100 µg/ml [58]. 
Liwa et al., described a HPLC-MS/MS method using an Agilent Zorbax column (150 x 
2.1mm, 5µm) with a gradient mobile phase of water and methanol both containing 0.1% 
formic acid [59]. The PAS concentrations were determined on a AB Sciex API 2000 tandem 
mass spectrometer equipped with an atmospheric turbo ion spray source. SRM transitions 
were used, with a m/z of 237.1→119.9 and 154.2→136.2 for PAS and ISTD (thiacetazone), 
respectively [59]. 
Pastorini et al., described a method for the determination of 5-aminosalicylic acid and its 
major metabolite N-acetyl-5-aminosalycylic acid in human plasma [60].  PAS was used as 
the ISTD. The method uses protein precipitation with methanol as extraction solvent.  The 
analytes were separated on a C18 column with a mobile phase consisting of 17.5 mmol/L 
acetic acid (pH 3.3) and acetonitrile (85:15, v/v) at a flow rate of 0.2 ml/min. Negative 
ionisation was used with a transition of m/z of 152 →108 for PAS [60]. 
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The analytical information is summarised and presented in Table 2. 
Table 2. PAS literature survey summary 
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4.3. Method development 
The literature and clinical protocol review revealed that a LC-MS/MS method was needed to 
cover a possible Cmax of up to 60 µg/ml and a LLOQ of at least 5 half-lives, therefore a 
calibration range of 0.391–100 µg/ml was chosen. LC-MS/MS was used, because it is more 
specific and sensitive than conventional HPLC using UV or fluorescence detection. Most 
conventional HPLC methods use mobile phases that contain high concentrations of non-
volatile buffer salts that are incompatible with LC-MS/MS methods. Based on the literature 
survey, most of the mobile phases used for LC-MS/MS analysis contained low 
concentrations formic acid, acetic acid or ammonium acetate and either methanol or 
acetonitrile as the organic solvent. A stock solution of PAS was prepared in methanol. From 
the prepared stock solution, three different diluted solutions were prepared for infusion, one 
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in methanol : water (50:50, v/v), the second in methanol : water : formic acid (50:49.9:0.1, 
v/v/v) and a third in methanol : water : ammonium hydroxide (50:49.9:0.1, v/v/v). Each 
were then infused separately into the mass spectrometer and the Q1 mass filter optimised for 
the best protonated ionisation response for the precursor ion with a m/z of 154.0.  The best 
ionisation response for the precursor ion was achieved with a mixture of methanol : water : 
formic acid (50:49.9: 0.1, v/v/v).  The protonated precursor ion was fragmented and the 
product ions optimised for a specific and sensitive MRM transition, the m/z of 154.1→80.2 
was monitored.  The product ion mass spectrum of PAS is presented in Figure 11.
 
Figure 11. Product ion mass spectrum of para-aminosalicylic acid (PAS) after collision 
induced dissociation in the fragmentation cell, showing the PAS precursor ion at m/z 154 as 
well as the product ions 
 
Chromatography development was started with a Phenomenex C18 (150 x 2.0 mm, 5µm) 
column, because this was the most commonly used column found in the literature.  An 
isocratic mobile phase of 0.1% formic acid in water and methanol (50:50, v/v) was used as 
the starting point, because of its good ionisation properties. Different ratios of this mobile 
phase were tested, but even with the best ratio between formic acid and methanol for good 
retention, good peak shapes could not be obtained. Possible solutions considered were to use 
a gradient mobile phase or to use different types of stationary phases with different 
selectivity. A range of columns was tested and the best chromatography, as well as good 
retention was obtained with a Phenomenex Synergi Hydro-RP (150 x 2.0 mm, 4µm) 
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column. Different concentrations of formic acid were tested in the mobile phase and the best 
sensitivity was obtained with a mobile phase containing 0.2% formic acid. In pure solutions, 
good linearity was obtained over the concentration range of 0.391–100 µg/ml. The next step 
was to develop an extraction method from human plasma.  Literature suggested protein 
precipitation as extraction method, and because methanol was used in the mobile phase, this 
was tested as the first protein precipitation reagent. This extraction method worked well over 
the concentration range, but an ISTD was needed to follow the analyte during extraction and 
the ionisation process. Normally, an isotopically labelled standard or analogue of the analyte 
are used as ISTDs, but were not available. Instead, different analytes with similar retention 
times and ionisation properties were evaluated as ISTDs for this assay. This method’s 
intended use was for clinical sample analysis, therefore TB drugs or anti-retrovirals were 
excluded. Different drugs were tested and rilmenidine was found to be the best ISTD.  The 
product ion mass spectrum of rilmenidine is presented in Figure 12. 
 
 
Figure 12. Product ion mass spectrum of the rilmenidine, ISTD, after collision induced 
dissociation in the fragmentation cell, showing the rilmenidine precursor ions at m/z 181 as 
well as the product ions 
The extraction method was optimised to include the ISTD and the final extraction method, 
HPLC conditions and MS/MS settings included in a SOP.  
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4.3.1. The final SOP extraction procedure 
 
An analytical batch is defined as follows: A single extraction procedure applied to a series of 
unknown samples, which must include a system performance verification (SYS) sample (of 
sufficient volume to inject at least six times) a minimum of eight calibration standards 
analysed in duplicate, three levels of quality controls analysed in duplicate, a blank and a 
double blank sample.  Calibration standards are spread throughout the run in order to capture 
instrument drift. Quality control samples are also spread over the run on order to control the 
analysis appropriately. Double blanks and blanks are run after the highest calibration 
standard, consecutively to ascertain the level of carryover for the batch.  
Extraction procedure: 
Thaw plasma samples, including calibration standards, quality control samples, blanks and 
unknown samples, are thawed at room temperature and vortexed briefly. 
Aliquot 20 µl plasma into 1.5 ml polypropylene micro-centrifuge tubes. 
Add 200 µl precipitation reagent containing the ISTD at 500 ng/ml to the samples (not more 
than 4 samples at a time). 
Vortex for 30 seconds and remember to extract the double blank with an aliquot of ISTD-
free acetonitrile. 
Centrifuge the samples at 16 000 rcf for 5 minutes. 
Transfer 150 µl of the supernatant into a 96-well plate and add 50 µl 0.2% formic acid in 
water. 
Inject 5 µl into LC-MS/MS instrument for PAS analysis. 
For dilutions: Only a 1:4 (sample : plasma, v:v) has been validated.  Dilutions are performed 
singly and the following procedure is followed:  
Pipette 20 µl of sample into a labelled polypropylene tube. 
Add 80 µl of blank plasma to this sample and vortex to mix. 
Pipette 50 µl of this mix into a clean labelled polypropylene microcentrifuge tube and 
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4.3.2. Final chromatography and mass spectrometry conditions 
 
The final HPLC and chromatographic conditions and MS/MS detector settings are presented 
in Tables 3-5.  








Phenomenex Synergi Hydro-RP (2.0 x 150 mm, 4µm) 
Column Temperature 
Room temperature (~24°C) 
Mobile Phase 
Methanol : 0.2% Formic acid (40:60, v/v) 
Pump Type  






96 well plate 
Injection Volume 
5 µl 
Autosampler Temperature 10 °C 
 
Table 4. Para-aminosalicylic acid (PAS) Electrospray Ionisation Settings  
Mass Spectrometer Identity API3000-1 
APCI/ESI ESI 
Parameter Value  
Nebuliser gas (Gas 1) (arbitrary unit) 
6 
Turbo gas (Gas 2) (arbitrary unit) 
8 
CUR (curtain gas) (arbitrary unit) 
6 
CAD (collision gas) (arbitrary unit) 
4 
TEM (Source Temperature) (°C) 
500 
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Protonated molecular ion mass (m/z) [M+H]+ 
154.1 181.2 
Product ion mass (m/z) Quantifier 
80.2 95.2 
Product ion mass (m/z) Qualifier 
136.2 67.0 
Dwell time (ms) 
150 150 
Declustering potential (V) 
30 31 
Focus potential (V) 
200 150 
Entrance potential (V) 
10 10 
Collision energy (eV) 
37 23 
Collision cell exit potential (V) 
4 6 
Scan Type MRM MRM 
Polarity Positive Positive 
Pause Time (ms) 5 5 
 
 
Pre-validation extractions of standards and controls in plasma showed good accuracy, 
precision and recoveries for PAS and the method was validated according to the FDA and 
EMA guidelines [30], [29]. 
 
4.4. Validation of the Assay Method 
4.4.1. Procedure 
 
Validation of an assay method is a process performed to objectively demonstrate and 
document the accuracy, precision, specificity, sensitivity and reproducibility of the assay 
method and the stability of the analyte for the purposes of assaying samples of unknown 
concentrations. 
To demonstrate acceptable within- and between-day accuracy and precision of the method 
over the desired concentration range, calibration standards and quality control samples were 
prepared and assayed in three consecutive runs. A full set of calibration standards and 
quality controls was prepared and stored frozen, and the required aliquots were thawed and 
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assayed in each run.  Each run consisted of all the calibration standards in duplicate to 
produce one calibration curve and six replicates of the prepared quality control samples.  A 
quality control spiked to a concentration above the upper limit of quantification was diluted 
(1:1 and 1:4) with blank plasma to validate the dilution of samples for which the 
concentrations potentially do not fall within the validated range. 
Standard curve fitting was determined by applying the simplest model that adequately 
describes the concentration-response relationship using appropriate weighting and statistical 
tests for goodness-of -fit. A calibration curve based on a well selected regression model 
must consist of at least six calibration levels covering the entire calibration range from the 
lower limit to the upper limit of quantification.  The regression model selected during the 
validation is used for the quantification of the study samples. In the case of a re-instatement 
(or partial) validation, the regression model that was used for the full validation must be 
used for the re-instatement validation. Table 6 summarises the regression and quantitation 
parameters used for PAS. 
Table 6. Para-aminosalicylic acid (PAS) quantitation parameters, ions monitored and 
retention times 
Software Analyst 1.5.2 
Algorithm Analyst Classic 
Calibration Fit Type  Quadratic 
Parameter Area 
Curve Weighting 1/x 
 PAS (4-Aminosalicylic Acid) 
Bunching factor 3 
Number of smoothes 3 
Precursor ion 154.1 
Product ion 80.2 
Retention Time (min) 2.4 
 Rilmenidine 
Bunching factor 2 
Number of smoothes 3 
Precursor ion 181.2 
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Product ion 95.2 
Retention Time (min) 1.6 
 
4.4.2. Calibration standard and quality control preparation 
 
4.4.2.1. Preparation of Stock Solutions of PAS and Rilmenidine 
Stock solutions (SS1, SS2) of PAS and (ISS1, ISS2) of rilmenidine were prepared by 
weighing a mass of the analyte or ISTD into a container and dissolving it in the desired 
volume of solvent.  The weighed mass of the analyte is also adjusted where applicable 
(purity, salt, etc.).  Stock solutions SS1 and SS2 (5000 µg/ml) and ISS1 and ISS2 (1000 
µg/ml) were prepared in methanol. All stock solutions were kept at ~ -80C until required. 
These stock solutions were prepared to spike blank biological matrix as required as 
presented in Tables 7–10. 
 
Table 7. Preparation of Para-aminosalicylic acid (PAS) stock solution (SS1) 
Solvent Volume Weighed Adjusted* SS1 
used Solvent mass of analyte mass of analyte concentration 
 
(ml) (mg) (mg) (µg/ml) 
Methanol 6.921 35.31 34.60 5000 
* Reason for Adjustment (e.g. purity, salt, hydrate): Purity 
* Calculation: 35.31 x 0.98 = 34.60 
Table 8. Preparation of Para-aminosalicylic acid (PAS) stock solution (SS2) 
Solvent Volume Weighed Adjusted* SS2 
used solvent mass of analyte mass of analyte concentration 
 
(ml) (mg) (mg) (µg/ml) 
Methanol 2.256 11.51 11.28 5000 
* Reason for Adjustment (e.g. purity, salt, hydrate): Purity 
* Calculation: 11.51 x 0.98 = 11.28 
Table 9. Preparation of Rilmenidine stock solutions (ISS1) 
Solvent Volume Weighed Adjusted* ISS1 
used solvent mass of analyte mass of analyte concentration 
 
(ml) (mg) (mg) (µg/ml) 
Methanol 2.133 3.28 2.13 1000.00 
* Reason for Adjustment (e.g. purity, salt, hydrate): Salt 
* Calculation: (3.28 x 180.25)/277.24 = 2.13 
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Table 10. Preparation of Rilmenidine stock solutions (ISS2) 
Solvent Volume Weighed Adjusted* ISS2 
used solvent mass of analyte mass of analyte concentration 
 
(ml) (mg) (mg) (µg/ml) 
Methanol 0.860 1.32 0.86 1000.00 
* Reason for Adjustment (e.g. purity, salt, hydrate): Salt 
* Calculation: (1.32 x 180.25)/277.24 = 0.86 
 
4.4.2.2. Preparation of Calibration Standards 
Calibration standards were prepared volumetrically in plasma (anticoagulant K3EDTA) at 
room temperature by spiking 100 µl of the analyte stock solution (SS1) into 4.90 ml of 
normal blank plasma (STD 1), which was then serially diluted with normal blank plasma to 
attain the desired concentrations of calibration standards (STD 2 - STD 9) as presented in 
Table 11.  Multiple 60 µl aliquots of each calibration standard are stored in individual 1.5 ml 
polypropylene tubes at approximately -80 °C to allow for duplicate 20 µl extractions from 
each tube. Stability has been shown at -80C for up to 2 weeks [48]. 
 
























STD 1 - 
ULOQ 
4.90 100     5.00 100 
STD 2 2.50   STD 1 2.50 5.00 50.0 
STD 3 2.50   STD 2 2.50 5.00 25.0 
STD 4 2.50   STD 3 2.50 5.00 12.5 
STD 5 2.50   STD 4 2.50 5.00 6.25 
STD 6 2.50   STD 5 2.50 5.00 3.13 
STD 7 2.50   STD 6 2.50 5.00 1.56 
STD 8 2.50   STD 7 2.50 5.00 0.781 
STD 9 -LLOQ 2.50   STD 8 2.50 5.00 0.391 
 
4.4.2.3. Preparation of Quality Control Samples 
Quality controls were prepared volumetrically in plasma (anticoagulant K3EDTA) at room 
temperature using the same methodology that was used for the calibration standards; spike 
160 µl of the analyte stock solution (SS2) into 4.84 ml of normal blank plasma to obtain QC 
Dilute.  This quality control is serially diluted with normal blank plasma to attain the desired 
concentrations (QC 1–6) as presented in Table 12. Multiple 60 µl aliquots of each quality 
control were stored in individual 1.5 ml polypropylene tubes at approximately -80 °C to 
Development and validation of selective and sensitive LC-MS/MS methods for the determination of para-Aminosalicylic Acid and 




Page 63  
allow for duplicate 20 µl extractions from each tube.  Stability has been previously been 
demonstrated at –80°C for up to 2 weeks [48]. 
 
Table 12. Preparation of quality control samples  
Standard  Blank Plasma Volume SS2 Dilution Source Dilution Source Total Volume PAS 
   volume (ml) spiked (µl)   Volume (ml) of dilution (ml) (µg/ml) 
QC Dilute  4.840  160     5.000 160 
QC 1  4.000    QC Dilute 4.00 8.00  80.0 
QC 2  4.000    QC 1 4.00 8.00  40.0 
QC 3  4.000    QC 2 2.00 6.00  13.3 
QC 4  4.000    QC 3 1.50 5.50  3.64 
QC 5  5.845    QC 4 1.60 7.45  0.781 
QC 6  2.000    QC 5 2.00 4.00  0.391 
Note:* The QC Dilute is used during a validation batch to quality control the dilution process. 
 
4.4.2.4. Preparation of ISTD Working Solution 
A stock solution (ISS1, 1000 µg/ml) of rilmenidine was prepared in methanol and multiple 
500 µl aliquots of ISS1 were stored in individual 1.5 ml polypropylene tubes and stored at 
approximately -80 °C. ISS1 was used to prepare the precipitation reagent (IWS1) in 
methanol when needed as represented in Table 13. 
A volume of 200 µl of this ISTD working solution (IWS1) was added to each sample 
(excluding double blank samples), as described in the assay procedure. 
Table 13. Working solution – Internal Standard (Rilmenidine) 
  Source Solvent Used Solvent Volume Volume Spiked Conc. Date Storage 
  Solution   (ml) (µl) (ng/ml) Prepared Temp. (°C) 
IWS1 ISS1 Methanol 20 5 250 20 May 2014 -20°C 
IWS1 ISS1 Methanol 20 5 250 26 May 2014 -20°C 
  
4.4.3. Validation Results 
 
Acceptance criteria: Accuracy is expressed as the concentration of analyte found as a 
percentage of the nominal concentration (% Accuracy) while precision is expressed as the 
coefficient of variation (% CV) seen in a batch of assays.   
The calculated calibration curve should fit the plot of measured responses vs. nominal 
concentrations of the calibration standards adequately, giving a r2 fit parameter of as close to 
one as possible. For a valid method, the within- and between-batch accuracy is required to 
be within 15 % (i.e. % Accuracy should be between 85–115%) over the entire calibration 
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range and within 20% of nominal concentration at the LLOQ.  For a valid method, the 
within- and between-batch precision is required to be less than 15 % (i.e. % CV should be 
less than 15 %) over the entire calibration range and less than 20 % at the LLOQ. Duplicate 
standards are analysed at each calibration point. Each one of these standards is used to 
define the calibration equation, unless one of those points does not meet the above criteria.  
In this instance, the invalid point would be excluded and only a single standard would be 
used at that level.  This allows for a single standard to fail at either the LLOQ or the ULOQ 
without effecting the resulting calibration range.  
4.4.3.1. Validation 1 (Day 1) 
Within-batch accuracy and precision are assessed by assaying all the calibration standards in 
duplicate, to produce one calibration curve, and 6 replicates of each quality control level in a 
single batch of assays. The regression equation used was Quadratic (weighted by 1/x 
concentration), f(x) = a + bx + cx2, as presented in Figure 13 and Table 14. 
 
Figure 13. Representative calibration curve for PAS - validation 1, day 1. 
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Table 14. Regression equation (weighted by 1/x concentration)  
Validation  Quadratic Calibration Curve Parameters 
Batch a B C r 
1 0.00281 0.0362 -1.11E-04 0.9997 
 
The within-batch accuracy and precision of the assay procedure are assessed by calculating 
the regression equation and constructing the calibration curve based on peak area ratios of 
analyte to ISTD, as presented in Table 15 and Table 16. 







Conc. Std Dev % CV % Accuracy N 
(µg/ml) (µg/ml) 
S9 0.391 0.381 0.00728 1.9 97.3 2 of 2 
S8 0.781 0.772 0.0458 5.9 98.9 2 of 2 
S7 1.56 1.61 0.176 10.9 103.1 2 of 2 
S6 3.13 3.22 0.159 4.9 102.9 2 of 2 
S5 6.25 6.25 0.126 2.0 99.9 2 of 2 
S4 12.5 12.2 0.199 1.6 97.7 2 of 2 
S3 25.0 24.8 0.747 3.0 99.1 2 of 2 
S2 50.0 50.8 1.85 3.6 101.5 2 of 2 
S1 100 100 0.0298 0.03 99.5 2 of 2 
 






Conc. Std Dev % CV % Accuracy N 
(µg/ml) (µg/ml) 
QC 6 0.391 0.434 0.0491 11.3 111.1 6 of 6 
QC 5 0.781 0.844 0.0456 5.4 108.1 *5 of 6 
QC 2 40.0 37.2 1.66 4.5 92.9 6 of 6 
QC 1 80.0 78.1 2.35 3.0 97.7 6 of 6 
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4.4.3.2.Validation 2 and 3 (Days 2 and 3) 
Between-batch accuracy and precision are assessed by assaying an additional two separate 
consecutive batches, each consisting of a double set of calibration standards designated for 
use in the assay of samples of unknown concentrations and 6 replicates of each of the 
quality control samples as presented in figures 14 – 15.  
 
 
Figure 14. Representative calibration curve for Para-aminosalicylic acid (PAS) - validation 
2, day 2. 
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Figure 15. Representative calibration curve for Para-aminosalicylic acid (PAS) - validation 
3, day 3.  
 
The regression equation was again applied (weighted by 1/x concentration), f(x) = a + bx + 
cx2, as presented in Tables 17 and 18. 
 
Table 17. Regression equation (weighted by 1/x concentration)  
Validation  Quadratic Calibration Curve Parameters 
Batch a B C r 
2 0.00431 0.0315 -8.2E-05 0.9997 
 
Table 18. Regression equation (weighted by 1/x concentration)  
Validation  Quadratic Calibration Curve Parameters 
Batch a B C r 
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The between-batch accuracy and precision of the assay procedure are assessed by 
constructing a calibration curve based on analyte/ISTD peak area ratios and calculating the 
regression equations as represented in Tables 19, 20, 21 and 22. 
 
Table 19. Summary of Para-aminosalicylic acid (PAS) calibration standards accuracy and 
precision - validation 2  
Sample ID 
Nominal Conc. Mean Observed Conc. 
Std Dev % CV % Accuracy N 
(µg/ml) (µg/ml) 
S9 0.391 0.366 0.0260 7.1 93.7 2 of 2 
S8 0.781 0.739 0.0157 2.1 94.6 2 of 2 
S7 1.56 1.60 0.00587 0.4 102.3 2 of 2 
S6 3.13 3.32 0.298 9.0 106.1 2 of 2 
S5 6.25 6.49 0.356 5.5 103.9 2 of 2 
S4 12.5 12.8 0.192 1.5 102.5 2 of 2 
S3 25.0 24.4 0.259 1.1 97.7 2 of 2 
S2 50.0 49.3 0.531 1.1 98.6 2 of 2 
S1 100 101 1.42 1.4 100.7 2 of 2 
 
Table 20. Summary of Para-aminosalicylic acid (PAS) intra-validation quality control samples - 
validation 2  
Sample ID 
Nominal Conc. Mean Observed Conc. 





QC 6 0.391 0.350 0.0192 5.5 89.5 6 of 6 
QC 5 0.781 0.841 0.0176 2.1 107.7 6 of 6 
QC 2 40.0 35.645 1.28 3.6 89.1 6 of 6 
QC 1 80.0 74.087 3.06 4.1 92.6 6 of 6 
 
Table 21. Para-aminosalicylic acid (PAS) calibration standards accuracy and precision -  
validation 3 
Sample ID 
Nominal Conc. Mean Observed Conc. 
Std Dev % CV % Accuracy N 
(µg/ml) (µg/ml) 
S9 0.391 0.345 0.0191 5.5 88.2 2 of 2 
S8 0.781 0.805 0.0730 9.1 103.1 2 of 2 
S7 1.56 1.64 0.0549 3.4 104.8 2 of 2 
S6 3.13 3.26 0.222 6.8 104.1 2 of 2 
S5 6.25 6.15 1.18 19.2 98.3 2 of 2 
S4 12.5 12.7 0.493 3.9 101.9 2 of 2 
S3 25.0 25.4 1.34 5.3 101.6 2 of 2 
S2 50.0 48.7 0.164 0.3 97.3 2 of 2 
S1 100 101 4.99 5.0 100.7 2 of 2 
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Table 22. Summary of Para-aminosalicylic acid (PAS) intra-validation quality control samples - 
validation 3 
Sample ID 
Nominal Conc. Mean Observed Conc. 
Std Dev % CV % Accuracy N 
(µg/ml) (µg/ml) 
QC 6 0.391 0.370 0.0401 10.8 94.6 6 of 6 
QC 5 0.78 0.855 0.0125 1.5 109.5 6 of 6 
QC 2 40.00 39.1 0.850 2.2 97.9 6 of 6 
QC 1 80.00 77.0 2.74 3.6 96.3 6 of 6 
 
4.4.3.3. Summary of the combined calibration standard and quality 
control results 
The overall accuracy and precision of the assay procedure is assessed by calculating the 
accuracy and precision statistics over the within- and between-batch validation batches (3 in 
total).  Accuracy is expressed as the concentration of the analyte found as a percentage of 
the nominal concentration (% Accuracy), while precision is expressed as the coefficient of 
variation (CV %). The combined regression, calibration standards and quality control results 
(all 3 validations) of PAS are summarised in tables 23, 24 and 25.   
 
Table 23. Overall Summary of calibration curve parameters - validation 1–3 
Validation  Quadratic Calibration Curve Parameters 
Batch a B C r 
1 0.00281 0.0362 -1.11E-04 0.9997 
2 0.00431 0.0315 -8.2E-05 0.9997 
3 0.00382 0.0296 -5.56E-05 0.9991 
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Conc. Std Dev % CV % Accuracy N 
(µg/ml) (µg/ml) 
S9 0.391 0.364 0.0219 6.0 93.1 6 of 6 
S8 0.781 0.772 0.0492 6.4 98.9 6 of 6 
S7 1.56 1.61 0.0843 5.2 103.4 6 of 6 
S6 3.13 3.27 0.186 5.7 104.3 6 of 6 
S5 6.25 6.29 0.58 9.2 100.7 6 of 6 
S4 12.5 12.6 0.386 3.1 100.7 6 of 6 
S3 25.0 24.9 0.82 3.3 99.5 6 of 6 
S2 50.0 49.6 1.296 2.6 99.2 6 of 6 
S1 100 100 2.40 2.4 100.3 6 of 6 
 






Conc. Std Dev % CV % Accuracy N 
(µg/ml) (µg/ml) 
QC 6 0.391 0.385 0.0516 13.4 98.4 18 of 18 
QC 5 0.781 0.847 0.0266 3.1 108.5 *17 of 18 
QC 2 40.0 37.3 1.918 5.1 93.3 18 of 18 
QC 1 80.0 76.4 3.11 4.1 95.5 18 of 18 
QC DIL 1:1 160 162 11.6 7.1 101.2 6 of 6 
QC DIL 1:4 160 156 8.7 5.6 97.3 6 of 6 
* = Outlier with MNR-ESD Outlier Test 
 
4.4.3.4.Calibration Range 
Results from the validation assays above indicate a valid calibration range of 0.391–100 
µg/ml for PAS.  The lower limit of quantification (LLOQ) was set at the concentration of 
the lowest validated standard for PAS, namely 0.391 µg/ml. 
 
4.4.3.5.Quantification Method 
The results show that the method provides sufficient accuracy and precision over the entire 
range based on analyte/ISTD peak area ratios with a quadratic calibration curve (weighted 
by 1/x concentration). 
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4.4.4. Stability assessment 
 
Various stability experiments were performed to ensure that the analyte concentrations were 
not affected by the assay procedure or associated conditions. The assay of study samples 
could be completed within the period for which the analyte is shown to be stable. 
 
4.4.4.1.Stock solution stability and accuracy 
Stock solutions SS1-4-aminosalicylic acid (prepared on the 14 May 2014) and ISS1-
rilmenidine (prepared on the 20 May 2014) were prepared in methanol and kept at -80°C.  
Test and control samples of these stock solution was left at room temperature, ~ 4°C and 
 ~ -20°C for 24 hours, respectively. Reference stock solutions, SS2-4-aminosalicylic acid 
(prepared on the 16 May 2014) and ISS2-rilmenidine (prepared on the 30 May 2014), were 
prepared after the storage period of the test and control samples. The reference, test and 
control samples were diluted with injection solvent to a concentration of 100 µg/ml and 
0.250 µg/ml, for the analyte and ISTD, respectively. These were analysed as per the method 
procedure. Peak areas of the test and control sample assays compared to the reference assays 
are presented in Tables 26 and 27, for the analyte and ISTD, respectively. Peak areas of the 
initial stock solution (kept at -80°C) and reference analyte stock solutions was compared for 
stability at -80°C and accuracy and are presented in Table 28. 
Table 26. Stock solution stability of Para-aminosalicylic acid (PAS)  
 
Reference Control (~- 20 ºC)  Control (~ 4 ºC)  Test (Room temp) 
Peak area 1 5540000 5960000 5920000 5680000 
Peak area 2 5530000 5410000 6340000 5420000 
Peak area 3 5500000 5720000 5460000 5520000 
Peak area 4 5610000 5760000 5450000 5420000 
Peak area 5 5420000 5370000 5390000 5450000 
Peak area 6 5280000 5180000 5110000 5400000 
Average 5480000 5566667 5611667 5481667 
STDEV 115758 292689 441697 105909 
% CV 2.1 5.3 7.9 1.9 
% Difference   1.6 2.4 0.03 
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Table 27. Stock solution stability of rilmenidine  
 
Reference Control (~- 20 ºC)  Control (~ 4 ºC)  Test (Room temp) 
Peak area 1 4290000 4090000 4090000 3990000 
Peak area 2 4130000 4070000 3910000 4040000 
Peak area 3 3940000 3990000 3910000 4090000 
Peak area 4 4130000 4060000 3880000 3920000 
Peak area 5 4070000 3920000 3810000 3780000 
Peak area 6 3700000 3580000 3490000 3700000 
Average 4043333 3951667 3848333 3920000 
STDEV 202550 192605 198436 152447 
% CV 5.0 4.9 5.2 3.9 
% Difference    -2.3 -4.8 -3.1 
 
Table 28. Stock solution accuracy of Para-aminosalicylic acid (PAS)   
 
Reference (SS1) Test (SS2) 
Peak area 1 3850000 3820000 
Peak area 2 3440000 3570000 
Peak area 3 3820000 3770000 
Peak area 4 3530000 3670000 
Peak area 5 3870000 3690000 
Peak area 6 3410000 3600000 
Average 3653333 3686667 
STDEV 216025 96056 
% CV 5.9 2.6 
% Difference   0.9 
Acceptance Criteria:  A high % CV (higher than 15%) of the measured values and a 
difference of more than 15 % from the reference solution could indicate instability in the 
stock/working solution. For accuracy, the % difference between two stock solutions should 
not be more than 5%. 
Conclusion:  From the peak areas tabulated above it can be concluded that PAS stock 
solutions prepared in methanol are stable for 24 hours stored at room temperature, ~ 4ºC and 
~ -20°C.  The initial stock solution kept at ~ – 80°C compared to the reference showed to be 
stable for 2 days and the % difference of 0.9 showed good accuracy. 
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4.4.4.2.Storage stability in matrix 
Samples for the long-term matrix stability assessment of PAS in human plasma have been 
prepared in-house on 21 May 2014 and was kept at ~ -80°C until 12 Mar 2016 when it was 
extracted and analysed.  The assessment should cover, at a minimum, the length of time 
from when the first sample was drawn during the clinical phase to the date of final sample 
analysis during the analytical phase of a study.  Long term matrix stability is presented in 
Table 29. 
Table 29. Long term matrix stability of Para-aminosalicylic acid (PAS) in plasma 
 
High Concentration Low Concentration 
 
Nominal conc. Observed conc. Nominal conc. Observed conc. 
 
(µg/ml) (µg/ml) (µg/ml) (µg/ml) 
Sample 1 80.0 66.3 0.781 0.738 
Sample 2   72.9   0.828 
Sample 3   79.1   0.766 
Sample 4   74.0   0.778 
Sample 5   71.8   0.792 
Sample 6   69.7   0.795 
 
Average 72.3 Average 0.783 
 
STDEV 4.3 STDEV 0.0303 
 
% CV  5.9 % CV  3.9 
 
% Difference  -9.6 % Difference  0.2 
 
Acceptance criteria:  A high % CV and a high % Difference (higher than 15%) of the 
measured values compared to nominal concentrations could indicate matrix instability. 
Discussion:  The % CV and % Difference for PAS are reported to be within 15% and 
therefore the long term matrix stability for PAS in plasma is indicated for at least 21 months. 
 
4.4.4.3. “Fresh” vs. “Frozen” stability 
In order to qualify the “fresh” vs. “frozen” effect, a fresh set of calibration standards were 
prepared in plasma and prior to aliquoting and freezing, tested against stored QC’s.  The 
fresh curve is used to quantify the QC’s. The calibration standards and quality control 
samples accuracy and precision are presented in Tables 30 and 31, respectively.  
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Table 30. Calibration standards accuracy and precision – “fresh” vs. “frozen” stability of Para-






Conc. Std Dev % CV % Accuracy N 
(µg/ml) (µg/ml) 
S9 0.391 0.354 0.00340 1.0 90.6 2 of 2 
S8 0.781 0.812 0.0182 2.2 104.0 2 of 2 
S7 1.56 1.50 0.0256 1.7 96.1 2 of 2 
S6 3.13 3.29 0.0517 1.6 105.1 2 of 2 
S5 6.25 6.55 0.292 4.5 104.8 2 of 2 
S4 12.5 12.7 0.746 5.9 101.4 2 of 2 
S3 25.0 24.9 0.957 3.8 99.5 2 of 2 
S2 50.0 49.0 0.0729 0.1 97.9 2 of 2 
S1 100 101 2.45 2.4 100.7 2 of 2 
 
Table 31. Quality control samples accuracy and precision – “Fresh” vs. “Frozen” stability of Para-






Conc. Std Dev % CV % Accuracy n 
(µg/ml) (µg/ml) 
QC 6 0.391 0.419 0.0232 5.5 107.1 6 of 6 
QC 5 0.78 0.854 0.0503 5.9 109.3 6 of 6 
QC 2 40.00 37.2 1.03 2.8 93.0 6 of 6 
QC 1 80.00 73.8 5.10 6.9 92.3 6 of 6 
 
 
Acceptance criteria:  The normal acceptance criteria for quality controls apply.  The 
accuracy is required to be within 15% (i.e. % Accuracy should be between 85–115%) and 
the precision is required to be < 15% (i.e.CV % should be < 15%). 
Discussion: The % CV and % Accuracy for the analyte are reported to be within 15%, 
which indicates that sample freezing does not influence the accuracy and precision of the 
assay.  It also indicates that the analyte is stable for at least 8 days when stored at ~ -80 °C. 
 
4.4.4.4. Freeze-thaw stability 
The freeze and thaw stability evaluation should mimic the intended sample handling 
conditions to be used during sample analysis. To ascertain freeze-thaw stability, low and 
high quality controls were frozen at ~ - 80ºC, and put through three consecutive freeze-thaw 
cycles. Sample aliquots were prepared and frozen for at least 24 hours prior to starting this 
experiment.  Each cycle consisted of sufficient thawing time at room temperature followed 
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by 12–24 hours freezing time.  These samples were analysed against a valid calibration 
curve and compared to controls from the batch, analysed at the same concentration.  The 
measured concentrations and calculated differences after three cycles for the two sets of 
quality control samples are presented in Table 32. 
Table 32. Freeze and thaw stability of Para-aminosalicylic acid (PAS)  
 
High Concentration  Low Concentration  
 
Observed Q1 Mean Observed F/T High Observed Q5 Mean Observed F/T Low 
 
(µg/ml) (µg/ml) (µg/ml) (µg/ml) 
Sample 1 74.1 74.4 0.841 0.772 
Sample 2   73.5   0.790 
Sample 3   71.5   0.846 
Sample 4   73.1   0.832 
Sample 5   79.7   0.797 
Sample 6   81.5   0.885 
 
Average 75.6 Average 0.820 
 
STDEV 4.01 STDEV 0.0419 
 
% CV 5.3 % CV 5.1 
 
% Difference 2.0 % Difference -2.5 
 
Acceptance criteria:  A high % CV and high % Difference (higher than 15 %) of the 
measured values could indicate freeze-thaw instability. 
Conclusion:  The % CV and % Difference for the analyte are reported to be within 15% 
which indicates that the analyte is stable in plasma for at least three freeze-thaw cycles. 
4.4.4.5. Benchtop stability 
To ascertain benchtop stability, low and high quality control samples were frozen at ~ -80ºC, 
and subsequently left on the bench for approximately 21 hours (maximum anticipated time 
that future study samples will be left thawed until extracted). Samples were removed on  
27 May 2014 at 12H00 and extracted on 28 May 2014 at 09H00.  These samples were 
analysed against a valid calibration curve. The measured concentrations and calculated 
accuracies for the two sets of quality control samples are presented in Table 33. 
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Table 33. On bench stability of Para-aminosalicylic acid (PAS)   
 
High Concentration  Low Concentration 
 Observed Q1 Mean Observed BT High Observed Q5 Mean Observed BT Low 
 (µg/ml) (µg/ml) (µg/ml) (µg/ml) 
Sample 1 74.1 76.0 0.841 0.843 
Sample 2   78.2   0.840 
Sample 3   74.2   0.814 
Sample 4   81.3   0.760 
Sample 5   76.7   0.912 
Sample 6   84.3   0.918 
 
Average 78.9 Average 0.849 
 
STDEV 3.95 STDEV 0.0670 
 
% CV 5.0 % CV 7.9 
 
% Difference 6.5 % Difference 0.9 
 
Acceptance criteria:  A high % CV and a high % Difference (higher than 15%) of the 
measured values could indicate on-bench instability. 
Conclusion:  The % CV and % Difference for PAS are reported to be within 15%. On-bench 
stability for PAS in plasma is indicated for at least 21 hours. 
4.4.4.6. Reinjection Reproducibility 
Reinjection reproducibility should be evaluated to determine if an analytical run can be 
reanalysed by reinjection in the case of instrument interruptions.  Following the injection of 
the first validation run (Validation 1), the extracted samples (96-well plate) remain in the 
autosampler at the method defined temperature. The extracts were reinjected following the 
injection of the second validation run (Validation 2) and third validation run (Validation 3). 
This provides evidence of reinjection reproducibility as presented in Tables 34–37. 
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Table 34. Calibration standards accuracy and precision – validation 1 reinjection 1  
Sample ID 
Nominal Conc. Mean Observed Conc. 
Std Dev % CV % Accuracy N 
(µg/ml) (µg/ml) 
S9 0.391 0.384 0.0234 6.1 98.3 2 of 2 
S8 0.781 0.719 0.00821 1.1 92.1 2 of 2 
S7 1.56 1.63 0.0830 5.1 104.3 2 of 2 
S6 3.13 3.22 0.182 5.6 103.0 2 of 2 
S5 6.25 6.35 0.129 2.0 101.7 2 of 2 
S4 12.5 12.8 0.386 3.0 102.3 2 of 2 
S3 25.0 25.0 0.167 0.7 99.9 2 of 2 
S2 50.0 48.9 1.46 3.0 97.8 2 of 2 
S1 100 101 1.33 1.3 100.8 2 of 2 
 
Table 35. Quality control samples accuracy and precision – validation 1, reinjection 1  
Sample ID 
Nominal Conc. Mean Observed Conc. 
Std Dev % CV % Accuracy N 
(µg/ml) (µg/ml) 
QC 6 0.391 0.396 0.0699 17.7 101.2 6 of 6 
QC 5 0.78 0.800 0.0566 7.1 102.4 6 of 6 
QC 2 40.00 38.9 1.38 3.5 97.3 6 of 6 
QC 1 80.00 80.4 4.02 5.0 100.5 6 of 6 
 






Conc. Std Dev % CV % Accuracy N 
(µg/ml) (µg/ml) 
S9 0.391 0.377 0.0397 10.5 96.5 2 of 2 
S8 0.781 0.752 0.01380 1.8 96.2 2 of 2 
S7 1.56 1.60 0.0611 3.8 102.4 2 of 2 
S6 3.13 3.19 0.067 2.1 101.9 2 of 2 
S5 6.25 6.41 0.162 2.5 102.6 2 of 2 
S4 12.5 12.8 0.323 2.5 102.5 2 of 2 
S3 25.0 24.6 0.440 1.8 98.3 2 of 2 
S2 50.0 49.6 0.30 0.6 99.1 2 of 2 
S1 100 100 1.38 1.4 100.4 2 of 2 
 






Conc. Std Dev % CV % Accuracy N 
(µg/ml) (µg/ml) 
QC 6 0.391 0.414 0.0381 9.2 105.8 6 of 6 
QC 5 0.78 0.831 0.0499 6.0 106.4 6 of 6 
QC 2 40.00 38.2 1.23 3.2 95.6 6 of 6 
QC 1 80.00 77.4 4.30 5.6 96.7 6 of 6 
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Acceptance criteria:  The normal acceptance criteria for quality controls apply. The 
accuracy is required to be within 15% (i.e. % Accuracy should be between 85–115%) and 
the precision is required to be < 15% (i.e. CV % should be < 15%). 
Conclusion:  The % CV and % Accuracy for the analyte is reported to be within 15% which 
indicates that a batch may be reinjected within 58 hours. 
4.4.4.7. Autosampler stability 
The high and low control standards that were extracted during the first validation batch 
(Validation 1), were reinjected after Validation 2 in Reinjection-Validation 1 and again after 
Validation 3 as Reinjection 2-Validation 1, having been kept in the autosampler throughout 
this period. The analytes/ISTD peak area ratios of the injections in Reinjection 1-Validation 
1 and Re-injection 2-Validation 1 were compared to the analytes/ISTD peak area ratios of 
the samples injected in Validation 1 to demonstrate autosampler stability.  The data is 
presented in Tables 38 and 39. 
Table 38. Autosampler stability for extracted samples - high concentration 
High Concentration (80.0 µg/ml) 
First Injection: 2014/05/27 16:11 PM 
Validation 1, Batch 
Start 
Peak area ISTD peak area Ratio 
QC 1 9580000 4360000 2.2 
QC 1 9760000 4450000 2.2 
QC 1 9500000 4390000 2.2 
QC 1 9020000 4280000 2.1 
QC 1 8990000 4290000 2.1 
QC 1 9020000 4240000 2.1 
Average 9311667 4335000 2.1 
STDEV 341199 78677 0.04 
% CV 3.7 1.8 2.0 
Time lapse from first sample injection: (2014/05/27 19:30 PM) ~3 hours 
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Validation 1 Re-
injection 
Peak area ISTD peak area Ratio 
QC 1 7970000 3480000 2.3 
QC 1 8330000 3530000 2.4 
QC 1 8080000 3520000 2.3 
QC 1 7740000 3530000 2.2 
QC 1 7830000 3550000 2.2 
QC 1 7690000 3590000 2.1 
Average 7940000 3533333.333 2.2 
STDEV 239666 36148 0.081 
% CV 3.0 1.0 3.6 
% Difference after Validation 1 Re-injection 4.7 
Time lapse from first sample injection: (2014/05/29 05:03 AM) ~ 32 hours 
    
Validation 3 Peak area ISTD peak area Ratio 
QC 1 5990000 2740000 2.2 
QC 1 6060000 2770000 2.2 
QC 1 6130000 2760000 2.2 
QC 1 5630000 2740000 2.1 
QC 1 5620000 2740000 2.1 
QC 1 5680000 2860000 2.0 
Average 5851667 2768333 2.1 
STDEV 233360 46655 0.10 
% CV 4.0 1.7 4.5 
% Difference after Validation 1 Re-injection 2 -1.5 
Time lapse from first sample injection: (2014/05/30 04:14 AM) ~ 55 hours 
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Table 39. Autosampler stability for extracted samples - low concentration  
Low Concentration (0.781 µg/ml) 
First Injection: 2014/05/27 16:23 PM 
Validation 1, Batch 
Start 
Peak area ISTD peak area Ratio 
QC 5 150000 4580000 0.0328 
QC 5 146000 4570000 0.0319 
QC 5 153000 4410000 0.0347 
QC 5 132000 4200000 0.0314 
QC 5 149000 4230000 0.0352 
QC 5 127000 4310000 0.0295 
Average 142833 4383333 0.0326 
STDEV 10685 165368 0.0021 
% CV 7.5 3.8 6.6 
Time lapse from first sample injection: (2014/05/27 19:42 PM) ~3 hours 
    
Validation 1 Re-
injection 
Peak area ISTD peak area Ratio 
QC 5 114000 3550000 0.0321 
QC 5 127000 3700000 0.0343 
QC 5 134000 3760000 0.0356 
QC 5 106000 3490000 0.0304 
QC 5 117000 3440000 0.0340 
QC 5 111000 3550000 0.0313 
Average 118167 3581667 0.0330 
STDEV 10458 123518 0.0020 
% CV 8.9 3.4 6.1 
% Difference after Validation 1 Re-injection 1.1 
Time lapse from first sample injection: (2014/05/29 05:16 AM) ~ 32 hours 
    
Validation 3 Peak area ISTD peak area Ratio 
QC 5 80900 2840000 0.0285 
QC 5 83700 2850000 0.0294 
QC 5 85300 2720000 0.0314 
QC 5 75800 2500000 0.0303 
QC 5 76200 2730000 0.0279 
QC 5 88600 2770000 0.0320 
Average 81750 2735000 0.0299 
STDEV 5104 127240 0.00161 
% CV 6.2 4.7 5.4 
% Difference after Validation 1 Re-injection 2 -8.2 
Time lapse from first sample injection: (2014/05/30 04:27 AM) ~ 55 hours 
Acceptance criteria:  A high % CV and a high % Difference (higher than 15%) of the 
measured values could indicate autosampler instability. 
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Conclusion:  The % CV and % Difference for the analyte concentrations are reported to be 
within 15 %.  On-instrument stability for the analyte was indicated for at least 55 hours. 
4.4.5. Specificity 
 
The very high specificity of the LC-MS/MS assay procedure precludes the detection of any 
compounds that do not possess the capability to produce the specific parent ion followed by 
formation of the specific product ion produced and monitored in the mass spectrometer. A 
representative chromatogram of STD 1 is presented in Figure 16. 
 
 




A double blank sample (without analyte and ISTD) was positioned in the injection sequence 
immediately after the highest calibration standard to assess possible carry-over effects.  A 
chromatogram of a double blank sample is presented in Figure 17. 
A blank sample (without analyte) was also included to determine the possible contamination 
of the analyte by the ISTD without an additional carry-over effect.  A chromatogram of a 
blank sample is presented in Figure 18. 
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Figure 17. Chromatogram of a double blank plasma sample 
 
 
Figure 18. Chromatogram of a blank plasma sample 
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Acceptance criteria:   
Double blank assessing carry-over:  A peak that is observed for the analyte should not be > 
20% of the area of the peak obtained at the LLOQ. A peak that is observed for the ISTD 
should not be > 5% of the peak observed for the ISTD at the working concentration. 
Blank assessing contribution:  A peak that is observed for the analyte when ISTD is present 
at the working concentration should not be > 20% of the area of the peak obtained at the 
LLOQ. 
Conclusion:  Small carry over peaks were observed but the peak areas was less than 20% of 




The LLOQ of this method is 0.391 µg /ml, representative chromatograms are presented in 
Figure 19 and the signal-to-noise chromatogram in Figure 20. 
 
Figure 19. Chromatogram of a lower limit of quantification (LLOQ) sample 
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Figure 20. Chromatogram of the S/N ratio of the lower limit of quantification (LLOQ) 
sample 
Acceptance criteria:  The mean analyte signal/noise response at LLOQ should be at least > 5 
times the response compared to blank response at the retention time of interest. 
Conclusion:  The raw LLOQ sample chromatograms showed acceptable intensities for the 




The extraction recovery pertains to the extraction efficiency of the analytical process within 
the limits of variability. It is determined by comparing the analytical response of blank 
matrix spiked with the analyte and extracted with the response of the blank matrix first 
extracted and then spiked with analyte (theoretical, represents 100% recovery).  No recovery 
of the ISTD is calculated. 
a. Extracted (test) samples: a minimum of six QCs at each concentration level (low, 
medium and high) are extracted as per the analytical method. 
b. Theoretical samples: samples are spiked at each concentration level (relative to the final 
concentration of the corresponding extracted QC’s level) in six-fold using extracted blank 
matrix. 
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The analyte peak areas found after extraction compared to the theoretical peak area 
expressed as a percentage recovery, the data is presented in Table 40. 
Table 40. Recovery for Para-aminosalicylic acid (PAS)   
 
High Concentration  
(100 µg/ml) 
Medium Concentration  
(50 µg/ml) 
Low Concentration  
(0.391 µg/ml) 
Precipitation:  




Precipitation:   









Sample 1 18600000 19500000 10900000 11200000 118000 121000 
Sample 2 18000000 18600000 11300000 10600000 119000 123000 
Sample 3 17600000 18300000 10900000 10800000 [266000]* 117000 
Sample 4 17100000 17600000 10400000 10400000 113000 102000 
Sample 5 16800000 16800000 10100000 10300000 120000 109000 
Sample 6 16600000 17600000 9750000 9300000 [258000]* 112000 
Average 17450000 18066667 10558333 10433333 117500 114000 
STDEV 763544 941630 578288 640833 3109 7899 
% CV 4.4 5.2 5.5 6.1 2.6 6.9 
% Recovery   96.6   101.2   103.1 
  
   
Average % Recovery 100.3 
 
Average % CV 3.3 
* = Outlier with MNR-ESD Outlier Test  
Acceptance Criteria:  The mean recovery of a quantitative drug assay should be consistent 
and the precision of the measured recovery, expressed as percentage coefficient of variation, 
should not exceed 15% for any particular concentration of the analyte at which it is 
determined.  Recovery reproducibility between concentration levels should not be > 15%. 
Conclusion:  The mean recovery of 4-aminosalicylic acid (PAS) from plasma over the 
calibration range is 100.3% with a %CV of 3.3. 
4.4.9. Matrix effect 
 
In biological chemical analysis, matrix refers to the components of a sample other than the 
analyte.  Matrix effects are of particular importance when dealing with LC-MS analyses, and 
may only become evident once novel clinical samples are analysed. The presence of co-
extracted matrix background components may impact analyte and ISTD ionization. 
Appropriate steps should be taken to minimize the influence of matrix components.  A 
matrix effect method was used that quantifies the effect across the calibration range of the 
assay [61]. 
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A minimum of eight different blank sources of the appropriate biological matrix and 
anticoagulant type was extracted.  Each individual matrix was spiked at low, medium and 
high concentration levels (taking into account any calculations for dilutions in the analytical 
method) and at one concentration of the ISTD. The results of the overall %CV’s of the 
slopes calculated, are presented in Table 41. 
Table 41. Para-aminosalicylic acid (PAS) / internal standard (ISTD) peak areas ratios  
 
High Conc.  Medium Conc.  Low Conc.  Area Ratio  
 
100  µg/ml 50.0 µg/ml 0.391 µg/ml v Conc.  
 
Peak Area Ratio Peak Area Ratio Peak Area Ratio Regression Slope 
K3EDTA 14/10/2011-01 4.0 2.2 0.0202 0.0399 
K3EDTA 14/10/2011-29 4.0 2.0 0.0218 0.0401 
K3EDTA 08/11/2013-05 3.9 2.0 0.0213 0.0390 
K3EDTA 07/12/2011-09 4.0 2.1 0.0208 0.0396 
K3EDTA 07/04/2014-50E 3.6 2.2 0.0226 0.0362 
K3EDTA 07/04/2014-46E 4.1 2.0 0.0223 0.0408 
K2EDTA 07/12/2011-10 3.9 2.1 0.0231 0.0390 
LiHep 923 SEP 2009 3.9 1.9 0.0222 0.0394 
Average 3.9 2.1 0.0218 0.0393 
STDEV 0.134 0.104 0.000978 0.00136 
% CV 3.4 5.0 4.5 3.5 
 
Acceptance criteria:  The peak area ratios of the analyte/ISTD for each level in each matrix 
source are used to generate regressions for each individual matrix.  The slope variability 
(%CV) for the 8 different matrix sources should not be > 5%. 
Conclusion:  The slope variability (%CV) for 8 different plasma samples was 3.5 for PAS, 
which indicates that matrix effects do not adversely influence the precision of the assay. 
 
4.4.10. Effect of Haemolysis 
 
The presence of haemolysed blood in samples could affect the ionization of the analyte and 
ISTD during analysis.  Evidence should be provided that haemolysis has no effect on analyte 
quantification.  If ionisation suppression is observed for the ISTD, and it is comparable to 
the extent of ionisation suppression observed for the analyte, the ISTD is regarded as 
providing sufficient compensation for the analyte.  Haemolysis was tested at 2% haemolysed 
blood in plasma.  
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The influence of haemolysed blood was assessed by the assay of 6 haemolysed samples at 
high and low PAS concentrations and compared to 6 normal human plasma samples 
prepared at the same high and low concentrations.   
The response ratios observed for PAS / ISTD in the haemolysed plasma samples were 
compared with the response ratios observed in the normal plasma samples.  The ability of 
the ISTD to provide sufficient compensation for PAS determination were assessed by 
comparing normal and haemolysed plasma response ratios at high and low concentrations as 
presented in Table 42. 
Table 42. Effect of 2% haemolysis on Para-aminosalicylic acid (PAS)  
  

















Sample 1 1.85 1.52 0.0224 0.0199 
Sample 2 1.54 1.54 0.0221 0.0172 
Sample 3 1.51 1.63 0.0200 0.0187 
Sample 4 1.68 1.37 0.0202 0.0206 
Sample 5 1.63 1.43 0.0230 0.0168 
Sample 6 1.52 1.60 0.0192 0.0196 
Average 1.62 1.52 0.0211 0.0188 
STDEV 0.130 0.101 0.00153 0.00152 




  -6.6   -11.1 
Acceptance criteria:  A high % Difference (higher than 15%) between the peak area ratios 
observed in haemolysed samples and normal samples and a high % CV (higher than 15%) 
indicates that haemolysis has an effect on the assay of the analyte and that the ISTD does not 
sufficiently compensate for the analyte.  
Conclusion:  The results reported above show that the % Difference are within 15 % for 




To determine if samples originally reported as above the upper limit of the standard curve 
(ALQ) may be diluted to within the calibration range with accuracy and precision, six extra 
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high QC samples were prepared at a concentration 2 times higher than the highest QC (160 
µg/ml) for PAS.  These were then diluted 1:1 and 1:4 with blank plasma.  The concentration 
was determined and compared with the nominal concentration to determine the percentage 
accuracy as represented in Table 43. 
Table 43. Sample Dilution  
Sample ID 
Nominal Conc. Mean Observed Conc. 
Std Dev % CV % Accuracy N 
(µg/ml) (µg/ml) 
QC DIL 1:1 160 162 11.6 7.1 101.2 6 of 6 
QC DIL 1:4 160 156 8.71 5.6 97.3 6 of 6 
 
Acceptance criteria:  The final mean calculated concentration (incorporating the dilution 
factor) is determined from the calibration curve and compared to the nominal concentration. 
The accuracy of the diluted samples is required to be within 15% (i.e. % Accuracy should be 
between 85–115%) and the precision is required to be less than 15% (i.e. CV% should be 
less than 15%). 
Conclusion: The resulted precision and accuracy fall within the accepted values. 
 
4.5. Discussion 
4.5.1. Validation data summary 
 
Accuracy and precision were assessed over three consecutive, independent runs and the 
calibration curve fits a quadratic (weighted by 1/x concentration) regression over the range 
0.391–100 µg/ml for PAS.  
A 1:1 and 1:4 dilution of the QC Dilution sample showed that concentrations of up to 160 
µg/ml of PAS in plasma could be analysed reliably when diluted into the calibration range. 
The method was specific for PAS, small carry over peaks were observed, but the peak areas 
were less than 20% of the LLOQ peak areas.  
Endogenous matrix components were found to have an insignificant effect on the 
reproducibility of the method when human plasma originating from eight different sources 
were analysed. Also, quantification of PAS in plasma was not significantly affected by the 
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presence of haemolysed blood (2%) or when Lithium Heparin was used as anti-coagulant 
instead of K3EDTA. 
PAS was found to be stable in human plasma for 21 months kept at ~ -80°C, for up to 21 
hours at room temperature and when subjected to 3 freeze-thaw cycles. Stock solutions of 
PAS are stable in methanol for 2 days when stored at ~ -80°C and for 24 hours stored at 
room temperature, ~ 4 ºC and ~ -20 ºC, respectively. PAS is shown to be stable 
on-instrument over a period of 55 hours.  Reinjection reproducibility experiments indicate 
that a batch may be re-injected within 58 hours.  In summary, the method is suited for the 
analysis of PAS in plasma.  
 
4.6. Clinical application of the method. 
This method was successfully used for the assay of samples in a clinical study.  
4.6.1.1. Summary of study protocol 
TITLE: PHARMACOKINETICS AND TOXICITY OF SECONDLINE 
ANTITUBERCULOSIS DRUGS IN HIV-INFECTED AND UNINFECTED CHILDREN 
NIH R01: 069169-01 
The project aims to improve the health of children with drug-resistant tuberculosis (DR-TB) 
in need of second-line anti-TB drugs, through examining the pharmacokinetics (PK), safety 
profile and toxicity of commonly used second-line anti-TB drugs in children, with and 
without HIV co-infection.  The specific aims were:  
1) to compare the PK of second-line anti-TB drugs in children (≤ 15 years) by age;  
2) to compare the plasma concentrations of anti-retroviral (ARV) drugs in HIV-infected 
children (≤ 15 years) on second-line anti-TB drugs to those not on anti-TB therapy; and  
3) to characterize the tolerability and toxicity of second-line anti-TB drugs in HIV-infected 
and uninfected children. 
 
Childhood TB represents 15–20% of the disease burden in settings where TB and HIV 
infection is prevalent. MDR-TB; i.e. TB resistance to both rifampin and isoniazid, is an 
emerging epidemic, with an estimated 489 000 global cases annually [13].  MDR-TB 
patients often experience prolonged diagnostic delay, resulting in transmission of these 
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strains especially to young children, with a sharp increase in the numbers of children on 
treatment and prophylaxis for MDR-TB. This hospital-based study was implemented in 
Cape Town, Western Cape Province, South Africa at 2 referral hospitals – Brooklyn 
Hospital for Chest Diseases and Tygerberg Children’s Hospital. The prevalence of MDR-TB 
amongst children with culture-confirmed TB was 8.6% and the prevalence of HIV infection 
in children with TB was 25-30% during 2009. The most frequently used second-line anti-TB 
drugs in children in this setting was ethionamide, fluoroquinolones, amikacin and terizidone. 
Capreomycin, linezolid and PAS were typically used for treatment of extensively drug-
resistant TB. Although second-line anti-TB drugs are routinely given and recommended in 
children, there is limited information available to inform the accurate dosing in young HIV-
infected children, who may have altered drug metabolism and unique drug-drug interactions. 
The literature provides limited data on toxicity of these anti-TB drugs in children, who are 
typically treated for 18–24 months for DR-TB.   
 
This study provides a longitudinal, hospital-based, observational PK observation of children 
aged 0–15 years who received routine chemotherapy or chemoprophylaxis for the treatment 
or prevention of DR-TB. Three hundred and eighteen children were enrolled for observation 
consecutively over 3.5 years, undergoing intensive PK sampling of second-line anti-TB 
drugs at baseline. The subjects were undertaking routine treatment for DR disease until 
treatment completion for clinical outcomes, including TB treatment response and drug 
adverse effects. 
Approximately 30% of the sample were co-infected with HIV. An equal number of HIV-
infected children with and without anti-TB therapy (concurrent controls; 42 on efavirenz and 
22 on lopinavir) were enrolled, based on the required age strata to allow for comparison of 
the effect of second-line TB drugs on ARV levels in HIV-infected children with and without 
TB treatment. HIV-infected children had ARV PK sampling done at baseline. Enrolment 
was balanced by HIV status and age to ensure adequate numbers of children 0–2 years of 
age and adequate numbers of HIV-infected children. 
The TB medication regimen was based on local and international recommendations for 
routine care. The PAS local and international dose recommendations for children with TB is 
150 mg/kg body weight up to a maximum of 1200 mg/day. This was therefore, not an 
interventional study. No new medications or new dosages were assessed. 
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4.6.1.2.Ethical approval of the study. 
The study was formally approved by the Faculty of Health Science Research Ethics 
Committee, see Appendix 2 for approval letter. 
 
4.6.1.3. Accuracy and Precision statistics of the study sample batches 
The method described in section 4.3 was applied to this study protocol. The method was 
accurate and precise, showing a coefficient of variation and bias within  
15% at all levels of quality controls analysed during 5 production batches of study samples, 
data presented in Table 44.  
Table 44. Summary of quality control data from 5 sample batches  
 High (80.0 µg/ml) Medium (40.0 µg/ml) Low (0.781 µg/ml) 
Mean % 
Accuracy 
95.0 102.2 102.0 
STDEV 6.05 5.76 6.73 
RSD (%) 6.4 5.6 6.6 
n 10/10 *9/10 10/10 
* = One outlier with MNR-ESD Outlier Test, excluded from table.  
The mean accuracy for the high, medium and low quality control concentrations were 




The calibration range of 0.391–100 µg/ml was appropriate for the quantification of PAS 
samples generated in this study, only 4% of the total number of sample (182) was below the 
limit of quantification and no sample was higher than the upper limit of the calibration 
range, the highest concentration found in this study was 59.6 µg/ml. 
 
4.6.1.5. Sensitivity 
The method was sensitive and the lower limit of quantification (LLOQ) of this method of 
0.391 µg/ml, enabled the determination of PAS concentrations over the total drug profile for 
at least 11 hours. With a half-live of 1 hour it was possible to follow the drug elimination for 
approximately 4 to 5 half-lives in the total 11 hour drug profile. 
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4.7. Drug levels measured in patient samples. 
The minimum inhibitory concentration (MIC) of PAS for Mycobacterium tuberculosis is  
1 µg/ml and two major considerations in the clinical pharmacology of PAS are: the prompt 
production of a toxic inactive metabolite under acid conditions and the short serum half-life 
of one hour for the free drug [47]. After 4–5 hours the plasma concentration of the drug is 
minimal, which justifies the need for doses of 10–12 g to maintain bacteriostatic activity. 
There was a high interpopulation variation for the Cmax of PAS in the study subjects, with 
the lowest at 5.14 µg/ml and the highest at 59.6 µg/ml and an average Cmax of 13.9 µg/ml. 
Even with this high variation a 1 µg/ml MIC was achieved in all the subjects. The Tmax also 
varied between 4 and 8 hours for most of the subjects as can be seen in the average 
concentration (standard deviation) versus time profile, as presented in Figure 21. 
 
 
Figure 21. Average concentration (standard deviation) vs time profile from 28 children 
receiving a 150 mg/kg body weight dose of Para-aminosalicylic acid (PAS)  
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4.8. Conclusion 
The developed LC–MS/MS method for PAS was successfully validated according to FDA 
guidance for industry (2001) and EMA guidelines on bioanalytical method development 
(2012) [29, 30]. The method was employed for quantitative determination of PAS 
concentrations in a clinical study following the oral administration of 150 mg/kg body 
weight dose of PAS in children with drug-resistant tuberculosis (DR-TB), in need of second-
line anti-TB drugs. The proposed method is affordable, reliable, simple, selective, rugged 
and reproducible. The method produced good peak shapes and low base line noise was 
observed. The mobile phase was optimised in simple isocratic mode, and one of the major 
advantages of this method is that only 20 µl of plasma is needed for analysis, which greatly 
facilitates the collection of blood samples in children. The method produced reliable data 
that contributed to the pharmacokinetics and understanding of PAS as a second line anti-TB 
drug. PK data generated with this assay will hopefully lead to better recommendations 
regarding dosing and duration of treatment needed to maximize efficacy with acceptable 
safety and tolerability for PAS as an oral bacteriostatic second line anti-TB drug in children. 
 
4.9. Publication in peer reviewed scientific journal 
An assay manuscript was submitted to the Analytical and Bioanalytical Chemistry on  
29 November 2017, and the submission letter are presented below and the manuscript is 





Manuscript No. ABC-02095-2017 
Title: Development, validation and application of a LC-MS/MS method to accurately 
quantify para-aminosalicylic acid in 20 µl human plasma 
Authors: Smit, Michiel; Wiesner, Lubbe; Castel, Sandra; Norman, Jenifer; Strydom, 
Natasha; Schaaf, Simon; Hesseling, Anneke 
 
Dear Mr. Smit, 
 
Thank you for the submission of your above-mentioned manuscript. Your manuscript has 
been received in the Analytical and Bioanalytical Chemistry Editorial Office and is in the 
process of being forwarded to the handling Editor. 
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Please be sure to mention the manuscript number in all future correspondence or when 
calling the office with questions.  If there are any corrections to your e-mail address or street 




Dr. Nicola Oberbeckmann-Winter 
 
Managing Editor 
Analytical and Bioanalytical Chemistry 
Springer 




www.springer.com/abc   
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5. METHOD DEVELOPMENT AND VALIDATION OF 
AN ASSAY METHOD FOR THE DETERMINATION 
OF CYCLOSERINE / TERIZIDONE IN HUMAN 
PLASMA 
5.1. Objective 
The objective was to develop a method for the analysis of cycloserine in human plasma that 
is sensitive and specific, and can be used to analyse samples generated in clinical studies 
after dosing with terizidone. Terizidone is not measurable in plasma, because it is 
hydrolysed completely into cycloserine pre-systemically [62]. 
The project aims to contribute to better understanding the pharmacokinetics and 
pharmacodynamics of cycloserine / terizidone as a second line anti-TB drug.  
 
5.2. Literature survey 
5.2.1. Clinical information 
 
A literature and clinical protocol review revealed a number of different techniques available 
for quantifying cycloserine. Cycloserine is produced by Streptomyces orchidaceous and was 
successfully synthesized in 1952 [47]. It is a structural analogue of D-alanine, an amino acid 
that is important to the formation of the bacterial cell wall. The mode of action of terizidone 
is similar to cycloserine and composes of two cycloserine molecules, which are linked with 
a phenyl ring. Cycloserine/terizidone acts by competition, inhibiting the enzymes D-alanyl-
D-alanine synthetase, alanine racemase, and alanine permease, which are indispensable for 
the synthesis of the peptidoglycan that confers rigidity and stability to the Mycobacterium 
tuberculosis cell membrane [53]. Although the mechanisms of Mycobacterium tuberculosis 
resistance to cycloserine have yet to be fully clarified, it is presumably due to genetic 
mutations in the aforementioned enzymes [63].  
Terizidone pharmacokinetic properties are poorly described in literature, mainly because it 
was development in the 1970’s when bioanalytical methods were limited. In these studies, 
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terizidone was not directly measured, but estimated, based on its active metabolite 
cycloserine, which was measured with colorimeter methods. It was not known if terizidone 
was systemically available [64]. The best marker for terizidone pharmacokinetics is the 
analysis of cycloserine, a small polar drug with limited potential for absorbing UV that 
makes it difficult to analyse [65]. Cycloserine was primarily used for the treatment of active 
pulmonary and extra-pulmonary tuberculosis, and currently cycloserine and terizidone are 
used as oral bacteriostatic second line anti-TB drugs for multidrug resistant tuberculosis 
[47]. 
According to all information currently available to the WHO prequalification of medicine 
team, terizidone is not measurable in plasma and consequently it seems to be hydrolysed 
completely into cycloserine pre-systemically [62].  
Cycloserine/terizidone are rapidly absorbed after oral administration, the bioavailability of 
the drugs ranges from 70% to 90% and the plasma levels of the drug peak within 3–4 hours 
after ingestion. At the usual doses, cycloserine has a bacteriostatic effect [47]. The half-life 
of cycloserine is 10 hours, the drug does not bind to plasma proteins, and only a small 
proportion of cycloserine is metabolized in the liver.  Most of the dose (70%) is excreted by 
the kidney, unaltered, within 72 hours and a small proportion of the drug is excreted in 
faeces. There is no cross-reaction between cycloserine and other anti-tuberculosis drugs and 
the MIC of cycloserine for Mycobacterium tuberculosis is 5–20 µg/mL [47].  
As an N-methyl-D-aspartate partial receptor agonist, cycloserine competes with γ-
aminobutyric acid in the brain, causing central nervous system side effects [53]. Dosing 
terizidone instead of cycloserine has advantages, the adverse effects are lowered, therefore it 
is better tolerated, which leads to better compliance and treatment outcomes [66]. 
 




Molecular formula: C14H14N4O4 
Molecular weight: 302.29 
Development and validation of selective and sensitive LC-MS/MS methods for the determination of para-Aminosalicylic Acid and 




Page 97  
 




Molecular formula: C3H6N2O2 
Molecular weight: 102.09 
 
Figure 23. Chemical structure of Cycloserine 
 
5.2.2.2. Analytical information 
The first analytical method by R.L. Jones were described in 1956, cycloserine was then 
already determined by colorimetric determination as a marker for terizidone [64].  David et 
al., described a method to determine cycloserine in human plasma by high performance 
liquid chromatography with fluorescence detection, using derivatization with p-
benzoquinone [65]. The derivatisation take place at the same time as the deproteinization 
with ethanol, the ratio between plasma volume and reagent solution used was 1:2 for a 
benzoquinone concentration of 1000 µg/ml. For chromatography, an isocratic mobile phase 
was used that consist of formic acid : water : methanol : acetonitrile (0.1:84.9:7.5:7.5, 
v/v/v/v) with a flow rate of 1 ml/min at 25°C on a XDB C18 column (250 x 4.6 mm, 5µm). 
Determination by fluorescence detection were achieved with an excitation wavelength of 
381 nm and an emission wavelength of 450 nm. The detection limit was 10 ng/ml for an 
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injection volume of 5 µl and a calibration curve with a range of 0.25 – 10 µg/ml was 
validated.  
Pesek et al., described a new approach to evaluate the analysis of cycloserine, a strong 
hydrophilic and very polar drug [67]. The method utilized aqueous normal phase 
chromatography with a silica hydride-base stationary phase and mass spectrometry 
detection. The column used was a Cogent Diamond Hydride column (150 x 2.1mm, 5µm) 
and significant retention could be observed for underivatized cycloserine under isocratic 
conditions, using a mobile phase consisting of 50: 50 (v/v) mobile phase A, consisting of 
water : 2-propanol : acetic acid (49.5:50:0.5, v/v/v), and mobile phase B, consisting of 
acetonitrile : water : acetic acid (97:2.9:0.1, v/v/v). Detection was in positive ion mode using 
the ion (M + H)+ at m/z of 103.05. While peak shape was acceptable with the isocratic 
mobile phase it was drastically improved with gradient elution. This method was used to 
determine impurities and degradation products of a cycloserine solution. The gradient 
method used a 5 minute column equilibration. A linear relationship was obtained over the 
concentration range 0.2 – 1.0 µg/ml with a limit of detection of 0.1 µg/ml. 
Polagani et al., described a simple, rapid and sensitive LC-MS/MS assay for the 
determination of cycloserine in plasma using carbamazepine as ISTD. Cycloserine was 
extracted from 50 µl human plasma via protein precipitation with acetonitrile [68]. The 
chromatographic separation was achieved on a Hypurity Advance C18 column (50 x 4.6 
mm, 5µm) by using a mixture of acetonitrile : water : formic acid (60:39.5:0.5, v/v/v) as the 
mobile phase at a flow rate of 0.8 ml/min. Stock solutions was prepared in methanol and 
found to be stable for 14 days at 2–8°C. The calibration curve obtained was linear over the 
concentration range 50–15 000 ng/ml. The detection was in positive ion mode, using a 
transition of m/z of 103.0 → 75.0 for cycloserine and m/z of 237.0 → 194.1 for the ISTD. 
The runtime of 2.5 minutes made it possible to analyse many samples in a short time. The 
analyte was stable in plasma for 47 days kept at -70°C, for 9 hours at room temperature, for 
3 freeze-thaw cycles and in extract solutions for 44 hours at room temperature. 
Patel et al., describe a selective and sensitive LC-MS/MS method for the determination of 
cycloserine in human plasma, using niacin as the ISTD. The analyte and ISTD were 
extracted from 500 µl human plasma via solid phase extraction on a Waters Oasis MCX 
cartridges [63]. Chromatographic separation was achieved on a Peerless Basic C18 (100 x 
4.6 mm, 5µm) column under isocratic conditions. Detection was done by LC-MS/MS, 
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operating in positive ion and multiple reaction monitoring acquisition mode. The protonated 
precursor to product ion transition monitored for cycloserine and niacin were at m/z 
103.1→75.0 and 124.1→80.1, respectively. Stock solutions of cycloserine in water were 
stable for 8 hours at room temperature and 27 days at 4°C. Plasma stability at -20°C was 
found for a period of 91 days. The limit of detection and LLOQ was 0.0013 µg/ml and 0.2 
µg/ml, respectively, with a linear dynamic range of 0.20 – 30.0 µg/ml for cycloserine. 
Fraschetti et al., described the role of solvents on the stability of cycloserine under ESI-MS 
conditions [69]. The effects of methanol and acetonitrile on the stability of cycloserine was 
studied. Infra-red multiphoton photo dissociation (IRMPD) spectroscopy of the ionic species 
from electrospray ionization tandem mass spectrometry of the different solutions points to 
dimerization of cycloserine to cis-3,6-bis(amino oxymethyl)-2,5 piperidinedione. 1D and 2D 
magnetic resonance experiments confirm these findings by showing the dimerization of 
cycloserine actually take place at room temperature in acetonitrile even before ESI-MS 
analysis. The analytical information provided by the literature review is summarised in  
Table 45. 
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5.3. Method development 
The literature and clinical protocol review revealed that a LC-MS/MS method was needed to 
cover a possible Cmax of up to 40 µg/ml and a LLOQ of at least 5 half-lives of this Cmax, 
therefore a calibration range of 0.313–40µg/ml was chosen. LC-MS/MS was chosen because 
it is more specific and sensitive than conventional HPLC using UV or fluorescence 
detection. Most conventional HPLC methods use mobile phases that contain high 
concentrations and non-volatile buffer salts that is incompatible with LC-MS/MS methods. 
Based on the literature survey for cycloserine most of the mobile phases used for LC-
MS/MS analysis contained low concentrations formic acid or acetic acid and either 
methanol or acetonitrile as the organic solvent. From the literature review, we concluded 
that cycloserine is not stable in acetonitrile and making stock solutions in acetonitrile should 
be avoided [69]. 
A stock solution of cycloserine was prepared in methanol. From the prepared stock solution 
three different diluted solutions were prepared for infusion, one in methanol : water (50:50, 
v/v), the second in methanol : water : formic acid (50:49.9:0.1, v/v/v) and a third in 
methanol : water : ammonium hydroxide (50:49.9:0.1, v/v/v). Each were then infused 
separately into the mass spectrometer and the Q1 mass filter optimised for the best 
protonated ionisation response for the precursor ion with a m/z of 103.0. The best ionisation 
response for the precursor ion was achieved with a mixture of methanol : water : formic acid 
(50:49.9:0.1, v/v/v).  The protonated precursor ion was fragmented and the product ions 
optimised for a specific and sensitive MRM transition, the m/z of 103.0→75.2 was 
monitored.  The product ion mass spectrum of cycloserine is presented in Figure 24. 
 
Development and validation of selective and sensitive LC-MS/MS methods for the determination of para-Aminosalicylic Acid and 




Page 101  
 
Figure 24. Product ion mass spectrum of cycloserine after collision induced dissociation in 
the fragmentation cell, showing the cycloserine precursor ion at m/z 103 and the productions  
 
To start with the chromatography a Synergi Hydro RP C18 (150 x 2.0, 4µm) column was 
chosen, from the literature we could conclude that a more specific column would be needed 
for this very small and basic drug. An isocratic mobile phase of methanol : water and formic 
acid (50:49.9:0.1, v/v/v) was used as the starting point. Different ratios of this mobile phase 
were tested, settling for the best ratio between formic acid and methanol with the most 
retention and the best peak shape. This optimum mobile phase conditions were found to be 
methanol: water : formic acid at a ratio of 30:70:0.1 (v/v/v). The extraction method, protein 
precipitation with methanol yielded high recoveries and precision. In pure solutions as well 
as with the methanol precipitated plasma calibration standards, good linearity was obtained 
with a signal-to-noise ratio of more than 1:5 for the LLOQ. 
This chromatography and extraction method was used for pre-validation testing. During the 
pre-validation testing of the matrix effects, the experiment failed to meet acceptance criteria 
and was repeated. The repeated results were still unacceptable, indicating that background 
matrix components have an inconsistent impact on the ionisation of cycloserine. Possible 
solutions to this were to use a different extraction technique or to change the 
chromatography to gain more retention and separate the analyte peak from the matrix. A 
 +MS2 (103.12) CE (30): 26 MCA scans from Sample 1 (TuneSampleName) of Cycloserine after_InitProduct_Pos.wiff (Turbo Spray) Max. 1.7e5 cps.
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range of columns and different mobile phases was tested but no better retention could be 
obtained. In the literature, a derivatisation method was described with p-benzoquinone in 
plasma, this was to increase retention and sensitivity of cycloserine [65].  A more mass 
spectrometry “friendly” derivatisation reagent was chosen, dansyl chloride, and cycloserine 
was derivatised during the protein precipitation step. The derivatisation reaction is presented 
in Figure 25. 
 
Dansyl chloride derivative 
Molecular formula: C15H17N3O4S 
Molecular weight: 335.38 
 
 
Figure 25. Structure of the cycloserine derivative 
 
New chromatography was needed for the derivative, and as with the analyte, the derivative 
was infused in different solutions as a starting point. The product ion mass spectrum of 
cycloserine derivative is presented in Figure 26.  
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Figure 26. Product ion mass spectrum of the cycloserine derivatised product after collision 
induced dissociation in the fragmentation cell, showing the cycloserine derivative precursor 
ion at m/z 336 as well as the product ions 
 
The best chromatography was obtained with a Gemini NX C18 (50 x 2.1mm, 5µm) column 
and an isocratic mobile phase containing water : formic acid : acetonitrile (69.9: 0.1:30, 
v/v/v). The derivative with dansyl chloride increase cycloserine sensitivity, so lower 
concentrations could be detected, and increased retention time on the analytical column. 
Validation experiments were repeated, including the matrix-effect experiment, and all 
criteria were met. The extraction method was optimised and the final extraction method, 
HPLC conditions and MS/MS settings included in a SOP. 
 
5.3.1. The SOP extraction and derivatization procedure for cycloserine 
 
Thaw the plasma samples, all calibration standards, quality control samples, blanks and 
unknown samples, at room temperature and vortex briefly. 
Aliquot 20 µl of the plasma by pipette into 1.5 ml polypropylene micro-centrifuge tubes. 
Add the precipitation and derivatisation reagent (methanol, 200 µl) containing dansyl 
chloride (2 mg/ml) to the samples (not more than 4 samples at a time).  
 +MS2 (336.00) CE (30): 26 MCA scans from Sample 1 (TuneSampleName) of Cycloserine Derivative_InitProduct_Pos.wiff (Turbo Spray) Max. 2.7e6 cps.
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Vortexed for approximately 30 seconds and centrifuge at approximately 16 000 rcf for 5 
minutes. 
Transfer 150 µl of the supernatant to a new clean 1.5 ml polypropylene micro-centrifuge 
tube and added and mix ammonium bicarbonate buffer (100 µl, pH 9.5). 
Incubate the sample on a heating block for 2 hours at ~ 50°C. 
Add formic acid (50 µl, 2%) to each sample to stop the derivatisation reaction and vortex 
briefly. 
Cool the samples at ~5°C for 15 minutes and centrifuge at approximately 16 000 rcf for 5 
minutes. 
Transfer 200 µl of the supernatant into a clean 96-well plate. 
Inject 5 µl of the extracted sample onto the analytical column for LC-MS/MS analysis. 
 
5.3.2.Final Cycloserine conditions and MS/MS settings 
 
The final HPLC and chromatographic conditions and MS/MS detector settings used are 
included in the final SOP method and are summarised in Tables 46 - 48. 
Table 46. Cycloserine instrumentation and chromatographic conditions 
Instrument used API 3000-2 
Project (Analyst) Cycloserine_Study 2014_166 
Acquisition method Method 11  
Analytical Column Phenomenex Gemini NX C18, 2.0 x 50 mm, 5µm 
Column Temperature Room temperature (~24°C) 
Mobile Phase Acetonitrile : Water: Formic acid (30:69.9,0.1 v/v/v) 
Pump Type  Agilent 1100 Quarternary Pump 
Flow Rate 300 µl/min 
Autosampler Type HTC PAL 
Sample arrangement 96 well plate 
Injection Volume 5 µl 
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Table 47. Cycloserine electrospray ionisation settings 
Mass Spectrometer Identity API3000-2 
APCI/ESI ESI 
Parameter Value  
Nebuliser gas (Gas 1) (arbitrary unit) 10 
Turbo gas (Gas 2) (arbitrary unit) 8 
CUR (curtain gas) (arbitrary unit) 6 
CAD (collision gas) (arbitrary unit) 8 
TEM (Source Temperature) (°C) 450 
IS (Ion Spray Voltage) (V) 3500 
 
Table 48. Cycloserine MS/MS Settings 
 Cycloserine derivative 
Protonated molecular ion mass (m/z) [M+H]+ 
335.9 
Product ion mass (m/z) Quantifier 
157.2 
Product ion mass (m/z) Qualifier 
170.1 
Dwell time (ms) 
150 
Declustering potential (V) 
61 
Focus potential (V) 
370 
Entrance potential (V) 
10 
Collision energy (eV) 
41 
Collision cell exit potential (V) 
8 
Scan Type MRM 
Polarity Positive 
Pause Time (ms) 5 
 
Pre-validation extractions of standards and controls in plasma showed good accuracy, 
precision and recoveries for the cycloserine derivative and the method was validated 
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5.4. Validation of the Assay Method 
5.4.1. Procedure 
 
Validation of an assay method is a process performed to objectively demonstrate and 
document the accuracy, precision, specificity, sensitivity and reproducibility of the assay 
method and the stability of the analyte for the purposes of assaying samples of unknown 
concentrations. 
In order to demonstrate acceptable within- and between-day accuracy and precision of the 
method over the desired concentration range, calibration standards and quality control 
samples were prepared and assayed in three consecutive runs.  A full set of calibration 
standards and quality controls was prepared and stored frozen, and the required aliquots 
were thawed and assayed in each run.  Each run consisted of all the calibration standards in 
duplicate to produce one calibration curve and six replicates of the prepared quality control 
samples.  A quality control spiked to a concentration above the upper limit of quantification 
was diluted (1:4) with blank plasma to validate the dilution of samples of which the 
concentrations potentially do not fall within the validated range. 
Standard curve fitting was determined by applying the simplest model that adequately 
describes the concentration-response relationship using appropriate weighting and statistical 
tests for goodness-of -fit. A calibration curve based on a well selected regression model 
must consist of at least six calibration levels, covering the entire calibration range, from the 
LLOQ to ULOQ.  The regression model selected during the validation was used for the 
quantification of the study samples, summarised in Table 49. In the case of a re-instatement 
(or partial) validation, the regression model that was used for the full validation must be 
used for the re-instatement validation. 
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Table 49. Cycloserine quantitation parameters, ions monitored and retention times 
Software Analyst 1.5.2 
Algorithm Analyst Classic 
Calibration Fit Type  Quadratic 
Parameter Area 
Curve Weighting 1/x 
 Cycloserine derivative 
Bunching factor 1 
Number of smoothes 3 
Precursor ion 335.9 
Product ion 157.2 
Retention Time (min) 1.5 
 
5.4.2.Calibration standard and quality control preparation 
 
5.4.2.1. Preparation of Stock Solutions (Cycloserine) 
Stock solutions (SS1 - Cycloserine) were prepared volumetrically.  The weighed mass of the 
analyte was also adjusted where applicable (purity, salt, etc.). Stock solution SS1 and SS2 
(1000 µg/ml) were prepared in water : methanol (1:1, v/v) as represented in Tables 50 and 
Table 51. All stock solutions were kept at ~ - 80C until required. These stock solutions are 
used to prepare by spiking blank biological matrix as required. 
Table 50. Preparation of Cycloserine stock solution (SS1-Cycloserine) 
Solvent  Volume Weighed Adjusted* SS1 
Used solvent mass of analyte mass of analyte concentration 
  (ml) (mg) (mg) (µg/ml) 
Water : MeOH (1:1) 7.987  8.15  7.987  1000  
* Reason for Adjustment (e.g. purity, salt, hydrate): Purity 
* Calculation: 8.15 x 0.98 = 7.987 mg. 
Table 51. Preparation of Cycloserine stock solution (SS2-Cycloserine) 
Solvent  Volume Weighed Adjusted* SS2 
Used solvent mass of analyte mass of analyte concentration 
  (ml) (mg) (mg) (µg/ml) 
Water : MeOH (1:1) 12.142  12.39  12.142  1000  
* Reason for Adjustment (e.g. purity, salt, hydrate): Purity 
* Calculation: 12.39 x 0.98 = 12.142mg 
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5.4.2.2. Preparation of Calibration Standards 
Calibration standards were prepared volumetrically in plasma (anticoagulant K3EDTA) on  
09 December 2014 at room temperature by spiking 240 µl of the analyte stock solution 
(SS1) into 5.760 ml of normal blank plasma (STD 1), which is then serially diluted with 
normal blank plasma to produce the desired concentrations for calibration standards 
(STD 2–8) as presented in Table 52. Multiple 60 µl aliquots of each calibration standard 
were stored in individual 1.5 ml polypropylene tubes at approximately - 80°C to allow for 
duplicate 20 µl extractions from each tube.  Stability has been shown at - 20C for at least 
91days [63]. 













spiked (µl)   
Volume 
(ml) 
of dilution (ml) (µg/ml) 
STD 1 – ULOQ 5.760  240     6.00 40.0 
STD 2 3.00    STD 1 3.00 6.00 20.0 
STD 3 3.00    STD 2 3.00 6.00 10.0 
STD 4 3.00    STD 3 3.00 6.00 5.00 
STD 5 3.00    STD 4 3.00 6.00 2.50 
STD 6 3.00    STD 5 3.00 6.00 1.25 
STD 7 3.00    STD 6 3.00 6.00 0.625 
STD 8 – LLOQ 3.00    STD 7 3.00 6.00 0.313 
 
5.4.2.3.Preparation of Quality Controls 
Quality controls were prepared volumetrically in plasma (anticoagulant K3EDTA) on 09 
December 2014 at room temperature using the same methodology that was used for the 
calibration standards.  Spike 320 µl of the analyte stock solution (SS2) into 4.680 ml of 
normal blank plasma to obtain QC Dilute.  This quality control is serially diluted with 
normal blank plasma to attain the desired concentrations (QC High – QC LLOQ) as 
presented in table 53.  Multiple 60 µl aliquots of each quality control are stored in individual 
1.5 ml polypropylene tubes and stored at approximately -80°C to allow for duplicate 20 µl 
extractions from each tube.  Stability has been shown at -20C for at least 91 days [63]. 
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QC Dilute 4.680  320     5.00 64.0 
QC 1 High 4.00    QC Dilute 4.00 8.00  32.0 
QC 2 Med 3.00    QC 1 3.00 6.00  16.0 
QC SYS 5.00    QC 2 1.00 6.00  2.67 
QC 3 Low 5.00    QC 3 2.08 7.08  0.783 
QC 4 LLOQ 3.00    QC 4 2.00 5.00  0.313 
Note:* The QC Dilute is used during a validation batch to quality control the dilution process. 
 
5.4.3. Validation Results 
 
Acceptance criteria:  Accuracy is expressed as the concentration of analyte found as a 
percentage of the nominal concentration (% Accuracy) while precision is expressed as the 
coefficient of variation (CV %) seen in a batch of assays.   
The calculated calibration curve should fit the plot of measured responses vs. nominal 
concentrations of the calibration standards adequately, giving a r2 fit parameter of as close to 
one as possible. 
For a valid method, the within- and between-batch accuracy is required to be within 15% 
(i.e. % Accuracy should be between 85–115%) over the entire calibration range and within 
20% of nominal concentration at the LLOQ.  For a valid method, the within- and between-
batch precision is required to be less than 15 % (i.e. CV %) should be less than 15%) over 
the entire calibration range and less than 20% at the LLOQ.  Duplicate standards are 
analysed at each calibration point.  Each one of these standards is used to define the 
calibration equation, unless one of those points does not meet the above criteria. In this 
instance, the invalid point would be excluded and only a single standard would be used at 
that level. This allows for a single standard to fail at either the LLOQ or the ULOQ without 
having an effect on the resulting calibration range.  
5.4.3.1.Validation 1 (DAY 1) 
Within-batch accuracy and precision are assessed by assaying all the calibration standards in 
duplicate, to produce one calibration curve, and 6 replicates of each quality control level in a 
single batch of assays as presented in Figure 27.  
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Figure 27. Representative calibration curve for cycloserine- validation 1, day 1 
The regression equation used was Quadratic (weighted by 1/x concentration), f(x) = a + bx + 
cx2, as presented in Table 54. 
Table 54. Regression equation, f(x) = a + bx + cx2 
Validation  Quadratic Calibration Curve Parameters 
Batch a b c r 
1 2.79E+03 6.88E+04 -316 0.9978 
 
The within-batch accuracy and precision of the assay procedure are assessed by calculating 
the regression equation and constructing the calibration curve based on peak areas of 
analyte, as represented in Table 55 and Table 56. 
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Table 55. Cycloserine Calibration Standards Accuracy and Precision – validation 1 
Sample ID 
Nominal Conc. Mean Observed Conc. 
Std Dev % CV % Accuracy N 
(µg/ml) (µg/ml) 
S8 0.313 0.312 0.0159 5.1 99.6 2 of 2 
S7 0.625 0.607 0.0712 11.7 97.1 2 of 2 
S6 1.25 1.26 0.141 11.2 100.7 2 of 2 
S5 2.50 2.58 0.143 5.6 103.1 2 of 2 
S4 5.00 5.11 0.423 8.3 102.3 2 of 2 
S3 10.0 9.59 1.18 12.3 95.9 2 of 2 
S2 20.0 20.3 2.62 12.9 101.6 2 of 2 
S1 40.0 39.9 0.595 1.5 99.8 2 of 2 
 
Table 56. Summary of Cycloserine intra-validation quality controls  
Sample ID 
Nominal Conc. Mean Observed Conc. 
Std Dev % CV % Accuracy N 
(µg/ml) (µg/ml) 
QC LLOQ 0.313 0.293 0.0384 13.1 93.7 6 of 6 
QC L 0.783 0.797 0.0673 8.5 101.8 6 of 6 
QC M 16.0 16.6 1.35 8.1 103.7 6 of 6 
QC H 32.0 34.1 4.06 11.9 106.6 6 of 6 
 
5.4.3.2.Validation 2 and 3 (DAYS 2 and 3) 
Between-batch accuracy and precision are assessed by assaying an additional two separate 
consecutive batches, each consisting of a double set of calibration standards designated for 
use in the assay of samples of unknown concentrations and 6 replicates of each of the 
quality control samples, represented in figure 28 and 29.   
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Figure 29. Representative calibration curve for Cycloserine- validation 3 
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The regression equation used was Quadratic (weighted by 1/x concentration), f(x) = a + bx + 
cx2, as presented in Tables 57 and 58. 
Table 57. Regression equation, f(x) = a + bx + cx2 
Validation  Quadratic Calibration Curve Parameters 
Batch a b c r 
2 4.75E+03 1.78E+05 -1.05E+03 0.9991 
 
Table 58. Regression equation, f(x) = a + bx + cx2 
Validation  Quadratic Calibration Curve Parameters 
Batch a b c r 
3 1.08E+04 1.50E+05 -992 0.9996 
 
The between-batch accuracy and precision of the assay procedure are assessed by 
constructing a calibration curve based on analyte peak areas and calculating the regression 
equations, as represented in Tables 59 - 62. 
 
Table 59. Cycloserine calibration standards accuracy and precision – validation 2 
Sample ID 
Nominal Conc. Mean Observed Conc. 
Std Dev % CV % Accuracy N 
(µg/ml) (µg/ml) 
S8 0.313 0.307 0.0236 7.7 98.2 2 of 2 
S7 0.625 0.647 0.0112 1.7 103.6 2 of 2 
S6 1.250 1.29 0.0147 1.1 102.8 2 of 2 
S5 2.50 2.42 0.106 4.4 97.0 2 of 2 
S4 5.00 4.74 0.180 3.8 94.9 2 of 2 
S3 10.0 10.4 0.260 2.5 104.2 2 of 2 
S2 20.0 19.9 1.61 8.1 99.4 2 of 2 
S1 40.0 40.0 1.96 4.9 100.0 2 of 2 
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QC LLOQ 0.313 0.317 0.0451 14.2 101.3 6 of 6 
QC L 0.783 0.819 0.0632 7.7 104.6 5 of 6 
QC M 16.0 16.3 1.49 9.2 101.6 6 of 6 
QC H 32.0 34.6 2.63 7.6 108.1 6 of 6 
 
Table 61. Cycloserine calibration standards accuracy and precision – validation 3 
 
Sample ID 
Nominal Conc. Mean Observed Conc. 
Std Dev % CV % Accuracy N 
(µg/ml) (µg/ml) 
S8 0.313 0.324 0.0376 11.6 103.6 2 of 2 
S7 0.625 0.610 N/A N/A 97.6 1 of 2 
S6 1.25 1.24 0.0453 3.6 99.6 2 of 2 
S5 2.50 2.44 0.0562 2.3 97.8 2 of 2 
S4 5.00 4.89 0.0735 1.5 97.9 2 of 2 
S3 10.0 10.6 N/A N/A 106.2 1 of 2 
S2 20.0 19.8 0.826 4.2 99.1 2 of 2 
S1 40.0 40.0 0.496 1.2 100.1 2 of 2 
 
Table 62. Summary of Cycloserine intra-validation quality controls - validation 3 
Sample ID 
Nominal Conc. Mean Observed Conc. 





QC LLOQ 0.313 0.316 0.0147 4.7 100.9 6 of 6 
QC L 0.783 0.771 0.0660 8.6 98.4 6 of 6 
QC M 16.0 14.4 1.23 8.5 90.3 6 of 6 
QC H 32.0 29.2 1.69 5.8 91.3 6 of 6 
 
5.4.3.3.Summary of the combined calibration standard and quality control 
results 
The overall accuracy and precision of the assay procedure is assessed by calculating the 
accuracy and precision statistics over the within- and between-batch validation batches (3 in 
total).  Accuracy is expressed as the concentration of the analyte found as a percentage of 
the nominal concentration (% Accuracy), while precision is expressed as the coefficient of 
variation (CV %). The combined regression, calibration standards and quality control results 
(all 3 validations) of cycloserine are summarised in Tables 63 - 65. 
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Table 63. Overall summary of calibration curve parameters- validation 1-3 
Validation  Quadratic Calibration Curve Parameters 
Batch a B C r 
1 2.79E+03 6.88E+04 -316 0.9978 
2 4.75E+03 1.78E+05 -1.05E+03 0.9991 
3 1.08E+04 1.50E+05 -992 0.9996 
 












STD 1 – 
ULOQ 
STD 2 STD 3 STD 4 STD 5 STD 6 STD 7 
STD 8 - 
LLOQ 
Nominal 
Conc. 40.0 20.0 10.0 5.00 2.50 1.25 0.625 0.313 
  (µg/ml) (µg/ml) (µg/ml) (µg/ml) (µg/ml) (µg/ml) (µg/ml) (µg/ml) 
Replicates Observed Conc. 
1  1 40.3 18.5 8.76 4.81 2.68 1.16 0.557 0.300 
  2 39.5 22.2 10.4 5.41 2.48 1.36 0.657 0.323 
2  1 38.6 18.7 10.6 4.62 2.35 1.27 0.655 0.291 
  2 41.4 21.0 10.2 4.87 2.50 1.30 0.639 0.324 
3  1 40.4 20.4 [24.6] 4.95 2.41 1.28 0.610 0.298 
  2 39.7 19.2 10.6 4.84 2.48 1.21 [1.13] 0.351 
  n  6 6 5 6 6 6 5 6 
 
Average 40.0 20.0 10.1 4.92 2.48 1.26 0.624 0.315 
 
STDEV 0.950 1.45 0.774 0.265 0.111 0.0700 0.0417 0.0225 
 




100.0 100.0 101.1 98.3 99.3 101.1 99.8 100.5 
[ ] = Outlier with MNR-ESD Outlier Test, excluded from regression. 
  
Development and validation of selective and sensitive LC-MS/MS methods for the determination of para-Aminosalicylic Acid and 




Page 116  
Table 65. Overall quality control accuracy and precision estimation 
Validation 
Batch 
Sample ID QC - DIL QC - High QC – Med QC - Low QC - LLOQ 
Nominal 
Conc. 64.0 32.0 16.0 0.783 0.313 
(µg/ml) (µg/ml) (µg/ml) (µg/ml) (µg/ml) 








 1   31.9 18.8 0.740 0.257 
2   30.1 15.8 0.726 0.337 
3   34.2 15.6 0.890 0.257 
4   34.9 15.2 0.810 0.342 
5   31.9 17.0 0.757 0.292 








 1   31.1 14.9 [0.491] 0.284 
2   32.9 16.9 0.846 0.304 
3   35.6 15.9 0.830 0.310 
4   38.4 18.2 0.785 0.396 
5   36.2 17.3 0.734 0.271 








1 61.2 29.6 13.6 0.749 0.336 
2 60.7 28.6 15.1 0.777 0.298 
3 57.5 27.3 14.1 0.718 0.305 
4 58.7 28.7 12.9 0.724 0.315 
5 60.0 28.8 14.6 0.898 0.331 
6 60.9 32.3 16.4 0.758 0.309 
n  6 18 18 17 18 
Average 59.8 32.6 15.8 0.794 0.293 
STDEV 1.45 3.74 1.61 0.0648 0.0382 
% CV 2.4 11.5 10.2 8.2 13.0 
% Accuracy 93.5 102.0 98.6 101.4 93.7 
[ ] = Outlier with MNR-ESD Outlier Test, excluded from regression. 
 
5.4.4. Calibration Range 
 
Results from the validation assays above indicate a valid calibration range of 0.313–40.0 
µg/ml for cycloserine. The LLOQ was set at the concentration of the lowest validated 
standard for cycloserine, 0.313 µg/ml. 
5.4.5. Quantification Method 
 
The results show that the method provides sufficient accuracy and precision over the entire 
range based on analyte peak area with a quadratic calibration curve (weighted by 1/x 
concentration). 
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5.4.6. Stability assessment 
 
Various stability experiments were performed to show that all the necessary precautions 
were taken to ensure that the analyte concentrations were not affected by the assay 
procedure or associated conditions. The results demonstrate that the assays of study samples 
could be completed within the period for which the analyte is shown to be stable. 
 
5.4.6.1.Stock solution stability and accuracy 
Stock solutions SS1-Cycloserine (prepared on the 17 Nov 2014) were prepared in equal 
parts water and methanol and kept at approximately -80°C.  Test and control samples of 
these stock solutions were left at room temperature, ~ 4°C and ~ -20°C for 18 hours, 
respectively. Reference stock solutions, SS2-Cycloserine (prepared on the 27 Nov 2014) 
were prepared after the storage period of the test and control samples. The reference, test 
and control samples were diluted with injection solvent to a concentration of 4.00 µg/ml for 
the analyte and were analysed according to the method procedure. Peak areas of the test and 
control sample assays were compared to the reference assays and are presented in Table 66 
and 67, for the analyte and derivative respectively. Peak areas of the initial stock solution 
(kept at approximately -80°C) and reference analyte stock solutions were compared for 
stability at ~ -80°C and accuracy and are presented in Table 68. 
Table 66. Stock solution stability of Cycloserine 
 
Reference (~ -80°C) Test (Room temp) Control (~ 4ºC)  Control (~ -20ºC)  
Peak area 1 4070000 3890000 3950000 4140000 
Peak area 2 3710000 3690000 3990000 4550000 
Peak Area 3 4110000 4010000 4140000 4840000 
Peak Area 4 4340000 4020000 4550000 3780000 
Peak Area 5 4130000 3580000 4200000 4590000 
Peak Area 6 4190000 3620000 4300000 4870000 
Average 4091667 3801667 4188333 4461667 
STDEV 209420 196715 219947 424802 
% CV 5.1 5.2 5.3 9.5 
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Table 67. Stock solution stability of Cycloserine derivative 
 
Reference (~ -80°C) Test (Room temp) Control (~ 4ºC)  Control (~ -20ºC)  
Peak area 1 27600000 26400000 27200000 26200000 
Peak area 2 25600000 25400000 26900000 24900000 
Peak Area 3 23000000 26300000 25700000 25900000 
Peak Area 4 23800000 26200000 26300000 25700000 
Peak Area 5 23700000 26500000 24300000 25500000 
Peak Area 6 27000000 26000000 25900000 25500000 
Average 25116667 26133333 26050000 25616667 
STDEV 1906218 398330 1031019 440076 
% CV 7.6 1.5 4.0 1.7 
% Difference    4.0 3.7 2.0 
 
Table 68. Stock solution accuracy of Cycloserine 
 
Reference (SS1) Test (SS2) 
Peak area 1 11000000 10400000 
Peak area 2 12800000 10700000 
Peak Area 3 11400000 10400000 
Peak Area 4 11300000 11200000 
Peak Area 5 9470000 11600000 
Peak Area 6 12500000 11200000 
Average 11411667 10916667 
STDEV 1188620 491596 
% CV 10.4 4.5 
% Difference    -4.3 
Acceptance Criteria:  A high CV (%) (higher than 15%) of the measured values and a 
difference of more than 15% from the reference solution could indicate instability in the 
stock/working solution.  For accuracy, the % difference between two stock solutions should 
not be more than 5%. 
Conclusion:  From the peak areas tabulated above it can be concluded that cycloserine stock 
solutions prepared in methanol and water are stable for 18 hours stored at room temperature, 
~ 4 ºC and ~ -20°C. The initial stock solution kept at ~ -80 °C compared well with the 
reference, and was also observed to be stable for 10 days, with a % difference of -0.6. 
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5.4.6.2. Storage stability in matrix 
Samples for the long-term matrix stability assessment of cycloserine in human plasma were 
prepared in-house on 09 Dec 2014 and was kept at ~ -80°C until 23 Mar 2016 when they 
were extracted and analysed, as represented in Table 69.  The assessment should cover, at a 
minimum, the length of time from when the first sample was drawn during the clinical phase 
to the date of final sample analysis during the analytical phase of a study. 
Table 69. Long term matrix stability of Cycloserine in plasma 
 















(µg/ml) (µg/ml) (µg/ml) (µg/ml) (µg/ml) (µg/ml) 
Sample 1 32.0 35.2 16.0 18.7 0.313 0.333 
Sample 2   34.1   18.7   0.332 
Sample 3   35.4   19.6   0.360 
Sample 4   35.6   17.1   0.269 
Sample 5   31.1   18.3   0.304 
Sample 6   31.5   16.1   0.280 
 
Average 33.8 Average 18.1 Average 0.313 
 
STDEV 2.0 STDEV 1.27 STDEV 0.0349 
 
% CV  6.0 % CV  7.0 % CV  11.1 
 
% Difference  5.7 % Difference  13.0 % Difference  0.0 
 
Acceptance criteria:  A high % CV and a high % Difference (higher than 15%) of the 
measured values compared to nominal concentrations could indicate matrix instability. 
Conclusion:  The % CV and % Difference for cycloserine were within 15% and therefore 
the long-term matrix stability for cycloserine in plasma is indicated for at least 17 months. 
5.4.6.3.“Fresh” vs. “Frozen” stability 
In order to qualify the “fresh” vs. “frozen” effect, a fresh set of calibration standards was 
prepared in plasma (14 Dec 2014) and prior to aliquoting and freezing, tested against stored 
QC’s (09 Dec 2014).  The fresh curve was used to quantify the QC’s and the data is 
represented in Tables 70 and 71. 
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Table 70. Calibration Standards Accuracy and Precision – “Fresh” vs. “Frozen” stability of 
Cycloserine  
Sample ID 
Nominal Conc. Mean Observed Conc. 
Std Dev % CV % Accuracy N 
(µg/ml) (µg/ml) 
S8 0.313 0.289 0.0142 4.9 92.2 2 of 2 
S7 0.625 0.623 0.0351 5.6 99.7 2 of 2 
S6 1.25 1.29 0.0612 4.8 103.1 2 of 2 
S5 2.50 2.44 0.00747 0.3 97.7 2 of 2 
S4 5.00 5.54 0.0758 1.4 110.7 2 of 2 
S3 10.0 10.1 0.0617 0.6 100.5 2 of 2 
S2 20.0 18.9 0.0620 0.3 94.7 2 of 2 
S1 40.0 40.6 2.46 6.1 101.4 2 of 2 
Table 71. Quality control samples accuracy and precision – “Fresh” vs. “Frozen” stability of 
Cycloserine 
Sample ID 
Nominal Conc. Mean Observed Conc. 
Std Dev % CV % Accuracy N 
(µg/ml) (µg/ml) 
QC L 0.783 0.764 0.0672 8.8 97.6 6 of 6 
QC M 16.0 16.2 1.03 6.4 101.5 6 of 6 
QC H 32.0 31.7 1.18 3.7 99.1 6 of 6 
Acceptance criteria: The normal acceptance criteria for quality controls apply. The accuracy 
is required to be within 15% (i.e. % Accuracy should be between 85–115%) and the 
precision is required to be < 15% (i.e. CV (%) should be < 15%). 
Conclusion:  The CV (%) and % Accuracy for the analyte was shown to be within 15% 
which indicates that sample freezing does not influence the accuracy and precision of the 
assay. It also indicates that the analyte is stable in plasma for at least 5 days when stored at ~ 
-80°C. 
5.4.6.4. Freeze-thaw stability 
The freeze-thaw stability evaluation should mimic the intended sample handling conditions 
to be used during sample analysis.  In order to ascertain freeze-thaw stability, low and high 
quality controls were frozen at ~ -80 ºC, and put through six consecutive freeze-thaw cycles. 
Sample aliquots were prepared and frozen for at least 24 hours prior to starting this 
experiment. Each cycle consisted of sufficient thawing time at room temperature followed 
by 12–24 hours freezing time. These samples were analysed against a valid calibration curve 
and compared to controls from the batch, analysed at the same concentration.  The measured 
concentrations and calculated differences after six cycles for the two sets of quality control 
samples are presented in Table 72. 
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Table 72. Freeze-thaw stability of Cycloserine 
 




Observed F/T High 
Nominal 
Concentration 
Observed F/T Low 
 
(µg/ml) (µg/ml) (µg/ml) (µg/ml) 
Sample 1 32.0 36.7 0.783 0.746 
Sample 2   34.4   0.758 
Sample 3   30.5   0.725 
Sample 4   29.9   0.763 
Sample 5   27.6   0.734 
Sample 6   29.0   0.796 
 
Average 31.4 Average 0.754 
 
STDEV 3.47 STDEV 0.0252 
 
% CV 11.1 % CV 3.3 
 
% Difference -2.0 % Difference -3.7 
Acceptance criteria:  A high CV (%) and high % Difference (higher than 15 %) between the 
test and control values could indicate freeze-thaw instability. 
Conclusion:  The CV (%) and % Difference for the analyte reported were within 15% which 
indicates that the analyte is stable in plasma for at least six freeze-thaw cycles. 
5.4.6.5.Benchtop stability 
In order to ascertain benchtop stability, low and high quality control samples were frozen at  
~ - 80ºC, and subsequently left on the bench for approximately 18 hours (maximum 
anticipated time that future study samples will be left thawed until extracted). Samples were 
removed on 12 December 2014 at 16H00 and extracted on 13 December 2014 at 10H00.  
These samples were analysed against a valid calibration curve. The measured concentrations 
and calculated accuracies for the two sets of quality control samples are presented in  
Table 73. 
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Table 73. On bench stability of Cycloserine 
 
High Concentration  Low Concentration 
 
Nominal Concentration Observed BT High Nominal Concentration Observed BT Low 
 
(µg/ml) (µg/ml) (µg/ml) (µg/ml) 
Sample 1 32.0 30.0 0.783 0.809 
Sample 2   30.2   0.703 
Sample 3   32.2   0.742 
Sample 4   31.3   0.760 
Sample 5   31.0   0.787 
Sample 6   32.7   0.854 
 
Average 31.2 Average 0.776 
 
STDEV 1.07 STDEV 0.0530 
 
% CV 3.4 % CV 6.8 
 
% Difference -2.4 % Difference -0.9 
*Note: Observed QC Mean conc. = Mean found conc. from Validation 3 
Acceptance criteria:  A high CV (%) and a high % Difference (higher than 15%) between 
the test and control samples could indicate on-bench instability. 
Conclusion:  The CV (%) and % Difference for Cycloserine were reported to be within 
15%.  On-bench stability for Cycloserine in plasma is indicated for at least 18 hours. 
5.4.6.6.Reinjection Reproducibility 
Reinjection reproducibility is evaluated to determine if an analytical run can be reanalysed 
by reinjection in the case of instrument interruptions.  Following the injection of the first 
validation run (Validation 1), the extracted samples (96-well plate) should remain in the 
autosampler at the method defined temperature. Reinjection of the extracts follows the 
injection of the second validation run (Validation 2). This demonstrates reinjection 
reproducibility, as presented in Tables 74 and 75. 
Table 74. Calibration Standards Accuracy and Precision – Validation 1 Reinjection 
Sample ID 
Nominal Conc. Mean Observed Conc. 
Std Dev % CV % Accuracy N 
(µg/ml) (µg/ml) 
S8 0.313 0.295 0.0348 11.8 94.2 2 of 2 
S7 0.625 0.579 N/A N/A 92.6 1 of 2 
S6 1.25 1.27 0.227 17.9 101.3 2 of 2 
S5 2.50 2.69 0.197 7.3 107.7 2 of 2 
S4 5.00 5.12 0.357 7.0 102.4 2 of 2 
S3 10.0 10.1 0.916 9.1 100.9 2 of 2 
S2 20.0 18.5 N/A N/A 92.6 1 of 2 
S1 40.0 40.4 0.0727 0.2 101.0 2 of 2 
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Table 75. Quality control samples Accuracy and Precision – Validation 1 Reinjection 
Sample ID 
Nominal Conc. Mean Observed Conc. 
Std Dev % CV % Accuracy N 
(µg/ml) (µg/ml) 
QC LLOQ 0.313 0.305 0.0210 6.9 97.4 6 of 6 
QC L 0.783 0.815 0.0758 9.3 104.0 6 of 6 
QC M 16.0 17.4 1.14 6.6 108.7 6 of 6 
QC H 32.0 35.7 4.31 12.1 111.7 6 of 6 
Acceptance criteria:  The normal acceptance criteria for quality controls apply. The 
accuracy is required to be within 15% (i.e. % Accuracy should be between 85–115%) and 
the precision is required to be < 15% (i.e. CV (%) should be < 15%). 
Conclusion:  The CV (%) and % Accuracy for the analyte are reported to be within 15 % 
which indicates that a batch may be reinjected within 29 hours. 
5.4.6.7.Autosampler stability 
In order to assess autosampler stability, the first validation run (day 1) was reinjected after 
the second validation run (day 2).  To assess autosampler (or processed sample) stability, the 
high and low QC peak areas from the first validation run and the reinjected run was 
compared. This provides an estimation of autosampler stability over at least 24 hours.  
This could not be repeated for a third validation run (day 3) as the reinjected quality controls 
samples evaporated and not enough sample was left for a third injection. The data are 
presented in Tables 76 and 77. 
 
Table 76. Autosampler stability for extracted samples -high concentration 
High Concentration  
Validation 1 Peak area 
Injection 1 1880000 
Injection 2 1790000 
Injection 3 1990000 
Injection 4 2020000 
Injection 5 1880000 
Injection 6 2320000 
Average 1980000 
STDEV 186226 
% CV 9.4 
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Re injected Validation 1 Peak area 
Injection 7 1580000 
Injection 8 1640000 
Injection 9 1630000 
Injection 10 1800000 
Injection 11 1750000 
Injection 12 2050000 
Average 1741667 
STDEV 171746 
% CV 9.9 
% Difference after Re injection -12.0 
 
Table 77. Autosampler stability for extracted samples - low concentration  
Low Concentration  
Validation 1 Peak area 
Injection 1 53600 
Injection 2 52600 
Injection 3 63800 
Injection 4 58300 
Injection 5 54800 
Injection 6 61800 
Average 57483 
STDEV 4590 
% CV 8.0 
Re injected Validation 1 Peak area 
Injection 7 44900 
Injection 8 46200 
Injection 9 54000 
Injection 10 55000 
Injection 11 50600 
Injection 12 53700 
Average 50733 
STDEV 4296 
% CV 8.5 
% Difference after re injection -11.7 
Acceptance criteria:  A high CV (%) and a high % Difference (higher than 15%) between 
the test and control samples could indicate autosampler instability. 
Conclusion:  The CV (%) and % Difference were found to be within 15%.  Autosampler 
stability for the analyte is indicated for at least 29 hours. 
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5.4.6.8. Whole blood stability on ice 
Stability under the appropriate conditions is assessed in order to estimate the maximum 
amount of time that the whole blood sample may be left on ice before being centrifuged to 
obtain plasma (i.e. to ensure stability during sample handling). Stability in whole blood was 
tested after 120, 60 and 30 minutes, the results are presented in Tables 78–80. 
Table 78. Whole blood stability of Cycloserine after 2 hours 
 
High Concentration  Low Concentration 
Storage: 0 min 
Peak Area 
Storage: 120 min 
Peak Area  
Storage: 0 min 
Peak Area 
Storage: 120 min 
Peak Area  
Sample 1 1110000 1080000 34000 23200 
Sample 2 1160000 1050000 32400 25800 
Sample 3 1210000 1040000 31400 25000 
Sample 4 1190000 1040000 30900 25500 
Sample 5 1210000 1010000 29700 26300 
Sample 6 1150000 990000 33000 29200 
Average 1171667 1035000 31900 25833 
STDEV 39200 31464 1547 1964 
% CV 3.3 3.0 4.8 7.6 
% Difference   -11.7   -19.0 
 
Table 79. Whole blood stability of Cycloserine after 1 hour 
 
High Concentration  Low Concentration 
Storage: 0 min 
Peak Area  
Storage: 60 min 
Peak Area  
Storage: 0 min 
Peak Area  
Storage:60 min 
Peak Area  
Sample 1 1090000 1020000 32900 23900 
Sample 2 1050000 1030000 33100 27700 
Sample 3 1150000 1020000 34500 24600 
Sample 4 1190000 999000 36500 23600 
Sample 5 1190000 1120000 32300 27400 
Sample 6 1150000 1120000 33300 23300 
Average 1136667 1051500 33767 25083 
STDEV 56095 54014 1521 1961 
% CV 4.9 5.1 4.5 7.8 
% Difference   -7.5   -25.7 
 
  
Development and validation of selective and sensitive LC-MS/MS methods for the determination of para-Aminosalicylic Acid and 




Page 126  
Table 80. Whole blood stability of Cycloserine after 30 minutes 
 
High Concentration  Low Concentration 
Storage: 0 min 
Peak Area  
Storage: 30 min 
Peak Area  
Storage: 0 min 
Peak Area  
Storage: 30 min 
Peak Area  
Sample 1 1090000 1040000 32900 33000 
Sample 2 1050000 1090000 33100 31500 
Sample 3 1150000 1060000 34500 36600 
Sample 4 1190000 1080000 36500 34100 
Sample 5 1190000 1070000 32300 36900 
Sample 6 1150000 1060000 33300 36300 
Average 1136667 1066667 33767 34733 
STDEV 56095 17512 1521 2213 
% CV 4.9 1.6 4.5 6.4 
% Difference   -6.2   2.9 
Acceptance criteria:  Peak areas of the test samples (120 min, 60 min and 30 min) were 
compared to the peak areas of the reference samples (0 min).  A high % Difference (> 15%) 
between the sets could indicate whole blood instability. 
Conclusion:  The observed % difference of the 60 and 120 minute samples did not fall 
within the accepted limits, indicating that Cycloserine is stable in whole blood on ice for 




The very high specificity of the LC-MS/MS assay procedure precludes the detection of any 
compounds that do not possess the capability to produce the specific parent ion followed by 
formation of the specific product ion produced and monitored in the mass spectrometer. A 
representative chromatogram of STD 1 is presented in Figure 30. 
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A blank sample (without analyte) was positioned in the injection sequence immediately after 
the highest calibration standard in order to assess possible carry-over effects.  A 
chromatogram of a blank sample is presented in Figure 31. 
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Figure 31. Chromatogram of a blank plasma sample 
Acceptance criteria:   
Blank assessing carry-over:  A peak that is observed for the analyte should not be > 20% of 
the area of the peak obtained at the LLOQ.  
Conclusion:  No carry over peaks were observed. 
5.4.9. Sensitivity 
 
The LLOQ of this method is 0.313 µg /ml and a representative chromatogram presented in 
Figure 32 and the signal -to-noise shown in Figure 33.  
 
Figure 32. Chromatogram of a lower limit of quantification (LLOQ) sample 
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Figure 33. Chromatogram of the S/N ratio of a lower limit of quantification (LLOQ)  sample 
Acceptance criteria:  The mean analyte signal/noise response at LLOQ should be at least > 
5 times the response compared to blank response at the retention time of interest. 
Conclusion: The raw LLOQ sample chromatograms showed acceptable intensities for the 
analyte with an average signal/noise ratio of 18:1 for cycloserine (N=2). 
5.4.10. Recovery 
 
The extraction recovery pertains to the extraction efficiency of the analytical process within 
the limits of variability. It is determined by comparing the analytical response of blank 
matrix spiked with the analyte and extracted with the response of the blank matrix first 
extracted and then spiked with analyte (theoretical, represents 100% recovery). 
a. Extracted (test) samples:  A minimum of six QCs at each concentration level (low, 
medium and high) were extracted as per the analytical method. 
b. Theoretical samples: Samples were spiked at each concentration level (relative to the 
final concentration of the corresponding extracted QC’s level) in six-fold using extracted 
blank matrix. 
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The analyte peak areas found after extraction compared to the theoretical peak area 
expressed as a percentage recovery as represented in Table 81. 
Table 81. Recovery for Cycloserine 
 
High Concentration  
(32.0 µg/ml) 
Medium Concentration (16.0 
µg/ml) 
Low Concentration  
(0.783 µg/ml) 
Precipitation:  Solution:  Precipitation:  Solution:  Precipitation:  Solution:  
Peak Area Peak Area Peak Area Peak Area Peak Area Peak Area 
Sample 1 2620000 3250000 1370000 1770000 65100 106000 
Sample 2 2610000 3040000 1390000 1770000 84800 115000 
Sample 3 2570000 3020000 1630000 1470000 77000 112000 
Sample 4 2520000 2950000 1430000 1880000 73600 126000 
Sample 5 2540000 3140000 1310000 1790000 84500 119000 
Sample 6 2460000 3070000 1400000 1800000 91800 125000 
Average 2553333 3078333 1421667 1746667 79467 117167 
STDEV 59889 104579 109621 141516 9516 7731 
% CV 2.3 3.4 7.7 8.1 12.0 6.6 
% 
Recovery 
  82.9   81.4   67.8 
  
   
Average % Recovery 77.4 
 Average % CV 10.7 
Acceptance Criteria:  The mean recovery of a quantitative drug assay method should be 
consistent and the precision of the measured recovery expressed as percentage coefficient of 
variation should not exceed 15% for any particular concentration of the analyte at which it is 
determined.  Recovery reproducibility between concentration levels should not be > 15%. 
Conclusion: The mean recovery of cycloserine from plasma over the calibration range is  
77.4 % with a CV (%) of 10.7. 
5.4.11. Matrix effect 
 
In biological chemical analysis, matrix refers to the components of a sample other than the 
analyte.  Matrix effects are of particular importance when dealing with LC-MS analyses, and 
may only become evident once novel clinical samples are analysed. The presence of co-
extracted matrix background components may influence analyte ionization. Appropriate 
steps should be taken to minimize the influence of matrix components. The Matuszewski 
method attempts to quantify the matrix effect across the calibration range of the assay [61]. 
A minimum of six different blank sources of the appropriate biological matrix and 
anticoagulant type was extracted. Each individual matrix is spiked at low, medium and high 
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concentration levels (taking into account any calculations for dilutions in the analytical 
method). The results are presented in Table 82 and the overall CV (%)’s of the slopes 
calculated. 
Table 82. Cycloserine peak areas 
 
High Conc.  Medium Conc.  Low Conc.  Area  
 
4000 ng/ml 2000 ng/ml 783 ng/ml v Conc.  
 
Peak Area Peak Area Peak Area Regression Slope 
K3EDTA 1 1340000 917000 51700 32.8 
K3EDTA 2 1200000 898000 54700 29.1 
K3EDTA 3 1240000 899000 57200 30.1 
K3EDTA 4 1250000 929000 65000 30.1 
K3EDTA 5 1260000 976000 62200 30.4 
K3EDTA 6 1300000 946000 71200 31.2 
Average 1265000 927500 60333 30.6 
STDEV 48888 29965 7203 1.26 
% CV 3.9 3.2 11.9 4.1 
Acceptance criteria:  The peak areas of the analyte for each level in each matrix source are 
used to generate regressions for each individual matrix. The slope variability (CV %) for the 
6 different matrix sources should not be > 5%. 
Conclusion: The slope variability (CV %) for 6 different plasma samples was 4.1% for 
cycloserine which indicates that matrix effects do not adversely influence the precision of 
the assay. 
5.4.12. Effect of Haemolysis 
 
The presence of haemolysed blood in samples could affect the ionization of the analyte 
during assay.  Evidence should be provided that haemolysis has no effect on analyte 
quantification. Haemolysis was tested at 2% haemolysed blood in plasma.  
The influence of haemolysed blood was assessed by the assay of 6 haemolysed samples at 
high and low cycloserine concentrations and compared to the assay of 6 normal human 
plasma samples at the same high and low concentrations.   
The areas observed for cycloserine in the haemolysed plasma samples were compared with 
the areas observed in the normal plasma samples, data represented in Table 83.  
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Table 83. Effect of 2% haemolysis  
 
High Concentration  Low Concentration 
Observed Normal 









Sample 1 2540000 2830000 81600 70600 
Sample 2 2620000 3050000 [100000] 81200 
Sample 3 2790000 2840000 69900 79300 
Sample 4 2670000 2970000 63700 75200 
Sample 5 2610000 2850000 69000 77500 
Sample 6 2870000 2870000 71000 75800 
Average 2683333 2901667 71040 76600 
STDEV 123558 88638 6536 3684 
% CV 4.6 3.1 9.2 4.8 
% Difference   8.1   7.8 
[] Outlier excluded from the analysis 
Acceptance criteria:  A high % Difference (higher than 15%) between the peak areas 
observed in haemolysed samples and normal samples and a high CV % (higher than 15%) 
indicates that haemolysis has an effect on the assay of the analyte.  
Conclusion:  The results reported above show that the % Difference are within 15% for 
cycloserine in 2% haemolysed plasma samples and has no significant effect on analyte 
quantification. 
 
5.4.13. Matrix anticoagulant effect 
 
To evaluate the influence of the matrix anticoagulant on the analytes ionization and 
accuracy, a set of quality controls was prepared in a matrix containing lithium heparin as the 
anti-coagulant, which differed from the K3EDTA used for the preparation of the initial 
calibration standards and quality controls and analysed in a validation batch. The results are 
presented in Table 84.  
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Table 84. Cycloserine anticoagulant effect  
High Concentration  Medium Concentration  Low Concentration  
Nominal Conc. Observed Conc. Nominal Conc. Observed Conc. Nominal Conc. Observed Conc. 
(µg/ml) (µg/ml) (µg/ml) (µg/ml) (µg/ml) (µg/ml) 
32.0 28.1 16.0 14.3 0.783 0.850 
  29.4   13.3   0.739 
  28.1   14.8   0.778 
  28.1   14.5   0.814 
  27.1   14.4   0.819 
  28.4   13.4   0.835 
Average 28.2 Average 14.1 Average 0.806 
STDEV 0.738 STDEV 0.618 STDEV 0.0407 
% CV 2.6 % CV 4.4 % CV 5.1 
% Difference -11.9 % Difference -11.8 % Difference 2.9 
Acceptance criteria:  The normal acceptance criteria for quality controls apply, the accuracy 
is required to be within 15% (i.e. % Accuracy should be between 85–115%) and the 
precision is required to be less than 15 % (i.e. CV (%) should be less than 15%). 
Conclusion:  The resulted precision and accuracy fall within the accepted values, which 
indicate that the use of lithium heparin vs. K3EDTA anticoagulant in the matrix has no 





To determine if samples originally reported as ALQ may be diluted to within the calibration 
range with accuracy and precision, six extra high QC samples were prepared at a 
concentration two times higher than the highest QC (64.0 µg/ml) for cycloserine.  These 
were then diluted 1:4 with blank plasma. The concentration was determined and compared 
with the nominal concentration to determine the percentage accuracy, data presented in 
Table 85. 
 
Table 85. Sample dilution  
Sample ID 
Nominal Conc. Mean Observed Conc. 
Std Dev % CV % Accuracy N 
(µg/ml) (µg/ml) 
QC DIL 64.0 59.8 1.46 2.4 93.5 6 of 6 
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Acceptance criteria:  The final mean calculated concentration (incorporating the dilution 
factor) is determined from the calibration curve and compared to the nominal concentration. 
The accuracy of the diluted samples is required to be within 15% (i.e. % Accuracy should be 
between 85–115%) and the precision is required to be less than 15% (i.e. CV (%) should be 
less than 15%). 
Conclusion: The resulted precision and accuracy fall within the accepted values. 
 
5.5. Discussion 
5.5.1. Validation data summary 
 
Accuracy and precision for the validation of the method were assessed over three 
consecutive, independent runs and the calibration curve fits a quadratic (weighted by 1/x 
concentration) regression over the range 0.313–40.0 µg/ml for cycloserine.   
A 1:4 dilution of the QC Dilution sample showed that concentrations of up to 64.0 µg/ml of 
cycloserine in plasma could be analysed reliably when diluted into the calibration range.  
The method was specific for cycloserine, with no carry over peaks observed.  
Endogenous matrix components were found to have an insignificant effect on the 
reproducibility of the method when human plasma originating from six different sources 
was analysed. Also, quantification of cycloserine in plasma was not significantly affected by 
the presence of haemolysed blood (2 %) and when K3EDTA was used as anti-coagulant 
instead of lithium heparin.   
Cycloserine was found to be stable in human plasma for 17 months at ~ -80°C, for up to 18 
hours at room temperature and when subjected to 3 freeze-thaw cycles. Stock solutions of 
cycloserine are stable in water and methanol for 10 days when stored at ~ -80°C and for 18 
hours stored at room temperature, ~4°C and ~ -20°C, respectively. Cycloserine is shown to 
be stable on-instrument over a period of ~29 hours. Reinjection reproducibility experiments 
indicate that a batch may be re-injected within 29 hours. Cycloserine is stable in whole 
blood (on ice) for up to 30 minutes.   
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In summary, the method is suited for the analysis of cycloserine in plasma using a 
derivatization procedure with dansyl chloride.  
 
5.6. Clinical application of the method. 
This method was successfully use for the assay of samples in a clinical study.  
5.6.1.1. Summary of study protocol 
TITLE: PHARMACOKINETICS AND TOXICITY OF SECONDLINE 
ANTITUBERCULOSIS DRUGS IN HIV-INFECTED AND UNINFECTED CHILDREN 
NIH R01: 069169-01 
The project aims to improve the health of children with drug-resistant tuberculosis (DR-TB) 
in need of second-line anti-TB drugs, through examining the pharmacokinetics (PK), safety 
profile and toxicity of commonly used second-line anti-TB drugs in children, with and 
without HIV co-infection.  The specific aims are:  
1) to compare the PK of second-line anti-TB drugs in children (≤ 15 years) by age;  
2) to compare the plasma concentrations of anti-retroviral (ARV) drugs in HIV-infected 
children (≤ 15 years) on second-line anti-TB drugs to those not on anti-TB therapy; and  
3) to characterize the tolerability and toxicity of second-line anti-TB drugs in HIV-infected 
and uninfected children. 
 
Childhood TB represents 15–20% of the disease burden in settings where TB and HIV 
infection is prevalent. MDR-TB; i.e. TB resistance to both rifampin and isoniazid, is an 
emerging epidemic, with an estimated 489 000 global cases annually [13].  MDR-TB 
patients often experience prolonged diagnostic delay, resulting in transmission of these 
strains especially to young children, with a sharp increase in the numbers of children on 
treatment and prophylaxis for MDR-TB. This hospital-based study was implemented in 
Cape Town, Western Cape Province, South Africa at 2 referral hospitals – Brooklyn 
Hospital for Chest Diseases and Tygerberg Children’s Hospital. The prevalence of MDR-TB 
amongst children with culture-confirmed TB was 8.6% and the prevalence of HIV infection 
in children with TB was 25-30% during 2009. The most frequently used second-line anti-TB 
drugs in children in this setting was ethionamide, fluoroquinolones, amikacin and terizidone. 
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Capreomycin, linezolid and PAS were typically used for treatment of extensively drug-
resistant TB. Although second-line anti-TB drugs are routinely given and recommended in 
children, there is limited information available to inform the accurate dosing in young HIV-
infected children, who may have altered drug metabolism and unique drug-drug interactions. 
The literature provides limited data on toxicity of these anti-TB drugs in children, who are 
typically treated for 18–24 months for DR-TB.   
 
This study provides a longitudinal, hospital-based, observational PK observation of children 
aged 0–15 years who received routine chemotherapy or chemoprophylaxis for the treatment 
or prevention of DR-TB. 318 children were enrolled for observation consecutively over 3.5 
years, undergoing intensive PK sampling of second-line anti-TB drugs at baseline. The 
subjects were undertaking routine treatment for DR disease until treatment completion for 
clinical outcomes, including TB treatment response and drug adverse effects. 
Approximately 30% of the sample were co-infected with HIV. An equal number of HIV-
infected children with and without anti-TB therapy (concurrent controls; 42 on efavirenz and 
22 on lopinavir) were enrolled, based on the required age strata to allow for comparison of 
the effect of second-line TB drugs on ARV levels in HIV-infected children with and without 
TB treatment. HIV-infected children had ARV PK sampling done at baseline. Enrolment 
was balanced by HIV status and age to ensure adequate numbers of children 0–2 years of 
age and adequate numbers of HIV-infected children. 
The TB medication regimen was based on local and international recommendations for 
routine care. The PAS local and international dose recommendations for children with TB is 
150 mg/kg body weight up to a maximum of 1200 mg/day. This was therefore, not an 
interventional study. No new medications or new dosages were assessed. 
 
5.6.1.2. Ethical approval for the study. 
The study was formally approved by the Faculty of Health Science Research Ethics 
Committee, see Appendix 2 for approval letter.  
 
5.6.1.3.Accuracy and Precision 
This method was accurate and precise, showing a coefficient of variation and bias within  
15% at all levels of quality controls used in each the 12 batches of unknown sample runs, 
data represented in Table 86.  
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Table 86. Summary of Quality Control data from 12 sample run batches 
 High (32.0 µg/ml) Medium (16.0 µg/ml) Low (0.783 µg/ml) 
Mean % 
Accuracy 
104.4 99.7 98.0 
STDEV 11.20 7.03 8.63 
RSD (%) 10.8 7.0 8.8 
N 24/24 *23/24 24/24 
* = One outlier with MNR-ESD Outlier Test, excluded from table. 
The mean % accuracy for the low, medium and high quality control concentrations were 
98.0, 99.7 and 104.4 with a precision CV % of 8.8, 7.0 and 10.8, respectively. 
 
5.6.1.4. Suitability 
The calibration range of 0.313–40 µg/ml was appropriate for the quantification of 
cycloserine samples generated in this study. Only 0.15% of the total number of sample (657) 
was below the limit of quantification and 6.8% of the sample was ALQ of the calibration 
range. All ALQ samples was diluted into the calibration range, none of the diluted samples 
was above the validated dilution range of 64 µg/ml. 
The method was sensitive and LLOQ of this method, 0.313 µg/ml, enabled the 
determination of cycloserine concentrations over the total drug profile for at least 8 hours. 
With a half-life of 10 hours it was possible to follow the drug elimination for approximately 
one half-life in the 8 hour drug profile. 
 
5.6.1.5. Drug levels measured in patient samples. 
The average plasma concentration (standard deviation) versus time profiles is shown in  
Figure 34 for 109 children dosed with terizidone at 10–20 mg/kg/day. The Cmax varied 
between subjects with 14.3 µg/ml as the lowest and 54.6 µg/ml as the highest Cmax 
concentration and an average Cmax of 26.8 µg/ml at an average Tmax at 2 hours. With a 
MIC for terizidone / cycloserine of 5–20 µg/ml this MIC was achieved in all of the subjects. 
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Figure 34. Average concentration with standard deviations vs time profile in children after 
receiving a terizidone dose of 10–20 mg/kg/day. 
 
5.7. Conclusion 
The developed LC–MS/MS method was successfully validated and employed for 
quantitative determination of cycloserine concentrations in a clinical study following oral 
administration of 10–20 mg/kg/day terizidone in children with DR-TB in need of second-
line anti-TB drugs. The proposed method is affordable, reliable, simple, selective, rugged 
and reproducible. The method was developed with good peak shape and low base line noise. 
The mobile phase was optimized in simple isocratic mode and one of the major advantages 
of this method is that only 20 µl of plasma is needed for analysis, which greatly facilitates 
the collection of blood samples in children. The method produced reliable data that 
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6. APPENDIX 1 
Development, validation and application of a LC-MS/MS method to 
accurately quantify para-aminosalicylic acid in 20 µl human plasma 
Smit MJ1, Castel S1, Norman J1, Strydom N1, Schaaf HS2, Hesseling AC2 and Wiesner L1. 
 
1. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, 7925, 
South Africa. 
2. Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health 
Sciences, Stellenbosch University, Cape Town, South Africa. Corresponding Author; Lubbe Wiesner, email: 
lubbe.wiesner@uct.ac.za, telephone: +27214066472. 
 
Abstract 
A selective and sensitive liquid chromatography-tandem mass spectrometry method (LC-MS/MS) was developed 
and validated for the quantification of para-aminosalicylic acid (PAS) in 20 μl human plasma over the range of 
0.391 to a 100 μg/ml. Sample extraction included protein precipitation with 200 μl of methanol containing 
rilmenidine as the internal standard. The mean recovery was 100.3% across low, medium and high test 
concentrations. The retention times for PAS and rilmenidine were 2.4 and 1.6 minutes respectively.  PAS was shown 
to be stable in methanol for two days at approximately -80°C, and for 24 hours at ~4°C and ~-20°C.  PAS was stable 
for up to 21 hours at room temperature and when subjected to three freeze-thaw cycles. Extracted samples were 
stable on instrument over a period of 56 hours. The overall accuracy of the validation batches ranged between 93.3 
and 108.5% with a percentage coefficient of variation below 5.1% for high, medium and low quality controls and 
13.4% for the lower limit of quantification.  The assay was robust and performed well when applied to paediatric 
clinical samples generated during a clinical multidrug-resistant tuberculosis research study in South Africa. 
 
 
Keywords: Tuberculosis, Para-aminosalicylic acid, LC-MS/MS. 
 
1. Introduction 
Para-aminosalicylic acid (PAS) is a second-line drug used to treat multidrug-resistant tuberculosis (MDR-TB) and is 
classified as a Group D drug for MDR-TB (i.e. an “add-on agent”) by the World Health Organisation[1]. It was the 
first drug discovered to be active against tuberculosis (TB) and was introduced for clinical use in 1946[2, 3], but its 
popularity decreased after the introduction of the more potent drugs: rifampicin and pyrazinamide[4]. The 
emergence of MDR-TB has raised the significance of PAS in combination therapies. PAS both delays resistance 
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against streptomycin and isoniazid[5] and has a relatively well-tolerated adverse effect profile compared to other 
second-line drugs[1]. Effective as a bacteriostatic prodrug, PAS impacts the mycobacterial folate pathway by 
targeting dihydropteroate synthase (DHPS) and dihydrofolate synthase (DHFS), generating a hydroxyl dihydrofolate 
antimetabolite, which inhibits DHFR activity[6]. Clinical studies have demonstrated bactericidal effects at higher 
concentrations[7]. 
 
Pharmacokinetic and pharmacodynamic studies to optimize the dosing of PAS in combination MDR-TB therapies 
are essential.  PAS has been shown to lower plasma rifampicin concentrations by half following oral 
administration[8]. Children account for approximately 25 000-32 000 cases annually[9,10]. Currently, treatment 
guidelines for children with MDR-TB are extrapolated from adult studies, despite children having different 
absorption and clearance profiles compared to adults[11]. Pharmacokinetic studies of second-line anti-tuberculosis 
drugs, including PAS, in children with MDR-TB are important as current data is limited to a few studies[12].  
 
Published bioanalytical methods to determine PAS concentrations require between 200 and 1000 μl plasma[13, 14], 
which is not optimal for therapeutic drug monitoring in young children where blood volumes are a major 
consideration [15].  
 
This paper presents a sensitive and selective bioanalytical method capable of measuring PAS over the range of 0.391 
to a 100 μg/ml from just 20 μl of plasma in order to study the pharmacokinetics of PAS, used in combination with 
other second-line TB drugs, in South African children. 
2. Materials and methods 
2.1. Materials and chemicals 
Methanol (Burdick and Jackson, LC-MS) was purchased from Honeywell International Inc. (Muskegon, MI, USA), 
formic acid was purchased from Merck (Darmstadt, Germany) and all water used, purified by a Milli-Q reverse 
osmosis system and a Synergy S Kit Millipore Water Purification System from EMD Millipore (Billerica, MA, 
USA).  PAS and rilmenidine reference standards were supplied by Toronto Research Chemicals (TRC, Ontario, 
Canada) and Shenzen Haorui Industrial Dev Co., Ltd. (Shenzhen, China), respectively. Drug free plasma was 
obtained from Western Province Blood Transfusion Services, South Africa. A Phenomenex Synergi Hydro-RP 4µm, 
150 x 2.0 mm analytical column (Phenomenex, USA) was used for the separation of PAS and the internal standard. 
2.2. Instrumentation 
Liquid chromatography-tandem mass spectrometry method (LC-MS/MS) analysis was performed using an Agilent 
1200 series binary pump (Agilent, CA, USA) interfaced with an AB Sciex API 3000 mass spectrometer (AB Sciex, 
Ontario, Canada) with an electrospray ionization (ESI) source.  An HTC PAL autosampler (CTC Analytics AG, 
Zwingen, Switzerland) was used to inject samples. 
 
2.3. Preparation of calibration standards and quality controls 
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Calibration standards and quality controls were prepared volumetrically in blank human plasma (anticoagulant 
K3EDTA) at room temperature. Two PAS stock solutions were prepared in methanol at 5000 μg/ml each and the 
first spiked into 4.90 ml blank plasma for the highest calibration standard of 100 μg/ml. This standard was serially 
diluted with normal blank plasma to produce a total of 9 calibration standards (50.0, 25.0, 12.5, 6.25, 3.13, 1.56, 
0.781, 0.391 μg/ml). Five quality control samples were prepared using the same methodology; namely a dilution, 
high, medium, low and lower limit of quantification (LLOQ) control at concentrations: 160, 80.0, 40.0, 0.781 and 
0.391 μg/ml, respectively. The samples were aliquoted into polypropylene tubes and stored at approximately -80°C 
to allow for duplicate 20 µl extractions from each tube. 
2.4. Extraction procedure 
A protein precipitation method was used to prepare samples at room temperature. Briefly, 20 μl of the thawed 
plasma sample was precipitated with 200 μl of a 250 ng/ml internal standard solution in methanol, except for the 
double blank sample, which was precipitated using pure methanol. Samples were vortexed for 30 seconds then 
centrifuged for 5 minutes at approximately 16 000 rcf. A hundred and fifty microliters of the supernatant was 
transferred to a 96 well plate and 50 μl of 0.2% formic acid in water (v/v) was added. Five microliters was injected 
onto the LC-MS/MS for quantification. 
2.5. Liquid Chromatography 
A Synergi Hydro-RP 4µm, 150 x 2.0 mm analytical column was used for chromatographic separation.  An isocratic 
mobile phase containing 0.2% formic acid in water (v/v) and methanol (60:40, v/v) was used at a flow rate of 300 
µl/min for 5 minutes. The retention times were between 1.60 and 1.70 minutes for rilmenidine and 2.20 and 2.40 
minutes for PAS (shown in Figure 1). 
 
Fig. 1. Chromatogram of PAS (para-aminosalicylic acid) and internal standard (rilmenidine) at the highest 
calibration standard concentration. 
2.6. Mass Spectrometry 
ESI was performed in the positive ion mode with zero air used as the nebulizing and turbo spray gas. Nitrogen was 
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used as curtain gas, with the optimum values set at 6, 8 and 6 (arbitrary values) for nebulizing, turbo spray and 
curtain gas, respectively. A heated nebulizer temperature of 500°C and ion spray voltage of 5000 V was used. The 
instrument response was optimized for PAS and the internal standard rilmenidine, by infusing a solution of the 
compounds dissolved in mobile phase at a constant flow rate. The instrument was operated at unit resolution in the 
multiple reaction monitoring (MRM) mode with their respective transitions shown in Table 1. The pause and dwell 
times were set to 5 milliseconds and 150 milliseconds, respectively, and the collision gas (N2) was set to medium 
(arbitrary value). The instrument was interfaced with a computer running Analyst software (version 1.4.2). 
 









Protonated molecular ion mass (m/z) [M+H]+ 154.127 181.156 
Product ion mass (m/z) Quantifier 80.151 95.1 
Product ion mass (m/z) Qualifier 136.2 67.0 
m/z = mass-to-charge ratio 
 
2.7. Method Validation 
2.7.1. Calibration standards, quality controls and dilution quality controls 
Intra- and inter-batch accuracy and precision were determined by validating the calibration curve over a period of 
three days. High, medium, low and LLOQ quality control samples were analyzed in six-fold while the calibration 
standards were analyzed in duplicate over the range 0.391 to 100 μg/ml. Calibration curves were constructed using a 
weighted quadratic regression (1/concentration) of the peak area ratio of PAS to the internal standard versus nominal 
concentration.  Accuracy and precision of the dilution procedure was evaluated by diluting and extracting six 
dilution quality control samples prepared at a PAS concentration double that of the highest quality control sample, 
namely 160 µg/ml.  The dilution quality control samples were diluted 1:1 and 1:4 with blank plasma and their 
respective concentrations determined and compared with the nominal concentration. 
 
2.7.2. Recovery 
Recovery was evaluated at high, medium and low concentrations. Blank plasma was extracted as described for 
reference samples and spiked with PAS to generate matrix containing reference samples in six-fold at high, medium 
and low concentrations. The recoveries were calculated by comparing the peak areas of the post-spiked quality 
controls representing 100% theoretical recovery with those of the reference samples, also performed in six-fold. 
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2.7.3. Stock solution stability 
Stock solution stability of PAS and rilmenidine in methanol was evaluated over 24 hours at room temperature, ~4°C, 
~-20°C and over 48 hours at ~-80°C. Reference stock solutions were prepared fresh. Reference and test samples 
were diluted with injection volume to 100 µg/ml and 0.250 µg/ml for PAS and rilmenidine, respectively, and the 
peak areas of six separate samples compared for each. 
 
2.7.4. Freeze-thaw stability 
Freeze-thaw stability was evaluated at high and low concentrations, with quality control samples frozen at ~-80ºC, 
and put through three consecutive freeze and thaw cycles. Samples were frozen for at least 24 hours prior to starting 
this experiment. Each cycle consisted of sufficient thawing time at room temperature followed by 12–24 hours 
freezing time. These samples were analyzed against a fresh calibration curve and compared to the observed mean of 
the quality controls analyzed within the batch.   
 
2.7.5. Benchtop and on-instrument stability, and reinjection reproducibility 
To evaluate benchtop stability, low and high quality control samples were frozen at ~-80ºC, and subsequently left on 
the bench at room temperature to thaw for approximately 21 hours. Samples were analyzed against a fresh 
calibration curve.  Reinjection reproducibility and on-instrument stability were determined by reinjecting the first 
validation batch after being kept in the autosampler at ~10C over the course of 56 hours. 
 
2.7.6. Whole blood stability, matrix effects, anticoagulant effect and haemolysis effect 
To replicate typical clinical sampling conditions, whole blood stability was evaluated over 2 hours on ice. Whole 
blood was spiked, as previously described for plasma samples, at concentrations similar to high and low quality 
control concentrations. Six reference samples were spiked and immediately centrifuged and plasma stored, while six 
test samples were left on ice for 2 hours before centrifuging and storing plasma. Both sets were stored at ~-80C 
before analysis. 
 
Matrix effect was determined using the Matuszewski method[16]. Six different blank sources of plasma were 
extracted and spiked with PAS at low, medium and high concentration levels and a single concentration of internal 
standard, rilmenidine. The peak area ratios of PAS and the internal standard for each level in each matrix source 
were used to generate and compare regressions for each individual matrix. To evaluate the influence of matrix 
anticoagulant effects on analyte and internal standard ionization, high, medium and low quality controls were 
prepared in plasma containing lithium heparin as an anticoagulant and compared to the nominal concentration of the 
corresponding quality controls, when analyzed against the calibration curve prepared in K3EDTA. 
 
The influence of haemolysed blood on ionization was evaluated by assaying 2% haemolysed samples at high and 
low  
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concentrations and comparing peak area ratios to six reference high and low quality controls. 
 
2.7.7. Long term matrix stability 
The long-term matrix stability in plasma was assessed by comparing test samples, prepared at high and low 
concentrations and kept for a period of time at approximately -80°C, to freshly prepared samples.  
3. Results and Discussion 
The LC-MS/MS method to determine PAS concentrations was successfully validated in accordance with the 
bioanalytical validation guidelines of the US Food and Drug Administration [17,18], European Medicines 
Agency[19,20], and White Paper publications[21–28]. The overall accuracy and precision of the assay procedure, as 
calculated by the accuracy and precision over the three validation batches, are shown in Table 2. A range of 93.3 to 
108.5% for quality control concentrations (N = 18, with one outlier observed for the low-quality control), is well 
within international accepted guidelines of 85–115% accuracy with a coefficient of variance (CV) below 15 and 20% 
for the LLOQ. Dilutions of 1:1 and 1:4 were successfully validated for concentrations of up to 160 μg/ml. The 
calibration curve fits a quadratic regression using peak area ratio of analyte to internal standard with 1/concentration 
weighting and showed high reproducibility with a mean r2 of 0.9995 over the three validation batches.  
 














QC 6 - LLOQ 0.391 0.385 0.0516 13.4 98.4 18 of 18 
QC 5 - Low 0.781 0.847 0.0266 3.1 108.5 *17 of 18 
QC 2 - Med 40.0 37.3 1.918 5.1 93.3 18 of 18 
QC 1- High 80.0 76.4 3.11 4.1 95.5 18 of 18 
QC DIL 1:1 160 162 11.6 7.1 101.2 6 of 6 
QC DIL 1:4 160 156 8.7 5.6 97.3 6 of 6 
* = Outlier with MNR-ESD Outlier Test 
 
The LLOQ for this method, when injecting 5 μl onto the column, was validated at 0.391 μg/ml.  A representative 
raw chromatogram is shown in Figure 2. The signal to noise ratio at LLOQ was well above the minimum 
international accepted criteria of greater than 5. Increasing injection volume could improve the sensitivity of this 
method, but this LLOQ was found to be adequate for this study. No interfering or late peaks were observed showing 
a highly specific LC-MS/MS method. 
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Fig. 2. Chromatogram of PAS (para-aminosalicylic acid) calibration standard at LLOQ (0.391 μg/ml). 
 
The protein precipitation method used showed satisfactory extraction efficiency, with a mean recovery of 100.3% 
and a reproducibility CV of 3.3% for test controls of 100, 50.0 and 0.391 μg/ml (N = 6). 
 
Stock solutions were shown to be stable under experimental conditions over a 24-hour period and had a percentage 
difference to fresh reference stocks of 1.6% at room temperature (CV% = 5.3, N = 6), 2.4% at ~4°C 
(CV% = 7.9, N = 6) and 0.03% at ~-20°C (CV% = 1.9, N = 6). The initial stocks kept at ~-80°C (CV% = 2.6, N = 6) 
were shown to be stable over 48 hours with a percentage difference to the freshly prepared reference stocks 
(CV% = 5.9, N = 6) of 0.9%.  
 
Freezing calibration samples were found to have no significant impact on stability after eight days at ~-80°C when 
compared to a freshly prepared calibration curve with high, medium, low and LLOQ controls showing 92.3 - 109.3% 
accuracy and a highest observed CV of 6.9%. Freeze thaw stability was performed over three cycles at high and low 
concentrations and analyzed against a valid calibration curve. The samples were within 2.5% of the nominal 
concentration (CV% = 5.1, N = 6) showing acceptable freeze-thaw stability over 3 cycles when stored at ~-80°C.  
 
Plasma samples were shown to be stable on bench over 21 hours at room temperature with a percentage difference of 
6.9% and 0.9% for high (CV% = 5.0, N = 6) and low (CV% = 7.9, N = 6) quality controls respectively.  
 
Reinjection reproducibility was determined by reinjecting the first validation run after both the second and third 
validation runs and showed satisfactory accuracy and precision, which indicated that a batch may be reinjected 
within 56 hours and quantified using the standards contained within the batch.  
 
On-instrument stability for the analyte was indicated for at least 56 hours using high (CV% = 7.9, N = 6) and low 
(CV% = 7.9, N = 6) quality controls stored at an autosampler temperature of ~10C. 
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PAS was shown to be stable for at least 2 hours on ice in whole blood for high (CV% = 5.2, N = 6) and low 
(CV% = 9.1, N = 6) quality controls with a difference of -2.2% and 0.9%, respectively.  
 
No significant matrix, matrix anticoagulant or haemolysis effects were observed. Six plasma sources were used to 
assess matrix effect and slope variability was found to be 4.1%. Precision and accuracy of high, medium and low 
lithium heparin quality controls compared to a valid calibration curve prepared in K3EDTA had no significant 
influence on the precision and accuracy of the analyte concentration and was found to be within the allowed ranges 
for accuracy and precision. High (CV% = 6.7, N = 6) and low (CV% = 8.1, N = 6) quality control levels were used 
to assess effect of haemolysis in 2% haemolyzed samples and had a percentage difference of -6.6 and -11.1%, 
respectively. PAS was stable in plasma for 21 months kept at approximately -80°C, at high (CV% = 5.9, 
Difference% = -9.6%) and low (CV% = 3.9, Difference% = 0.2%) concentrations. 
 
Small carry-over peaks were observed in the double blank samples positioned immediately after the highest 
calibration standard, but the peak areas were less than 20% of the LLOQ peak areas of the analyte and less than 5% 
of the internal standard peak areas, shown in Figure 3. 
 
Fig. 3. Chromatogram showing minimal PAS (para-aminosalicylic acid) and rilmenidine carryover in the double 
blank sample after injecting the highest calibration standard. 
 
This method was successfully used for the analysis of samples from a clinical study in children with MDR-TB, with 
and without HIV co-infection (NIH R01: 069169-01).  All TB medications were dosed according to local and 
international recommendations for routine TB care in children. For PAS, this dose was 150 mg/kg body weight up to 
a maximum of 12 000 mg/day. This method proved to be accurate and precise, showing a coefficient of variation and 
bias below 7% for all quality control concentrations, high (CV% = 6.4, N = 10), medium (CV% = 5.6, N = 10) and 
low (CV% = 6.6, N = 10).  A mean concentration versus time profile from 28 children is presented in Figure 4.  Full 
clinical results will be reported elsewhere.  
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Fig. 4. Mean concentration vs. time profile from 28 children receiving a 150 mg/kg body weight dose of PAS (para-
aminosalicylic acid). 
4. Conclusions 
A robust method to quantify PAS in 20 μl of plasma by LC-MS/MS using a simple protein precipitation extraction 
was successfully validated and applied to clinical samples. PAS was shown to be stable across various sample 
handling conditions and the extraction of 20 μl plasma showed high recovery, making this method ideally suited for 
high-throughput sample analysis and appropriate for monitoring PAS in adult and pediatric pharmacokinetic studies. 
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